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The world has suffered immensely and disproportionately from the 
ravages of HIV and AIDS. Oral PrEP is a single pill taken once daily that can 
reduce the risk of sexually transmitted HIV infection by up to 92% (CDC, 
2014a). 
This study describes African American females’ awareness, beliefs, and 
perception of PrEP and identifies factors that may motivate women to either 
accept or reject PrEP. This cross-sectional study occurred over a 3-month 
period from November 2017 to January 2018, following from a previous pilot 
study. The sample comprised African American women aged 18 and over 
receiving STD or HIV screening services at a FQHC in Brooklyn, New York. 
Women were interviewed using the five characteristics of the Diffusion of 
Innovation theory and also completed a risk assessment for HIV using CDC 
recommended guidelines for screening heterosexual women for PrEP. 
Awareness of PrEP remained extremely low among the 72 African 
American women interviewed in the study. Using the CDC guidelines, all 
women reported one or more risk factors for PrEP indication. Awareness about 
PrEP, negative reactions from partners and shared experiences from female 
PrEP users were cited as factors that may predict and motivate African 
American women to use PrEP. Additionally, skills in pill-taking, cost and 
insurance, and maintaining privacy while using PrEP were strong enabling 
factors to support PrEP use. Factors such as initiating couple’s PrEP use as an 
intervention, medical doctors overtly directing PrEP for women, and the role of 
older women in promoting PrEP use were persuasive factors in reinforcing the 
utilization of PrEP among African American women in the study. 
Creative programming within high burden communities is critically 
important to penetrate with messages of new innovations and best practices. 
The results of the current research speak volumes to the continued work 
needed to educate communities with prevention messages. 
 





















 Copyright Suzanne Robinson Davis 2018 
 
All Rights Reserved 








I am forever grateful to the incredible 82 African American and Mixed women 
who participated in both studies. 
 
“The way to right wrongs is to turn the light of truth upon them.” 








This dissertation is a product of much work. Its completion would not have 
been possible without the guidance, support and contribution of so many. 
First of all, I would like to thank my academic advisor and sponsor, Dr. 
Charles Basch, the Richard March Hoe Professor of Health Education. His 
constant input and feedback ensured that I kept the course and that the research 
remained innovative, accurate and targeted. His detailed and thoughtful reviews 
were always promptly provided in the most gentle but firm manner, giving that 
confidence to press on.  
I must also thank Dr. Angela Aidala, Associate Research Scientist in the 
Mailman School of Public Health, who provided her expertise freely and ensured 
that the focus of the paper had practical relevance. I thank also Dr. Laudan 
Jahromi, Associate Professor of Psychology and Education and Dr. George V. 
Gushue, Associate Professor of Psychology and Education, who exercised 
flexibility and provided keen reviews of the dissertation. The collective input into 
my doctoral experience by the faculty and administration staff at Teachers 
College Columbia University was beyond par.  
Professor Judith Auerbach and Dr. Yohance Whiteside, whose work 
continues to demonstrate their passion for HIV prevention research and who 
willingly shared their data collection tools, which proved to be important in the 
development of my own survey instrument. Likewise, I am grateful for the 
financial support provided by the Dean’s Grant for Student Research, which 
helped offset the tremendous cost of conducting field research. 
  v 
And speaking of field research, I thank the many women who participated 
in both the main study and the pilot study. Although their identities remain 
confidential, their willingness to open up about such sensitive and personal 
issues as sexuality and health was what allowed this study to make breakthrough 
findings. I thank the FQHC CEO/President and staff who supported the 
recruitment of participants, in particular Dr. Yunique A. Desire Brisard who went 
above and beyond.   
I also want to thank the Gottesman Library at Teachers College Columbia 
University, for being an invaluable resource. The welcoming staff, private rooms 
and online resources were all necessary inputs that contributed to my finished 
work. Additionally, I spent hours on end in the Queens Libraries. What a 
wonderful public resource. I thank them for their welcome, patience and 
understanding; and for being that quiet space I needed in this city that never 
sleeps. 
Working and studying full-time is no easy feat. I am privileged to have a 
supervisor who showed flexibility and compassion, and who allowed me to 
balance the need for high productivity with the demands of academic pursuits. 
Thank you Mrs. Patricia Fernandez. 
In those times when the end looked distant, and the road too steep, I 
depended on a team of cheerleaders for support. My mother Winna Reid, stood 
by me like only a mother could. Thanks for every prayer, every meal, every late-
night hug and cup of tea, and every word of encouragement. I thank my sister, 
Dionne, for jumping to the rescue when I believed I would not even be able to 
  vi 
start. I thank my cousin, Stacy-ann, who having just taken this same journey 
willingly shared her experiences – and academic resources.  To my husband and 
unofficial editor-in-chief, Kurt, your support has been incredible. You have 
sacrificed much to enable me to spend time, resources and lots of grey matter on 
this study. Words cannot express my gratitude – I love you.  To my son, James, 
my nephew Jaden, and my future children, I want this work to inspire you to 
achieve more and do more; it is all within your reach, take it.  
And most of all I thank God. For me, science and faith are not competitors. 
They are complementary in my earnest desire to make people’s lives better. I 
thank God for being the rock I stand on to start, undertake and complete this 
work.  
 S. R. D. 
  vii 





Chapter I—INTRODUCTION ............................................................................. 1 
Global HIV/AIDS Epidemic...................................................................... 1 
HIV/AIDS Epidemic in the United States ................................................ 2 
Introduction of Pre-Exposure Prophylaxis (PrEP) .................................. 3 
Purpose of the Study ............................................................................... 5 
Specific Aims ........................................................................................... 5 
Rationale for the Study ............................................................................ 6 
 
Chapter II—LITERATURE REVIEW ................................................................ 12 
 Overview of Descriptive Epidemiology of HIV/AIDS Globally and 
  in the United States ....................................................................... 13 
  Global Prevalence ......................................................................... 13 
  Time Trends in the U.S. ................................................................ 13 
  The Intra-national Comparisons ................................................... 14 
  Local (New York) Comparisons .................................................... 16 
  HIV Risk Factors in the U.S. ......................................................... 17 
  Emergence of Antiviral Medication ............................................... 18 
 Current (2014) CDC Clinical Practice Guidelines for PrEP ................. 19 
  Recommended Questionnaire Used to Screen Heterosexual 
   Women for PrEP ................................................................... 20 
  Guidelines Provided for Additional Risk Factors .......................... 20 
  Recommended Indications for PrEP Use by Heterosexually 
   Active Men and Women ....................................................... 21 
 U.S. Women Who Have Indications for PrEP ...................................... 21 
 Female-Controlled PrEP Modalities...................................................... 22 
  Intimate Partner Violence ............................................................. 27 
 U.S.-based Pre-exposure Prophylaxis Studies .................................... 29 
 U.S. Clinicians' Attitude, Knowledge, and Prescribing Practices ......... 35 
 PrEP Uptake in the United States ......................................................... 42 
 Sero-discordant Relationships .............................................................. 46 
 Theoretical Framework ......................................................................... 48 
  Diffusion of Innovations in Health Promotion ............................... 49 
  Diffusion of Innovations................................................................. 49 
   Rogers's five perceived attributes of innovations ................ 50 
  Grounded Theory .......................................................................... 55 
  PRECEDE Planning Framework .................................................. 56 
 
Chapter III—METHODS ................................................................................... 61 
 Study Design ......................................................................................... 61 
 Pilot Study .............................................................................................. 61 
  Aim 1: Adequacy of the Interview Instrument .............................. 62 
 Study Setting ......................................................................................... 65 
  viii 
 Target Population Eligibility ................................................................... 66 
  Inclusion/Exclusion Criteria ........................................................... 67 
 Delimitations of the Study ..................................................................... 68 
 Sampling and Recruitment .................................................................... 69 
 Informed Consent .................................................................................. 72 
 Measurements ....................................................................................... 73 
  PrEP Awareness and Acceptability .............................................. 74 
 Data Collection ...................................................................................... 76 
 Coding, Data Analysis, and Synthesis .................................................. 77 
 Credibility of the Research .................................................................... 79 
  Trustworthiness ............................................................................. 79 
  Validity ........................................................................................... 80 
 
Chapter IV—RESULTS .................................................................................... 81 
 Risk Characteristics of the Study Sample ............................................ 81 
 Individual Case Presentations .............................................................. 82 
  Case Presentation 1 ..................................................................... 82 
  Case Presentation 2 ..................................................................... 83 
  Case Presentation 3 ..................................................................... 84 
  Case Presentation 4 ..................................................................... 85 
  Case Presentation 5 ..................................................................... 86 
  Case Presentation 6 ..................................................................... 87 
  Case Presentation 7 ..................................................................... 88 
  Case Presentation 8 ..................................................................... 89 
  Case Presentation 9 ..................................................................... 90 
  Summary of Case Presentations .................................................. 91 
 Classification of Factors ........................................................................ 91 
 Predisposing Factors............................................................................. 95 
  Lack of Awareness about PrEP .................................................... 95 
  Beliefs about PrEP ...................................................................... 101 
  Potential Users of PrEP .............................................................. 105 
  Partner's Influence on Black Women's PrEP Use...................... 106 
  Impact of Negative Reactions by Partner ................................... 109 
  Expected Reactions from Friends .............................................. 113 
  Perceived Need of Using PrEP .................................................. 115 
  Importance of Shared Experience and Learning ....................... 117 
  Beliefs That May be Barriers to PrEP Uptake ............................ 119 
   Assessment of risk, stigma, and promiscuous behavior ... 121 
  PrEP and Condom Use............................................................... 123 
  Limited Nature of PrEP ............................................................... 125 
 Enabling Factors.................................................................................. 127 
  Pill-taking Behaviors ................................................................... 127 
  Privacy and PrEP Use ................................................................ 129 
  Cost and Insurance Coverage .................................................... 131 
 Reinforcing Factors ............................................................................. 131 
  Couple Use in Normalizing PrEP................................................ 132 
  ix 
  Doctors' Role in Advancing PrEP among Black Women ........... 133 
  Pointers for Health Care Providers in Promoting PrEP 
   among Black Women.......................................................... 135 
  Older Black Women as Resources of Behavior Change ........... 137 
  Fear of Extreme Side Effects ...................................................... 138 
 
Chapter V—DISCUSSION ............................................................................. 141 
 Awareness of PrEP ............................................................................. 141 
 Accepting/Rejecting PrEP ................................................................... 143 
 Impact of Partners' Reaction to PrEP ................................................. 144 
 Barriers to PrEP................................................................................... 145 
 Adherence Concerns........................................................................... 147 
 Privacy in PrEP Use ............................................................................ 149 
 Doctors' Role in Advancing PrEP among Black Women ................... 149 
 Limitations of the Study ....................................................................... 150 
 Implications for Practice ...................................................................... 154 
  Disconnect Between Perception of PrEP Uptake and 
   Practice ............................................................................... 154 
  Increase Education with Providers ............................................. 155 
  New PrEP Navigation Model for Black Women ......................... 156 
 Implications for Future Research ........................................................ 159 
  Leveraging Older Women as Resources for Behavior 
   Change ................................................................................ 159 
  Couple Use in Normalizing PrEP................................................ 160 
  Future of PrEP Prescription for Black Women ........................... 161 
 Final Comments .................................................................................. 162 
 
REFERENCES ............................................................................................... 165 
 
APPENDICES 
Appendix A—Pilot Questionnaire................................................................... 174 
Appendix B—Frequently Asked Questions (FAQ) ........................................ 175 
Appendix C—Site Permission ........................................................................ 177 
Appendix D—Study Flyer ............................................................................... 178 
Appendix E—Informed Consent .................................................................... 179 
Appendix F—Institutional Review Board (IRB) Approval .............................. 180 
Appendix G—Interview Instrument ................................................................ 181 
Appendix H—Emails from Researchers ........................................................ 187 
  x 





 1 Pilot Study Feedback about Interview Questions...................... 63 
 2 Selected Characteristics of Study Participants ......................... 72 
 3 Classification of Positive and Negative Predisposing, 
  Enabling, and Reinforcing Factors Reported by Black 
  Women Regarding PrEP Use Based on Data Collected 
  in Brooklyn, New York, November 2017 to January 2018 ........ 92 
  xi 





 1 Diagnoses of HIV Infection in the U.S. in 2015 by 
  Race/Ethnicity and Region ......................................................... 15 
 2 A Paradigm of Variables Determining the Rate of 





Global HIV/AIDS Epidemic 
The world has suffered immensely and disproportionately from the ravages 
of human immunodeficiency virus (HIV) and acquired immunodeficiency 
syndrome (AIDS). Globally, 36.7 million people are living with HIV, while each 
year approximately 2 million people become newly infected with the virus 
(UNAIDS, 2017a). According to the Joint United Nations Programme on 
HIV/AIDS (UNAIDS, 2017b), women and girls share equally in the burden of 
HIV/AIDS. In 2016, 18.6 million women and girls were living with HIV and 
accounted for nearly 1 million of the 1.8 million new HIV infections globally. While 
there has been a tremendous decline in AIDS-related deaths, with declines of up 
to 48% recorded in many parts of the world, approximately 1 million people die 
from AIDS-related causes each year. Significantly, only 54% of people infected 
by HIV/AIDS have accessed antiretroviral therapy (UNAIDS, 2017a). At the end 
of 2016, East and Southern Africa accounted for 43% of new HIV infections and 
have recorded a 29% decrease in new infections from 2010 to 2016 (UNAIDS, 
2017a). In most regions of the world, there have been decreases in new HIV 
infections in 2016, but Eastern Europe and Central Asia have recorded rises in 
new infections of 60% between 2010 and 2016 (UNAIDS, 2017a). 
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HIV/AIDS Epidemic in the United States 
In 2010, under the endorsement of President Barack Obama, the White 
House unveiled the National HIV/AIDS Strategy, A Vision for Our Future, the first 
national strategic document that recognized the impact of HIV/AIDS on the U.S. 
and its territories. The National HIV/AIDS Strategy (NHAS) for the country sought 
to provide policy direction, measures, targets, and harness a synergetic 
collaboration among federal partners to address the HIV epidemic. In 2014, the 
strategy was revised and expanded to include, among other updates, national 
actions and the advancement of PrEP as an HIV prevention tool. 
In 2016, 973,846 persons in the United States were living with HIV (Centers 
for Disease Control and Prevention [CDC], 2016a, p. 9). Similar to other parts of 
the world, the U.S. has recorded uneven declines in new HIV diagnoses from 
40,234 to 39,513 in 2014 and 2015, respectively. However, in 2016, a slight 
increase was recorded of 39,782 (CDC, 2016a). Of the 39,782 HIV diagnoses in 
the United States in 2016, men who have sex with men (MSM) comprise 67.5% 
of these new infections. Among MSM new diagnoses in 2016, racial and ethnic 
disparities are particularly evident. Collectively, African American and Hispanic 
MSM account for 67% of all new HIV diagnoses, with African American MSM 
having the heaviest burden of 38%. 
Racial and ethnic minorities carry the burden of HIV/AIDS in the U.S. In 
particular, the African American population continues to be disproportionately 
affected by AIDS, new HIV diagnoses and AIDS-related deaths. In 2016, African 
Americans accounted for 44% of new HIV diagnoses while Hispanics accounted 
for 25.9% of new HIV diagnoses (CDC, 2016a). Similarly, African Americans 
account for 17.5% of all deaths of people diagnosed with HIV infections, which is 
the highest rate among all race and ethnicity groups (CDC, 2016a). 
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In 2016, African American women accounted for approximately 60% of all 
new HIV diagnoses among women in the U.S. (CDC, 2016a). This is striking 
since African American women only comprise 12.7% of the population (Catalyst, 
2015). African American women in the U.S. experience extreme disparity in new 
HIV diagnoses. The rate of new HIV diagnoses among African American women 
in 2015 was 16 times more likely than of White women to receive a HIV 
diagnosis (CDC, 2017). Amongst women, heterosexual contact is the primary 
transmission route (86%) through which HIV is acquired, while injecting drugs 
accounts for 13% of transmissions. 
There is an urgent need for more effective HIV prevention strategies to 
decrease and ultimately end the epidemic in Black women, and in the U.S.. 
Further, given the racial and ethnic disparities in HIV morbidity and mortality 
among women, research is desperately needed to inform HIV prevention efforts 
among this group. 
Introduction of Pre-Exposure Prophylaxis (PrEP) 
As of April 2018, HIV remains without a cure. A number of biomedical 
advances have proven useful in mitigating the impact of HIV with the ultimate aim 
of eliminating AIDS as a threat to public health. One biomedical intervention that 
has been replicated in different efficacy and effectiveness trials is oral 
antiretroviral prophylaxis. Oral antiretroviral prophylaxis is “highly effective in 
preventing HIV among gay men and other men who have sex with men and 
among sero-discordant couples” (UNAIDS, 2015, p. 7). In 2012, the Food and 
Drug Administration approved the only medication in the U.S. that can effectively 
protect against the transmission of HIV among adults. 
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Pre-exposure Prophylaxis (PrEP) is a single pill taken once daily that can 
reduce the risk of sexually transmitted HIV infection by up to 92% (CDC, 2014a, 
p. 9; Grant et al., 2010, p. 2597). The formulation of the medication is the primary 
drugs of Tenofovir-Emtricitabine (TDF 300 mg co-formulated with FTC 200 mg) 
(CDC, 2014a). This formulary is within one pill commonly called “Truvada” that is 
used daily to protect against HIV (CDC, 2014a, p. 9). Taking Truvada to protect 
against HIV is a preemptive decision based on the perceived increased likelihood 
of HIV exposure. 
Since 2009, the iPrEX (Pre-exposure Prophylaxis Initiative), the Partners 
and the Bangkok clinical trials have demonstrated both PrEP efficacy and 
effectiveness in preventing HIV among key populations most affected by 
HIV/AIDS. In the United States, key populations affected by HIV/AIDS are men 
who have sex with men (MSM), injecting drug users (IDUs), people with trans 
experience, and heterosexuals, in particular, heterosexual women. These trials 
have reinforced the FDA’s decision to approve PrEP as an HIV prevention 
method. 
Among female PrEP trials, evidence has shown the effectiveness of PrEP 
in preventing HIV in women. Further studies have shown that vaginal microbiota 
aids in tenofovir (PrEP) uptake and concentration. Secondary analyses of the 
Center for the AIDS Program of Research in South Africa 004 (CAPRISA) data 
showed a correlation between tenofovir diphosphate (TFV-dp) in genital tissues 
and TFV in the plasma to “markers of bacterial vaginosis (Nugent score, 
increased G vaginalis and Atopobium vaginae)” when applied “intravaginally” 
(Hillier et al., 2017). Detection of normal or abnormal bacterial vaginosis are not 
factors that reduces PrEP effectiveness in women. According to data from the 
Partners PrEP Study of oral PrEP, women who achieved over 80% PrEP 
adherence levels and had overall efficacy of >70%, PrEP had “comparable 
  
5 
efficacy of HIV prevention among women with normal microbiota (efficacy=77%), 
intermediate microbiota (73%), and bacterial vaginosis (63%)” (Heffron et al., 
2017). 
Purpose of the Study 
The purpose of this study is to describe Black females’ awareness, beliefs, 
and perception of PrEP, and to identify factors that may motivate Black women to 
either accept or reject PrEP. Black/African American women will be defined 
based on self-identification. For the purposes of this current study, the term 
“Black women” will be used and includes all women of African ancestry. The 
study is also intended to provide insights into lessons that could be learned by 
practitioners and stakeholder networks working in the area of HIV prevention to 
scale-up PrEP use among this population of women. 
Specific Aims 
1. To describe the awareness, beliefs, motivations and perceptions of 
PrEP among African American women.  
2. To identify factors that may influence Black women’s motivations to 
either accept or reject PrEP. 
3. To describe lessons that could be learned by HIV prevention 
practitioners and stakeholder networks to scale-up PrEP use among this 
population of women.  
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Rationale for the Study 
In 2014, the U.S. Public Health Service published the first clinical practice 
guidelines for Preexposure Prophylaxis (PrEP) for the prevention of HIV Infection 
in the United States (CDC, 2014a). The clinical practice guidelines identify three 
groups eligible for PrEP as Men Who Have Sex with Men (MSM), Heterosexual 
Women and Men, and Injecting Drug Users (IDUs). For each group, the guideline 
defines the meaning for substantial risk of acquiring HIV infection (CDC, 2014a, 
p. 11). Substantial risk in the MSM group is described as (a) partner with an HIV-
positive status, (b) recent bacterial sexually transmitted diseases (STIs), (c) high 
number of sex partners, (d) history of inconsistent or no condom use, and 
(e) engagement in commercial sex work. Among Heterosexual Women and Men, 
substantial risk is described as (a) partner with an HIV-positive status, (b) recent 
bacterial sexually transmitted diseases (STIs), (c) high number of sex partners, 
(d) history of inconsistent or no condom use, (e) engagement in commercial sex 
work, and (f) reside or associate in high HIV-prevalence area. Substantial risk as 
described for Injecting Drug Users includes injecting partner is HIV-positive and 
sharing injecting equipment and recent drug treatment (but currently injecting). 
Although this guideline is overlapping and broadly describes “substantial risk,” 
they provide practitioners direction for PrEP eligibility. 
As mentioned above, PrEP has been shown to be as much as 92% 
effective at reducing new HIV infections (Grant et al., 2010). The drug 
combination Tenofovir-Emtricitabine (TDF-FTC) has proven to be a critical tool in 
the fight to end the HIV/AIDS epidemic. The drug combination formulary, 
commonly referred to as Pre-Exposure Prophylaxis (PrEP) significantly reduces 
new HIV infections among groups at higher risk of HIV infection (Baeten et al., 
2012; Choopanya et al., 2013; Marcus et al., 2013). Since 2009, gold standard 
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PrEP clinical trials have investigated the efficacy and effectiveness of PrEP 
among high-risk groups, such as men who have sex with men (MSM), 
transgender women, injecting drug users (IDUs), heterosexual women and 
heterosexual men. 
The multi-nation iPrEX trial examined the effectiveness of PrEP among 
2,499 transgender women and men who have sex with men from 11 sites and 
across six countries, Peru, Ecuador, Brazil, Thailand, South Africa, and the 
United States (Grant et al., 2010). The study results revealed a “92% reduction in 
the risk of HIV acquisition in participants with detectable levels of TDF/FTC 
versus those with no drug detected” (p. 2597). Interestingly, risk compensation, 
to increase unprotected sexual acts resulting from PrEP use, has been flagged 
as an argument against PrEP. However, the iPrEX trial found no risk 
compensation. In fact, the trial found reduction in the number of sexual partners 
among those enrolled in the treatment group, a finding supported by other 
studies (Marcus et al., 2013; Minnis et al., 2013). 
In the literature, almost all studies included adherence as a factor in PrEP 
trials. Studies show that consistent use of PrEP is positively related to reduced 
HIV infection. Among people in Bangkok who injected drugs (Choopanya et al., 
2013), PrEP reduced new HIV infections by 49% to 74% in those participants 
who had higher drug concentrations in their blood. Similar findings are evidenced 
among heterosexual couples. In the Partners Study in Kenya and Uganda, 
although there were high rates of sero-conversion, the study found that “high 
adherence is essential to achieve clinical benefits from antiretroviral agents for 
HIV-1 treatment, and emerging evidence suggests that adherence to pre-




Further examination is needed regarding PrEP uptake and adherence 
among high-risk HIV-negative women in the United States as this is relatively 
unknown (Auerbach, Kinsky, Brown, & Charles, 2015). Although evidence of 
PrEP effectiveness has been shown in mix-gender (male and female) studies 
such as the Partners trial, similar successes in female-centered studies have not 
been found. The two major clinical trials contributing data on PrEP effectiveness 
in preventing new HIV infections among women have both failed to produce 
definitive results. 
These studies are FEM-PrEP and the VOICE (Vaginal and Oral 
Interventions to Control the Epidemic) trials. In the FEM-PrEP trial, low 
adherence was viewed as the primary reason for the failure of the intervention. 
The study documented 68 sero-conversions, a result attributed to low adherence. 
Interestingly, of the women who remained HIV-negative, 40% had detectable 
levels of medication (Van Damme et al., 2012). Although much is known about 
PrEP and adherence, little is known about how both factors impact women in the 
United States. Van Damme et al. believed that “a better understanding of 
indicators of adherence among women at high-risk for HIV infection is needed to 
ensure the effectiveness of future pre-exposure prophylaxis programs” (p. 422). 
Similarly, the VOICE trial experienced less than 30% adherence to 
medication resulting in 312 sero-conversions among 5029 women enrolled in the 
three treatment and two control arms of the trial (Marrazzo et al., 2015, p. 513). 
The study recruited 12,320 women from South Africa, Uganda, and Zimbabwe 
with 5029 women enrolling in the trial. Although the results were disappointing, 
the trial gave optimism and direction for future studies: “Our results reaffirm the 
need for effective and acceptable prevention interventions for women at high-risk 
for sexual acquisition of HIV-1 and suggest that more accurate measures are 
critical for the estimation of product use during biomedical HIV-1–prevention 
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trials” (p. 517). Although these findings have been compelling, other studies have 
shown that women are adherent to PrEP medication and achieve high rates of 
effectiveness by using PrEP (Corneli et al., 2015). As part of The Partners Study, 
97.7% adherence was found for non-pregnant women in the study. The study 
used multiple methods of measuring adherence among the women and found 
high adherence levels among pregnant and non-pregnant HIV-negative women 
(Matthews et al., 2014). 
Although Healthy People 2020 does not address women as a vulnerable 
group directly, objective HIV-2 clearly includes women: “reduce the number of 
new HIV infections among adolescents and adults,” unequivocally outlining the 
national and policy-level commitment to reduce new HIV infection among all 
adults and adolescents who are at risk of HIV acquisition. To achieve this Health 
People 2020 objective, attention directed toward U.S. women vulnerable to HIV 
acquisition is an imperative (Celum et al., 2015). There is a dearth of evidence to 
guide PrEP practice for women, especially Black women in the United States 
who are at substantial risk of becoming HIV-positive. Although some studies 
have focused on women, not much is known about U.S. women who use PrEP 
nor U.S. women’s ability to adhere to PrEP medication, which protects them from 
getting HIV and maintaining their HIV-negative status in a manner that empowers 
and is “female-controlled” (Auerbach et al., 2015; Flash et al., 2014). 
Globally, MSM have received most attention in PrEP related studies as the 
burden of the HIV/AIDS epidemic resides in this population. Noting that this does 
not take away from the fact that Black women are consistently at high-risk of 
contracting HIV and require attention (Auerbach et al., 2015). The proposed 
study will extend the body of knowledge that exists for women at risk of HIV to 




Through this study, PrEP providers will further understand that PrEP 
creates multiple practical uses for women at risk for HIV. The medication serves 
not only the disease prevention goal of ending HIV transmission but also 
facilitates a broader societal construct of creating walls of safety and security for 
women. Flash et al. (2014) reported from their U.S. women PrEP study that 
“women thought a pill would be easy to conceal and to ingest surreptitiously, thus 
eliminating the need to discuss concerns about their partner’s level of risk” 
(p. 638). Historically, women have faced barriers in negotiating condom use, 
communicating relationship concerns, and having open discussion about sexual 
health. The introduction of PrEP has become, for many women, a silent 
protector, providing opportunities to protect themselves and reduce their risk of 
acquiring HIV without involving their partners. The proposed study is intended to 
describe lessons that could be learned by HIV prevention practitioners and 
stakeholder networks to scale-up PrEP use among this population of women 
most vulnerable to HIV. 
The National HIV/AIDS Strategy introduced two pieces of information 
relevant to the importance of PrEP in ending the HIV/AIDS epidemic in the 
United States. The first was the “2014 U.S. Public Health Service issued clinical 
practice guidelines for PrEP” (National HIV/AIDS Strategy, p. 1) and the second 
was the identification of state and local plans to end AIDS (p. 17), particularly the 
states of New York and Washington and the city and county of San Francisco. In 
2014, Governor Andrew Cuomo appointed members to the New York State Task 
Force to End the HIV Epidemic by 2020. Although at the time little was known 
about how this would be achieved, in 2015, the Governor presented a plan, the 
“Blueprint for Ending the Epidemic,” which was the result of months of 
consultation by the Task Force. The Plan presents a 3-point strategy for ending 
the HIV epidemic in the state by 2020. The strategy comprises “identifying 
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persons with HIV, linking and retaining persons diagnosed with HIV in health 
care, and facilitating access to Pre-Exposure Prophylaxis (PrEP) for high-risk 
persons to keep them HIV-negative (Blueprint on Ending the HIV Epidemic in 
New York State, p. 4). 
The proposed research is quite timely as increasing programmatic focus 
and funding are being channeled to increase PrEP uptake in New York State and 
the wider United States. This study is intended to support existing programs, 
particularly those with state-funded mandates, to scale-up PrEP use among 
groups identified as at “substantial risk” of HIV infection, of which the population 





The aim of this literature review is to present a selective brief description of 
the current epidemiology of HIV/AIDS globally and in the U.S. A review of pre-
exposure prophylaxis (PrEP) prevention strategies and their impact on Black 
women is outlined. The literature review achieves this aim by presenting, in the 
first section, a synopsis of the global and intra-national U.S trends, including 
factors that fuel the HIV epidemic and an introduction to antiviral treatment as 
prevention. The literature review transitions into the second section by 
introducing the 2014 Centers for Disease Control and Prevention guidelines for 
PrEP use indications for women and other high-risk populations. The third 
section provides a review of PrEP studies and the impact on women in the U.S. 
and Africa. Although the review focuses on female-focused studies, PrEP uptake 
in the U.S. represents a broader look at the diffusion of PrEP as an innovation in 
the U.S. The final section introduces three theoretical frameworks used to 
underpin the dissertation and ties together the literature review, coding and 
synthesis and results to each of the theoretical frameworks. 
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Overview of Descriptive Epidemiology of 
HIV/AIDS Globally and in the United States 
Global Prevalence 
The HIV epidemic has disproportionately affected the world’s poorest and 
most disadvantaged regional populations. According to The Joint United Nations 
Programme on HIV/AIDS (UNAIDS, 2017a), in 2016, Eastern and Southern 
Africa is considered the epicenter of the impact of HIV/AIDS and accounts for 
52.9% of the people living with HIV globally, and over 43% of all new infections. 
Although Latin American and the Caribbean have an HIV burden of 2.1 million 
people, because of smaller population size, the region is second only to Eastern 
and Southern Africa as carrying the heaviest HIV burden. Country-level 
epidemiological data show that, compared with Western countries, East and 
Southern parts of Africa continue to be the most affected by HIV, with higher 
prevalence, higher incidence, higher morbidity, and greater rates of mortality 
coupled with a lower number of persons on treatment. 
Time Trends in the U.S. 
Despite progress in the U.S., there remain significant racial and ethnic 
disparities in HIV infections in the U.S. Racial and ethnic and sexual minorities 
are disproportionately burdened by HIV infection and remain at substantial 
increased risk of HIV infection. Within the African American population, the 
burden of HIV is significantly higher and outpaces all other racial and ethnic 
populations. African Americans account for 44% of new diagnoses, more than 
any other racial and ethnic group, according to the CDC (2016a). 
The number of new HIV infections in the U.S. has been steadily declining 
since the mid-1980s. At the height of the HIV epidemic, the CDC (2016b) 
estimated that new infections peaked at 130,000 cases during 1985. By the 
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2000s, new HIV diagnoses remained relatively steady at 50,000 new infections 
per annum until for the first time the number of new diagnoses fell to their lowest 
ever recorded number of 39,513 in 2015 (CDC, 2016a). Just under 1 million 
people are living with HIV/AIDS in the U.S., and this will continue to increase as 
people access treatment, care, and prevention services and are able to live 
longer. 
The Intra-national Comparisons 
According to the CDC (2016c), lifetime risk of HIV diagnosis is highest in 
the District of Columbia, followed by Maryland, Georgia, Florida, Louisiana, New 
York, Texas, New Jersey, Mississippi, South Carolina, North Carolina, Delaware, 
and Alabama. Rates of HIV and AIDS diagnoses are higher in the South (CDC, 
2016c), and the “Southern states account for approximately 44% of people living 
with an HIV diagnosis” in the U.S. (CDC, 2016c). The Southern states not only 
carry a higher intra-national HIV infection burden, but they also account for 
higher rates of HIV/AIDS-related morbidity and mortality compared to other 
states. Additionally, according to the CDC, there are also more people living in 
the Southern states who are not aware of their HIV status (CDC, 2016c). In the 
four regions in the U.S., 55% of new HIV diagnoses occur in the Southern states 
among African Americans (see Figure 1), a significantly higher rate for a single 
racial group compared to any other region in the U.S. The Hispanic/Latino 
population primarily carries the burden of new HIV diagnoses in the West. 
Outside of the South, the Midwest region continues to widen the levels of 
disparity of HIV among racial and ethnic groups. Although African Americans 
comprise 10.3% of the population in the Midwest (Race and Ethnicity in the 
Midwest, 2015), they are weighted with 47% of HIV diagnoses. Of the four 
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Figure 1. Diagnoses of HIV Infection in the U.S. in 2015 by Race/Ethnicity and 
Region. Source: Adapted from HIV in the United States by Geographic 
Distribution, Centers for Disease Control and Prevention (2016c). 
 
The CDC (2014b) uses the Office of Management and Budget (OMB) 
metropolitan statistical areas (MSAs) to define metropolitan and non-metropolitan 
areas. Rural or non-metropolitan areas are described as areas with fewer than 
50,000 people, while urban and large metropolitan areas range from 50,000 to 
over 500,000 people in a given area. In the U.S., HIV tends to be more prevalent 
in urban areas compared with rural areas. According to the CDC (2014b), in 
2014, non-metropolitan areas accounted for a rate of 6.4% of people diagnosed 
with HIV compared with urban areas with an inordinately high rate of 20.1% of 
people with an HIV diagnoses. 
The population most affected by HIV does not change throughout the 
MSAs; however, it is important to note higher rates of HIV incidence among the 
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Hispanic population in urban areas. Rural-urban differences are seen in the 
Southern states such as in Florida, where only 3% of people living with HIV 
reside in rural areas compared to 97% who live in urban areas (Florida 
Department of Health, 2013). Compared to rural areas, urban areas in the larger 
cities tend to offer more HIV-related services, including HIV testing, treatment 
and medication coverage, as well as support services. 
Local (New York) Comparisons 
In 2016, there were 2,881 new HIV infections in the State of New York 
(NYSDOH, 2017). New York City accounted for 2,279 of all new HIV infections in 
2016 (NYC DOHMH, 2017). Based on the HIV epidemic in New York City, there 
remain differences of HIV prevalence among the five boroughs. HIV diagnosis is 
generally distributed across racial and ethnic lines, with African Americans 
accounting for 43.5% and Hispanics 33.7% (NYC DOHMH, 2017). Brooklyn 
leads the boroughs of New York City with the highest rate of 25.5%, followed by 
Bronx (22.8%), Manhattan (20.5%), and Queens (18.2%). Staten Island has a 
significantly lower rate of HIV diagnosis of 2.7%, an incredibly small rate 
considering the local HIV epidemic (NYC DOHMH, 2017). 
According to the 2016 surveillance report for New York City, racial and 
ethnic disparities among women with new HIV diagnoses are tremendously 
disproportionate. Black women had over 14 times higher rates for HIV diagnosis 
compared to White women and had 2.7 times higher rates than Hispanic/Latina 
women (NYC DOHMH, 2017, p. 5). 
Although the HIV epidemic has slowed its trajectory, it has had a 
disproportionate effect on African Americans, MSM (men who have sex with 
men) of color, people of trans experience, young people, and people who had a 
prior/existing sexually transmitted infection (STI). African Americans comprise the 
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largest number of persons diagnosed with HIV (44%), outpacing all other racial 
and ethnic populations in the U.S., according to the CDC (2016a). Additionally, 
MSM accounted for 67% of all persons diagnosed with HIV in 2016 (CDC, 
2016a). This statistic ties closely with the transmission rates and risk factors for 
acquiring HIV, as unprotected anal sex carries a higher risk of HIV transmission, 
second only to blood transfusion, which is no longer considered a high-risk factor 
in the United States (CDC, 2016b). 
HIV Risk Factors in the U.S. 
Age and current STI diagnoses significantly increase the risk of HIV 
infection in the U.S. According to the CDC (2016b), people aged 13-24 years 
accounted for 1-in-5 new HIV diagnoses in 2014. In addition, people within this 
age group are at even higher risk if they practice anal sex. MSM and bisexual 
males aged 13-24 years account for 80% of new HIV diagnoses (CDC, 2016b). 
Furthermore, people engaging in unprotected sexual acts, having multiple 
partners, or engaging in sexual acts while under the influence of drugs and/or 
alcohol increase risk of both STI and HIV infection (CDC, 2016b). The 
transmission of HIV often occurs as a result of breaks or sores in the genital 
areas, elevating HIV risk for people with STIs. 
Social determinants of health can predict and compound the impact of HIV 
transmission. These include income, education, peer support, accessing health 
services, and economic status for persons at higher risk of getting HIV. Other 
studies have found higher rates of unemployment and low income were 
associated with new HIV diagnosis among Black MSM (Mayer et al., 2014). 
According to Forsyth and Valdiserri (2015), local studies have found higher rates 
of AIDS diagnosis among MSM who experience wider income inequalities. They 
noted, however, that the presence of protective social factors such as peer 
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support is associated with lower rates of new HIV diagnosis among MSM. 
Further enabling support services such as attainment of education (skills, 
qualification, knowledge) and treatment of an HIV-infected partner to reduce HIV 
transmission have been cited among protective factors from HIV/AIDS (Zhu 
et al., 2015). 
Although the rates of HIV transmission by people who inject drugs have 
significantly declined, there remains increased risk of HIV transmission during 
sexual events while persons were under the influence of drugs. Mayer et al. 
(2014) found that 47% of their participants (MSM, MSM of color, general 
population) indicated using drugs and/or alcohol during their last anal sex 
encounter. The study raised a perennial issue in public health around sexual 
behaviors, namely the reduction in condom use during sexual encounters. 
Frequency of sexual acts and condom use impact HIV transmission (Zhu 
et al., 2015). Condom use has been shown to have high efficacy levels in 
protecting against HIV transmission. More recent HIV prevention messages are 
encouraging the concurrent use of condoms and other forms of protection 
(Goparaju et al., 2015). 
Emergence of Antiviral Medication 
The year 1996 brought advancement in the treatment of people living with 
HIV/AIDS. Treatment as prevention (TasP) is one of several effective strategies 
used to slow/counter-act the HIV epidemic worldwide. In the latest 2016 
recommendations of the International Antiviral Society-USA, “all HIV-infected 
individuals with detectable viremia, regardless of their CD4 cell count, should 
begin antiretroviral therapy (ART) as soon as possible after diagnosis to prevent 
disease progression, improve clinical outcomes, and limit transmission” 
(Günthard et al., 2016, p. 192). The evolution of treatment has become 
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prominent and vital to sustain HIV gains and reverse the epidemic. However, 
engaging individuals at greatest risk of getting HIV continues to be a challenge. 
As evidenced by their determination to end AIDS, many United States public 
health institutions have expanded the continuum of HIV care to include HIV-
negative individuals at substantial risk of getting HIV. The emergence of a drug to 
protect HIV-negative people from HIV is the newest biomedical HIV intervention 
available in medical settings. While not a vaccine, antiretroviral pre-exposure 
prophylaxis (PrEP) is “tailored for individuals who have a recurring risk of being 
infected with HIV” (Mayer, Krakower, & Boswell, 2016, p. 867). Pre-exposure 
prophylaxis (PrEP) is the taking of oral “tenofovir daily, with or without 
emtricitabine,” which was shown to be “protective in trials involving heterosexual 
HIV-discordant African couples, men who have sex with men, transgender 
women, and injecting drug users” (Mayer et al., 2016, p. 867). 
Current (2014) CDC Clinical Practice Guidelines for PrEP 
In 2014, the CDC published the U.S. Public Health Service’s Clinical 
Practice Guideline for Pre-Exposure Prophylaxis for the Prevention of HIV 
Infection in the United States (CDC, 2014a). The guideline summarizes PrEP 
clinical trial evidence across the three priority risk groups in the U.S. (MSM, 
injecting drug users [IDU], and heterosexual men and women). Although the 
guideline equips providers with steps to prescribe PrEP, there is also support for 
special populations such as women who become pregnant or who breastfeed 
while using PrEP, adolescent care and people diagnosed with chronic renal 




Recommended Questionnaire Used to Screen Heterosexual Women for 
PrEP (CDC, 2014a, p. 27) 
In the past 6 months:  
• Have you had sex with men, women, or both?  
• (if opposite sex or both sexes) How many men/women have you had 
sex with? 
• How many times did you have vaginal or anal sex when neither you nor 
your partner wore a condom?  
• How many of your sex partners were HIV-positive?  
• (if any positive) With these HIV-positive partners, how many times did 
you have vaginal or anal sex without a condom?  
Guidelines Provided for Additional Risk Factors (CDC, 2014a, p. 27) 
• For all sexually active patients, clinicians may want to consider reports 
of diagnoses of bacterial STIs (chlamydia, syphilis, gonorrhea) during 
the past 6 months as evidence of sexual activity that could result in HIV 
exposure. For heterosexual women and men, sex without a condom (or 
its correct use) may also be indicated by recent pregnancy of a female 
patient or sexual partner of a male patient.  
• Clinicians should also briefly screen all patients for alcohol abuse 
(especially before sexual activity) and the use of illicit non-injection 
drugs (e.g., amyl nitrite, stimulants). The use of these substances may 
affect sexual risk behavior, hepatic or renal health, or medication 
adherence, any of which may affect decisions about the 
appropriateness of prescribing PrEP medication. In addition, if 
substance abuse is reported, the clinician should provide referral for 
appropriate treatment or harm-reduction services acceptable to the 
patient.  
• Lastly, clinicians should consider the epidemiologic context of the 
sexual practices reported by the patient. The risk of HIV acquisition is 
determined by both the frequency of specific sexual practices (e.g., 
unprotected anal intercourse) and the likelihood that a sex partner has 
HIV infection. The same behaviors when reported as occurring in 
communities and demographic populations with high HIV prevalence or 
occurring with partners known to have HIV infection, are more likely to 
result in exposure to HIV and so will indicate greater need for intensive 
risk- reduction methods (PrEP, multisession behavioral counseling) than 
when they occur in a community or population with low HIV prevalence.  
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Recommended Indications for PrEP Use by Heterosexually Active Men and 
Women (CDC, 2014a, p. 29) 
• Adult person 
• Without acute or established HIV infection  
• Any sex with opposite sex partners in past 6 months  
• Not in a monogamous partnership with a recently tested HIV-negative 
partner  
AND at least one of the following  
• Is a man who has sex with both women and men (behaviorally bisexual) 
• Infrequently uses condoms during sex with 1 or more partners of 
unknown HIV status who are known to be at substantial risk of HIV 
infection (IDU or bisexual male partner)  
• Is in an ongoing sexual relationship with an HIV-positive partner.  
U.S. Women Who Have Indications for PrEP 
Smith et al. (2015) provided a huge breakthrough in understanding the 
context and providing researchers with a baseline for the estimated number of 
U.S. women who have indications for PrEP based on the CDC 2014 PrEP clinical 
guideline. Smith et al. analyzed national level population-based surveys to 
estimate the percentages and numbers of persons with indications for PrEP in 
each of three “transmission-risk populations” (p. 1292). Smith et al. utilized two 
primary surveys to determine national estimates for the analysis were the 
National Health and Nutrition Examination Survey (NHANES) and the National 
Survey on Drug Use and Health (NSDUH). The CDC used three risk categories 
including: MSM, heterosexually active adults, and persons who inject drugs. To 
estimate prevalence, the CDC 2014 guideline indications of PrEP eligibility 
among the risk categories were used to define the size of the target populations. 
More narrowly, to estimate the number of heterosexually active men and women 
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at risk of HIV who were between the age 18 to 59 years and therefore in need of 
PrEP, Smith et al. utilized three years of data from NHANES and also 2013 data 
from National Survey of Family Growth. The National Survey of Family Growth 
data included the number of men and women aged 18 to 44 years who “reported 
sex with two or more opposite sex partners and either of the following: 1) sex 
with an HIV-infected partner; or 2) sex without a condom in the past 4 weeks and 
sex with a high-risk partner in the past 12 months” (p. 1292). For women, the 
study defined high-risk partners as male partners known to also have sex with 
men (behaviorally bisexual). 
According to Smith et al. (2015), 0.4% of heterosexually active adults aged 
18–59 years is estimated to have indications for PrEP (624,000 [CI = 404,000–
846,000]) (p. 1292). Among heterosexually active women, an estimated 468,000 
women have indications for PrEP based on the CDC 2014 clinical practice 
guideline. Although 468,000 women represent a high absolute number, despite 
the results, the overall percentage of 0.4 is low. 
Female-Controlled PrEP Modalities 
A PrEP-informed decision can support women to assert their sexual health 
rights. In a male dominated society, a woman’s decision to assert her sexual 
rights can be manifested in many ways. Of most importance, is making a 
decision that works for the woman, regarding using the most affordable and 
effective HIV prevention method available. 
Although fewer studies focus on women and PrEP, of those studies that 
actually chronicle PrEP and women stories, the concentration is on adherence 
and only a negligible number of studies actually report women and their 
intersections with PrEP uptake. It is therefore relevant to explore these limited 
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studies to capture the barriers to PrEP adherence, and to discover issues relating 
to low PrEP uptake and their influence on adherence among women. 
Based on a review, despite the paucity of studies, the single most 
documented concern for women taking PrEP has been adherence difficulties. 
Studies report (Marrazzo et al., 2015; Van Damme et al., 2012) that taking a daily 
pill is inherently challenging for women. Longer acting formulations have been 
proven positive in increasing adherence by preventing common issues such as 
“missing doses or treatment fatigue to prescribed medication” (Boffito, Jackson, 
Owen, & Becker, 2014, p. 7). Although several clinical studies in Africa, Europe, 
and the U.S. have shown promising results in PrEP for women in forms such as 
injectable, topical (gel), vaginal tablets and vaginal rings, in the U.S. the only 
approved medication to prevent HIV-negative women from HIV transmission is 
limited to the oral formulation of the medication. Over the next few years, 
American women may have longer acting formulation PrEP options from which to 
choose the best lifestyle method and prevention needs. Importantly, these long 
acting forms are seeking to provide protection not only against HIV but also other 
STIs and unwanted pregnancies (Guthrie et al., 2015; McConville, Major, Devlin, 
& Brimer, 2016). 
CAPRISA 004 was a double-blind two arm randomized placebo-control 
microbicide trial conducted in KwaZulu-Natal, South Africa between May 2007 to 
March 2010. According to Karim et al. (2010), HIV-negative women between 18 
and 40 years were recruited from an urban STD clinic and rural family planning 
clinics to participate in the study. The study’s aim was to assess the 
effectiveness and safety of 1% tenofovir gel in preventing HIV infection among 
women. Almost three times as many women were recruited from the rural clinic 
research site (Karim et al., 2011) with a total of 445 women randomly assigned to 
the tenofovir gel group and 444 women assigned to the placebo group. To 
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ensure optimal effectiveness of the tenofovir gel, based on previous studies 
especially successful outcomes from mother-to-child reduction strategies, women 
were asked to dose “before and after” sex acts (Karim et al., 2010, p. 3). The 
dosing strategy, as referred by Karim et al. (2010), was called “BAT24,” which 
meant women were to insert one dose of gel “within 12- hours before sex and a 
second dose of gel” within “12 hours after sex” but “no more than two doses of 
gel in a 24-hour period” (p. 4). The study calculated gel adherence by three 
measures: (1) returned used applicator adherence—the number of used 
applicators returned to the research site monthly by each woman; (2) self-
reported adherence—women answered questions relating to the number of sex 
acts including the last day they had sex to determine the use of the “BAT24” 
strategy; and (3) applicator-based adherence—the primary measure of 
adherence. This was calculated by the “dividing the number of reported sex acts 
per month by half the number of returned used applicators for that month” 
(Mansoor et al., 2014, p. 815). 
A total of 98 women sero-converted during the study, 38 new HIV 
diagnoses in the tenofovir gel arm and 60 new diagnoses in the placebo gel arm 
(Karim et al., 2010). Interestingly, self-reported gel adherence was exceptionally 
high (97.4%), with 95.2% of applicators returned during the study. The reported 
findings showed that among the 336 women considered high gel adherers, their 
HIV incidence decreased by 54% in the tenofovir gel arm compared to 
intermediate gel adherers, who experienced a 38% lower HIV incidence, and 
28% lower HIV incidence for low gel adherers (Karim et al., 2010). Although 
safety was high, participants reported adverse events during the study. Diarrhea 
was more common among women in the tenofovir gel arm than in the placebo 
gel arm. There was one death occurring in the study, which was reported as 
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unrelated to the study. No reports of renal toxicity, an important tenofovir-related 
safety concern, were found in the study. 
A limitation of this study is the sample population used, which limits the 
generalizability of the study. The study does show the effectiveness of 1% 
tenofovir gel in reducing HIV infection among at risk women in need of HIV 
prevention (Karim et al., 2010). 
Dapivirine vaginal ring is another female-controlled HIV prevention PrEP 
option for women. Developed by the International Partnership for Microbicides 
(IPM), the vaginal ring is a monthly, self-inserted ring with “sustained release of 
antiretroviral drugs (dapivirine) over time” that protects women against HIV 
infection (Nel et al., 2016, p. 2134). Across seven sites in South Africa and 
Uganda, Nel et al. conducted a phase 3 randomized, double-blind placebo-
controlled study of 1,957 HIV-negative women aged 18 to 45 years with a 2:1 
ratio of treatment to placebo assignment. The aim of the study was to evaluate 
the “safety and efficacy of extended use of a vaginal ring containing dapivirine for 
the prevention of HIV infection” (p. 2133). The ring contained 25 mg of dapivirine 
with the rings (dapivirine and placebo) constructed of “platinum-catalyzed silicone 
matrix” (p. 2134). With replacement rings provided every 4 weeks or 28 days, 
1,307 and 652 women were assigned to the dapivirine and placebo arms, 
respectively, over 24 months. 
According to Nel et al. (2016), one research site discontinued the study, 
affecting 29.8% of participants, because of observed non-adherence and high 
rates of non-compliance with the study protocol (p. 2136), resulting in higher 
sero-conversion. Other factors for discontinuation included relocations, 
withdrawal of consent, and pregnancy. 
The results identified 3.6 and 5.4 sero-conversions per 100 person-years in 
the dapivirine (excluding the discontinued research site) and the placebo groups, 
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respectively. According to Nel et al. (2016), in actual numbers, there were 77 
women who sero-converted in the dapivirine group and 56 in the placebo group. 
Dapivirine was effectively shown to lower HIV infection by 31% in the dapivirine 
group compared to the placebo group. Age was a determining factor in 
effectiveness of the dapivirine ring. Women over 21 years in the dapivirine group 
experienced a 37% lower rate of HIV infection, and women younger than 21 
years experienced a 15% lower rate (Nel et al., 2016). Factors possibly 
contributing to higher sero-conversion rates among younger women were more 
frequent vaginal or anal sex, higher rates of non-adherence and physiological 
differences in the genital tract or a combination of these factors. 
The appropriateness of the pre-specified criteria based on plasma 
concentrations and residual dapivirine in the used ring was questioned, as it 
indicates adherence. Suggestions that the pre-specified criteria may have over-
estimated adherence because the quick release of dapivirine in the plasma only 
after 1 hour of ring insertion could have misled the criteria for adherence. 
Although further work is needed to determine the appropriate level of both 
plasma and dapivirine needed to provide greater HIV protection against HIV 
infection, studies have begun examining extended duration of vaginal rings from 
28 days to 60 and 90 days (Boyd et al., 2016). 
A large-scale study HPTN 083 has started recruiting adults in 2016 through 
a double-blind safety and efficacy study of injectable cabotegravir for PrEP 
(HPTN 083, 2017). The study will compare the incidence of HIV infection among 
people using Cabotegravir and tenofovir/emtricitabine in long-lasting injectable 
and oral forms taken at 4 weeks and 8 weeks apart. The study design is 
projected at 4.5 years, extending to four countries: U.S., Brazil, India, and South 
Africa, recruiting 4,500 MSM and trans-female (TMF) in the target study 
population with an equal number randomized in each arm of the study 
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(HPTN 083, 2017, p. 42). Although women are not included in this phase of the 
trial, the data from the target participants, HIV-negative men, and transgender 
women who have sex with men are significant to support clinical research in 
injectable PrEP for women. 
Intimate Partner Violence 
The use of barrier protection to prevent HIV, STIs, or unwanted 
pregnancies varies across relationships. For some women, male partners are the 
sole decision-makers in determining the “course of the sexual relationship and 
whether or not they used barrier protection” (Choi, Wojcicki, & Valencia-Garcia, 
2004, p. 257). Framing PrEP into the wider social context for women is important 
in reducing their risk for HIV and increasing the benefits afforded to them through 
this method. As a female-controlled prevention strategy, PrEP provides higher 
levels of efficacy beyond those of vaginal microbicides and diaphragms and 
removes the need for partner consent as with female condoms (Braksmajer, 
Senn, & McMahon, 2016). According to Braksmajer et al., critical advantages of 
PrEP for women experiencing intimate partner violence (IPV) or male-dominated 
relationships, are the “potential covert or autonomous use, coital independence, 
dual protection against sexual and injection HIV risk, and facilitated connections 
to social services” (p. 276). 
Garfinkel, Alexander, McDonald-Mosley, Willie, and Decker (2016) 
conducted a study at two family planning clinics in Baltimore City and in one of its 
northern suburbs between January and April of 2014. Women aged 18 and 35 
years were recruited during their clinic visit resulting in 75 women participating 
from the Baltimore City and 71 from northern suburb sites. A 15-minute self-
administered survey was administered using Audio Computer Assisted Survey 
Instrument (ACASI). Major survey categories included “demographics, health 
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care seeking patterns, sexual and reproductive health behavior, violence 
experiences and access to and engagement with local support services” (p. 752). 
According to the authors, over 50% of the sample was Black (51.4%), with 
38.4% White and 10.3% identified as multicultural. A total of 67% of the 
participants either had some college experience or finished college. 
Approximately half of the participants had a previous HIV test but not in the last 
3 months, while 36.6% indicated being tested within 3 months; but 14.5% 
indicated that they never had an HIV test. Of the 38.4% with a history of IPV, 
25% indicated that they were worried about HIV, which, according to Garfinkel 
et al. (2016), highlights the need for PrEP within this population of women. In an 
incongruent manner, however, IPV affected women were less likely to accept 
PrEP (57.14%) compared to non-IPV participants (62.22%). This was an area of 
concern for Garfinkel et al., indicating the need to address violence and trauma 
to improve HIV outcomes for women as a national priority (p. 754). 
Women experiencing IPV, as aptly described by Garfinkel et al. (2016), do 
face trauma, a barrier to protection, including prevention approaches to HIV. In 
addition, other barriers faced by women IPV-affected survivors that affect PrEP 
uptake and adherence include partner resistance, difficulties with covert use, cost 
(particularly outside New York State), and gendered norms regarding sexuality. 
U.S.–based Pre-exposure Prophylaxis Studies 
Kwakwa et al. (2016) conducted a study in eight Federally Qualified Health 
Centers in Philadelphia to determine the openness to PrEP in African American 
adults in Philadelphia. The study recruited 5,606 men and women between May 
2012 and December 2014. The PrEP openness survey was administered by 
rapid testers during the voluntary acceptance of HIV rapid tests. Although 9 
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African American women tested positive for HIV during the length of the study, 
none of these women perceived their risk as moderate or high for an HIV 
infection. Similarly, 26 African American men tested HIV positive, but only 19.2% 
of these perceived their risk as moderate or high-risk of getting a HIV infection. 
Kwakwa et al. reported that of the women who tested HIV positive, 44.4% 
expressed disinterest in PrEP, while 46.2% of men testing HIV positive 
expressed disinterest in PrEP prior to the results being known. 
According to Kwakwa et al. (2016), African American women and men 
expressing disinterest in PrEP had as their main reasons low risk perception, 
medication concerns, and preference for other methods (condoms). Unlike men, 
women found celibacy as more of a reason than men. Where men indicated 
distrust as a reason for not being open to PrEP, this appeared not to be a 
concern for women (p. 1447). Participants indicated three primary reasons for 
openness to PrEP: fear of HIV, importance of a prevention strategy, and high-risk 
perception.  
Smith et al. (2012) conducted one of the first qualitative studies by focus 
group to “elicit attitudes about, and preferences for, PrEP services from inner-
city, African American young adult men and women at risk for HIV transmission” 
because of both sexual and drug-related behaviors (p. 411). Of the 10 focus 
groups conducted between June and August of 2009 in Atlanta, Georgia, 8 focus 
groups comprising 58 people were mixed-gender and two MSM-only focus 
groups comprising 19 men. The study utilized audio recording, which was 
transcribed verbatim and uploaded in NVivo analysis software (QSR International 
Pty Ltd. Version 8, 2008). 
Of the five themes identified in the focus groups, barriers to PrEP uptake 
and maintenance received noted attention. According to Smith et al. (2012), 
barriers to PrEP uptake included “side effects, medication cost, partial 
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effectiveness, low perceived personal susceptibility to contracting HIV, burden of 
taking a daily medication, reaction of peers to taking HIV medication, and for the 
MSM groups only, fear of risk compensation (decrease use of condoms and 
other safer sex practices)” (p. 413). The study found the importance of scaling up 
efforts for continuing education and counseling about PrEP in high-risk, African 
American young men and women. 
Wingood et al. (2013) conducted a nationally representative, random-digit 
telephone dial household survey of 1,042 African American women and 411 
White women aged 20-45 years in the U.S. between October 2006 and May 
2007. In an attempt to oversample African Americans, a dual-frame sampling 
design was used in which the larger frame looked at counties with 10% or greater 
African American and White population while the smaller frame targeted high 
density counties where African American women exceeded 7% greater. 
According to Wingood et al. (2013), women who were more likely to report 
potential use of PrEP were of lower socioeconomic status and less educated, 
with a high school completion or less. Compared with women having at least a 
college education, less educated women had 2.04 times higher odds of 
potentially using PrEP. Compared with women with full-time jobs, unemployed 
women had 1.8 times higher odds of potential use PrEP. African American 
women were significantly more likely to report potential PrEP use compared to 
White women, 69.1% and 54.2%, respectively (p. 98). Peer and provider 
influences were significant factors in PrEP use in African American women. 
According to Wingood et al., compared with White women, “African American 
women were 2.2 times as likely to report potential PrEP use” if their friends are 
perceived to also use PrEP (P ≤ 0.001) and “1.65 times as likely to report 
potential PrEP use if it was recommended by a health-care provider” (p. 99). One 
major limitation of the study was that it was conducted early in the PrEP clinical 
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trials and before FDA licensure of PrEP. This could have significant impact on 
the applicability of the findings for African American and White women in a PrEP- 
FDA-approved era and where significant scale-up and PrEP education has taken 
place. 
While not specifically about PrEP, the study by Flash et al. (2014) has 
relevance. They recruited 26 Black women aged 20-50 years from the Dimock 
Community Health Center and 15 affiliated sites located in Boston, 
Massachusetts to participate in five focus groups. Women responded to flyers 
posted in the waiting rooms of the health centers and self-identified as Black 
female. During the 2-hour focus group, participants completed demographic 
surveys, recording age, race, education, HIV risk perception, focus group 
experience, zip code. The facilitator utilized a semi-structured discussion guide 
that focused on “HIV risk perception and perception of the ideal prevention 
strategy” (p. 636). 
In heterosexual women, risky sexual behaviors included “barriers to 
condom use because of fear of perceived unfaithfulness, financial barriers, 
personal perception of being low-risk, educational status, desire to conceive, and 
intimate partner violence” (Flash et al., 2014, p. 635). Using the theory of Gender 
and Power, categories of “sexual division of labor, structure of cathexis and 
sexual division of power are examined in relation to HIV-related exposures, risk 
factors and effective interventions for women” (p. 635). According to Flash et al., 
although women found condoms to be an effective and low-cost HIV prevention 
method, women have to negotiate condom use, highlighting the sexual division of 
power. The women reported the need for a “female-controlled strategy” as an 
ideal prevention strategy (p. 637). Oral PrEP was found to satisfy the definition of 
“female-controlled” because of the “perception that it offered greater potential for 
undisclosed use” and also because PrEP complements “condoms, needle-
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exchange behavioral strategies and enhanced testing” (p. 639). To emphasize 
the point, one participant was quoted as saying: 
I don’t think you should trust anyone even if you are married, or 
something like that. I mean you should, because it’s like your partner 
but, they can step out of the marriage just like a single person. You 
should use a condom regardless of anything. (p. 637) 
Whiteside, Harris, Scanlon, Clarkson, and Duffus (2011) conducted a 
cross-sectional study in 2009 and 2010 at a South Carolina STD clinic with 
attendees who had an appointment or walked into the clinic for services. A 
20-minute self-administered paper questionnaire was completed by 405 
participants, each of whom received a $20 incentive to show gratitude for their 
participation. Inclusion criteria included being over the age of 16 years, reported 
sex within the past 6 months, self-reported HIV-negative status, seeking STD 
services and not previously completing the questionnaire. The questionnaire 
used a Likert scale to rate questions that determined participants’ risk 
perceptions and knowledge of PrEP. Unlike many other studies assessing risk 
perception and PrEP awareness, this study included a predominately 
heterosexual sample (90%). A total of 89% of the participants identified as 
African American, with 52% of the participants aged 17-24 years and 53% with 
college education. Interestingly, among participants reporting multiple sex 
partners (2-4 partners) in the past 3 months, they were 2.35 times as likely to 
have a “lower level of agreement” with the statement, “I believe I am at risk of 
getting HIV” compared to participants reporting 1 sexual partner in the past 3 
months (p. 367). The study found women to be more receptive than men to using 
dual protection in the form of condoms and daily-PrEP to reduce HIV infections. 
An equally important finding was that over 81% of the participants indicated they 
were not aware of PrEP. 
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Goparaju et al. (2015) conducted a unique study involving both HIV-
negative and HIV-positive women that focused on their “knowledge, attitudes, 
and potential behaviors (KAB) of biomedical prevention strategies, namely, PrEP 
and Treatment as Prevention (TasP)” (p. 3). This study was conducted among 
the Women’s Interagency HIV Study (WIHS) in Washington, DC. At the time of 
publication, WIHS was the “largest prospective, observational qualitative study of 
HIV-infected and at-risk HIV- uninfected women in the U.S” (p. 3). The 
Washington, DC arm of the study conducted eight focus groups segregated 
equally by sero-status, which were conducted from February to May 2014. A total 
of 39 women participated, 20 HIV-negative and 19 HIV-positive, aged 31 to 62 
years, with the median age being 49 years. African American was the major race 
involved in the study, representing 80% in the HIV-negative group and 100% in 
the HIV-positive group. Risk assessment at intake revealed that only 25% of HIV-
negative women reported using a condom in the last 6 months and 95%-100% of 
HIV-positive women reported being adherent to antiretroviral medication in the 
last 6 months. To allow comparison, both sero-status focus groups addressed 
the same topics. Topics discussed included, “HIV-negative women’s experiences 
with HIV; perceptions of their own risk of HIV infection; HIV-negative and HIV-
positive women’s awareness of PrEP; acceptability of PrEP; preferred HIV 
prevention method; concerns about the PrEP package; and potential target 
groups for PrEP outreach” (p. 4). The focus groups were digitally recorded with 
verbatim transcription. The study utilized NVivo 10 qualitative analysis software. 
Using the KAB measures, codes included knowledge, attitude and potential 
behaviors with inter-coder reliability conducted by two investigators. 
Goparaju et al. (2015) found almost polar opposites between sero-status 
groups concerning PrEP. Although HIV-negative women were excited to learn 
about PrEP, HIV-positive women were less enthusiastic and gave caution to its 
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use. All HIV-negative women perceived themselves to be at risk of HIV and all 
were closely impacted by the HIV epidemic. Combination of PrEP plus condom 
was viewed as the best prevention approach by HIV-negative women, while 
“HIV-positive women preferred condoms alone” (p. 4). The researchers found 
extremely low level of PrEP awareness across both sero-status groups. Although 
all participants were briefed on PrEP before the focus group sessions, the study 
noted that of the 39 participants, only 5 had previously heard about PrEP: 4 sero-
positive and 1 sero-negative woman. Importantly, the 1 sero-negative woman 
who previously heard about PrEP, understood PrEP use in the context of gay 
men protection but did not know it could be used to protect women. This speaks 
to the extremely slow diffusion of PrEP into the lives of priority populations (since 
PrEP was approved in the U.S. in 2012). The sero-negative women’s awareness 
of PrEP was in the “context of gay men” and most of the women did not know 
PrEP “could work for women too” (p. 6). An interesting observation was made by 
the sero-negative women, who mentioned that PrEP is asking for “too much 
commitment,” particularly for young adults and that it may be “difficult to convince 
young adults to follow the PrEP regimen” (p. 19). 
U.S. Clinicians' Attitude, Knowledge, and Prescribing Practices 
Clinicians are important in the narrative of successful PrEP implementation. 
Understanding providers’ knowledge, attitudes, willingness and current PrEP 
prescribing practices as well as “perceived assessment of potential barriers” are 
critical aspects of any PrEP conversation (Blumenthal et al., 2015, p. 803). 
Blumenthal et al. (2015) conducted a study to compare HIV and non-HIV 
providers to: (a) quantify PrEP knowledge, (b) determine the current rate of PrEP 
prescription, (c) evaluate attitudes toward future PrEP provision, and 
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(d) determine barriers and motivators to PrEP provision (p. 803). A total of 122 
HIV providers and 111 non-HIV providers were recruited from three U.S. cities, 
New York, San Diego, and Los Angeles, while attending the International AIDS 
Society meeting in New York, AIDS rounds at University of California San Diego 
(UCSD), Grand Rounds at UCSD and Scripps Mercy Hospital. Individual provider 
targeting was conducted, during their office hours, for providers who did not 
attend these settings. Touchscreen tablet technology was used to self-
administered a 35-question survey to assess providers’ knowledge about PrEP. 
Although the majority of respondents were identified as from Southern 
California (70%), 27% were stretched across New York, New Jersey, and 
Connecticut. Race and ethnicity of providers who participated in the study 
included: White (52%), Asian (19%), non-Hispanic (70%) and Black (7%) 
(Blumenthal et al., 2015, p. 805). The study had roughly an equal spread of HIV 
and non-HIV providers, 52% and 48%, respectively (p. 806). Providers in the 
New York tri-state area were more likely to have prescribed PrEP compared to 
providers in Southern California. While 21% of eligible prescribing providers 
reported giving a PrEP prescription, 64% indicated their willingness to prescribe 
PrEP in the future. There was an association found in providers who gave a 
PrEP prescription and providers who were older, were “private practitioners,” 
completed patient sexual histories, had “higher knowledge scores,” and who “felt 
most comfortable determining PrEP candidacy” (p. 805). 
Perceived barriers have been cited as limitation to prescribing PrEP by 
providers. Blumenthal et al. (2015) found that over 80% of providers wanted 
more evidence from studies and recommendations from CDC (as this study was 
prior to CDC 2014 guidelines). One-third of HIV providers perceived risk 
compensation as a concern more than non-HIV providers but where both groups 
of providers mutually shared concern it was about cost and insurance coverage 
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as unknown factors should they consider prescribing PrEP. Blumenthal et al. 
(2015) noted an almost equal split in where to prescribe PrEP. Although 35% of 
providers thought HIV clinics were the most fitting of settings to offer PrEP 
services, 31% thought non-HIV clinics were also adequate settings to prescribe 
PrEP to community residents. Interestingly, only 10% thought STD clinics were 
fitting settings to prescribe PrEP, with a higher number of providers (21%) 
supporting public health departments as appropriate settings. 
One of the main limitations to the Blumenthal et al. (2015) study was the 
sampling method. Convenience sampling not only limited the geographical 
regions in the study but it also restricted the generalizability of the study. The 
study drew on people attending an IAS meeting in New York and a AIDS Grand 
Rounds in California, which may have resulted in there being more non-HIV 
providers supportive of HIV prevention, whose responses would not necessarily 
represent non-HIV providers’ attitudes and prescribing practices regarding PrEP 
across the U.S. 
Smith et al. (2016) assessed U.S. primary care providers’ responses to 
Porter Novelli’s annual web-based DocStyles surveys to “determine the strength 
of association between clinicians willing to prescribe PrEP to at least one high-
risk group” and eight clinician characteristics: “age, sex, race/ethnicity, clinician 
specialty, clinician work setting, number of clinicians in practice, number of years 
in practice, having provided anti-retrovirals for post-exposure prophylaxis (PEP) 
or treatment of HIV infection” (p. 3). The high-risk group was inclusive of the CDC 
expanded risk categories to include “PWID, MSM, persons with an existing STD, 
people who change sexual partners frequently, HIV discordant couples, HIV 
discordant couples attempting to conceive” (p. 3). 
Surveys were drawn from two sources over the period of analysis. Although 
in 2009, 2010, 2012 and 2013, DocStyles surveys were drawn from Epocrates 
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Allied Health Panel, 2014 and 2016 surveys were taken from SERMO’s Global 
Medical Panel. The process of double opt-in verification was completed for both 
Panel sources. Interestingly, for the first time in 2012, pharmacists were included 
in the surveys as providers. Response rates for each of the six survey years 
ranged from a low of 34% to a high of 84% among clinicians and nurse 
practitioners across the U.S., resulting in actual numbers surveyed in: 2009 
(n = 1,500), 2010 (n = 1,504), 2012 (n = 1,503), 2013 (n = 1,507), 2014 
(n = 1,508), and 2015 (n = 1,501) (Smith et al., 2016, p. 1). 
From 2009 to 2015, prescribing anti-retroviral medication by providers was 
reported at 24% and 10% for non-occupational and occupational post-exposure 
prophylaxis (PEP), respectively (Smith et al., 2016). Although from 2011 to 2013, 
clinicians reported low exposure to CDC clinical guideline for PrEP use among 
the risk groups, evidence of incremental increase in awareness of the guideline 
increased in 2014 (p. 9). The authors reported a significant increase in 
prescribing PrEP medication over the first three survey years. According to Smith 
et al., in the combined years of 2009, 2010, and 2012, only 1% of clinicians 
prescribed PrEP. There was a steady increase reported in prescribing PrEP 
medication from 4% in 2014 to 7% in 2015. Smith et al. disaggregated the 7% 
data for 2015 to show who received PrEP prescriptions: 73% prescribed for 
MSM, 22% for PWID, 22% for “uninfected men,” 27% for “uninfected women in 
HIV discordant couples during conception attempts,” 45% for “uninfected women 
in an HIV discordant couple not planning conception,” and 30% for “uninfected 
men in this situation” (p. 5). Smith et al. found that clinicians were more willing to 
prescribe PrEP for: “uninfected partner in an HIV discordant couple” (79%), MSM 
(66%) and PWID (63%), “HIV discordant couples planning conception” (61%), 
“persons who change sexual partners frequently” (56%), and “persons with a 
diagnosed STD” (34%) (p. 6). 
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One of the primary limitations of the study was the timing of assessing 
clinicians’ attitudes during the early phase of PrEP roll out in the U.S. The 
effectiveness of PrEP reported in clinical trials ranged from 75% in 2009 to ~90% 
in 2012 to 2015. The study postulates that it “may not be a realistic 
approximation of primary care clinicians’ attitudes in the U.S. in this early phase 
of introducing PrEP as a clinical HIV prevention method” (Smith et al., 2016, 
p. 9). Further studies on clinicians’ knowledge, attitudes, and prescribing 
practices of PrEP as the intervention is scaled-up would be important to monitor. 
In their review of U.S. based studies on serodiscordant heterosexual 
couples, McMahon et al. (2014) identified HIV-sero-discordant couples as the 
most “ideal candidates for PrEP” (p. 464). The authors observe that although 
traditional clinical settings treating HIV patients are uniquely positioned to provide 
PrEP services to partners in sero-discordant relationships, providers in other 
non-traditional settings also present additional opportunities to engage this 
population. 
Additionally, in an opinion-based survey of U.S. and Canadian providers, 
Karris, Beekmann, Mehta, Anderson, and Polgreen (2014) surveyed 1,175 active 
members of the Infectious Diseases Society of America’s (IDSA) “Emerging 
Infections Network (EIN), a provider-based network of infectious disease 
physicians actively involved in clinical practice who belong to IDSA” (p. 705). 
Between June and July of 2013, a 10-question survey was distributed to elicit 
current practices and attitudes related to PrEP among expert HIV providers. 
Encouraging a high response rate, two reminder notices were sent to “non-
respondents at 1-week intervals” (p. 464). A total of 48.8% of participants 
responded to the survey, which was characteristic for the network. Although 
astoundingly, 74% of providers supported the use of PrEP, only 9% ever 
prescribed PrEP in their practice. Of the 74% of providers who supported PrEP, 
  
39 
43% would prescribe PrEP, but 34% believed PrEP was not relevant to their 
practice. Providers identified barriers to providing PrEP in their practice: 77% of 
providers identified adherence and the risk for future resistance, 57% raised the 
issue of “cost and reimbursement” (p. 705), while 53% raised issues of toxicity 
and insufficient evidence to support real-world efficacy of PrEP. 
According to Karris et al. (2014), providers described additional barriers to 
prescribing PrEP. These included risk compensation, noting that limited efficacy 
evidence creates a “false sense of security”; “concerns about irresponsible 
sexual activity”; “lack of resources and information”; insufficient knowledge to feel 
comfortable to prescribe; “lack of effectiveness data in local context”; limited 
resource allocation; HIV “transmission can be prevented without medications”; 
“concern about the selling of PrEP from HIV positives to HIV-negatives”; “moral 
issues”; “medicine should not attempt to reverse bad behaviors artificially”; and 
finally, the “balance is not right in terms of risks/benefits” (p. 705). 
These are two limitations to the study. Firstly, it is a self-selected 
convenience sample. Although the EIN database was used as the sampling 
frame, clinicians who register with the Network may not represent the general 
body of providers in the U.S. and Canada and it raises selection bias as a 
concern. Secondly, the survey received a relatively low response rate, 
compounding the external validity concerns (Karris et al., 2014, p. 711). 
In a recent study, Calabrese et al. (2016) interviewed 18 medical providers 
who prescribed PrEP to one of more patients from September 2014 to February 
2015. These were conducted either by email or in-person interviews lasting 60 to 
90 minutes. The interviews were audio recorded, later transcribed verbatim, and 
analyzed. Of the 18 providers, 88.8% practiced in the Northeast (14) and the 
remainder in the South (4). The study aimed to explore “PrEP providers’ firsthand 
experiences relative to six commonly-cited barriers to prescription—financial 
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coverage, implementation logistics, eligibility determination, adherence concerns, 
side effects, and anticipated behavior change (risk compensation)” (p. 1). Each of 
the six commonly cited barriers was addressed by PrEP prescribing providers 
and their approaches to mitigate these individual challenges. 
Although most providers did not cite financial coverage as a major problem, 
a majority of the providers indicated the diverting of staff and resources to 
paperwork and telephone conversations to maintain patient coverage as an 
issue. Calabrese et al. (2016) quoted a provider who experienced a decline in 
coverage. This individual stated, “bit of a pain in the neck,” although admitting 
that “it’s never been a show stopper” and was “nothing out of proportion with 
what we see on a regular basis with insurance companies” (p. 6). 
Providers demonstrated their flexibility in working with PrEP users through 
a series of examples in which they adjusted patients’ medical visits, the act of 
pill-taking, and adjusted for pregnancy outcomes to address each individual’s 
needs. Although providers used CDC guidelines, they were just that—guidelines; 
they therefore either adapted for each patient or implemented as outlined. There 
was a general sense that staff support was essential in developing PrEP care 
systems. The function of these care systems was to “educate patients about 
PrEP, communicate with insurance companies, help patients complete 
paperwork, schedule and remind patients about appointments, and/or perform 
risk and adherence counseling, which alleviated provider burden” (Calabrese 
et al., 2016, p. 7). 
Not surprisingly, the CDC guidelines are the backbone of any risk 
assessment. Notwithstanding this, providers tended to utilize an empowerment 
model, a “patient-first” principle of assessing risk. One provider phrased it as 
“harm reduction, so, try to meet them where they’re at. So, I really try never to tell 
people what to do” and another provider phrased it as “do you/could you see 
  
41 
yourself, in the future, being at risk? Is this something that you could incorporate 
into your life?” (Calabrese et al., 2016, p. 7). 
According to Calabrese et al. (2016), perspectives vary on this subject, 
which we have seen in the literature. Self-referred patients were seen as more 
adherent than patients who were encouraged to take PrEP. One provider 
“estimated that 80% took PrEP” and this was “with incredible anal retentive 
fidelity” (p. 8). Another provider noted that “more than half of my patients who are 
younger than 25 years old—there’s not a single thing in their day that they do at 
the same time” (p. 8). 
Although patients reported minimal to no side effects, during the first 2 to 4 
weeks, a small number of patients experienced “nausea, headaches and other 
symptoms such as rash and fatigue” (Calabrese et al., 2016, p. 8). In extremely 
rare situations, patients may exhibit change in kidney functions, which can 
prompt PrEP discontinuation; for the latter, only one provider experienced an 
issue. 
Providers reported “no change in condom use after initiating PrEP” 
(Calabrese et al., 2016, p. 8). The study found that people who reported no 
condom before PrEP continued in their behavior while patients reporting frequent 
condom use before PrEP reported frequent condom use while on PrEP. One 
provider with the highest number of patients (n = 325) observed, “We’re certainly 
not seeing people who are having a hallelujah risk compensation effect” (p. 8). 
Calabrese et al. (2016) highlighted other challenges to PrEP 
implementation. One concern lies in the inability in “accessing and engaging 
priority populations” in PrEP care (p. 9). One provider elaborated on this point by 
stating that “either the community isn’t aware enough about it or their primary 
care providers are still not talking about it enough, are not confident enough, or 
are not able to answer their questions, so that there’s a gate and the gate is 
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really closed off before people actually get to me” (p. 9). Another concern was 
the inappropriate labeling of PrEP as a “gay man’s prevention tool” (p. 9). 
Providers were also willing to share patients’ perceived barriers, which included 
“lack of PrEP awareness, medical mistrust, absence of existing ties to the 
medical system, and structural hurdles, e.g., health centers’ daily hours of 
operation failing to accommodate those with less work flexibility” (p. 9). 
This study utilized a convenience sample, which limits the generalizability 
of the findings. Despite this limitation, Calabrese et al. (2016) successfully 
achieved a rethinking of barriers experienced earlier at the beginning of PrEP’s 
introduction with more up-to-date accounts, surmounting previous barriers but 
highlighting the continued work needed to address structural and access to care 
barriers that exist for populations at risk for HIV. 
PrEP Uptake in the United States 
Currently in 2018, HIV surveillance does not capture PrEP utilization at 
national or local levels, nor is there a unified system in which PrEP utilization is 
captured. Although public health departments are attempting to address this 
information, localized community studies and database analyses have attempted 
to fill this gap. In the absence of generalized large-scale PrEP uptake data in the 
U.S., this literature review draws on limited real-world data, specialized PrEP 
programs and demonstration projects (Bien, Patel, Blackstock, Uriel, & Felsen, 
2017). 
Wu et al. (2017) analyzed 2009-2014 data from MarketScan Commercial 
Claims and Encounters, a large commercial employer-sponsored health 
insurance database that each year contains 43-53 million Americans’ health 
insurance information. The data capture patient-level data on demographic, 
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gender, age, residence, health plans, health claims, diagnoses, procedures, and 
prescriptions (p. 145). Due to the early nature of this analysis, PrEP diagnostic 
and procedural codes were not available. To address this challenge, Wu et al. 
created an algorithm for persons prescribed TDF-FTC (tenofovir and 
emtricitabine). This formulation is used in treating non-PrEP specific medical 
conditions and treatment, such as HIV infection, hepatitis B, and post-exposure 
prophylaxis (PEP), conditions that were used as exclusion criteria for the study. 
As expected, the results showed incremental PrEP increase over the 
5-year period, which would correspond to FDA approval in 2012 and CDC 
release of guidelines for clinical practice in 2014. Over the 5-year period, Wu 
et al. (2017) indicated that the number of PrEP users grew from 111 in 2010 to 
237 in 2012 and to 2,564 in 2014. In 2014, only 3.7% were female PrEP users, 
while male PrEP users accounted for 97.5%. The West showed an increase of 
43% of PrEP users, and nationally the mean age was 38 years down from 44 
years in 2010 (p. 146). The Northeast only accounted for 18.6% of PrEP users 
behind the South with 24.9% of PrEP users. 
Limitations to this study included the use of a commercial insurance 
database, which restricts the generalization of the findings. The database was 
limited in its ability to classify risk behaviors of PrEP users, a helpful detail in 
comparing to CDC risk categories. Additionally, the algorithm used in the study 
could have been too restrictive and excluded actual PrEP users. 
Bush, Ng, Magnuson, Piontkowsky, and Mera-Giler (2015) conducted a 
study to understand PrEP increase in the U.S. by using a national prescription 
database to analyze 39% of TVD (Truvada) prescriptions between January 1, 
2012 and March 31, 2015. Similar to Wu et al. (2017), Bush et al. (2015) 
excluded diagnosis codes for other possible Truvada uses because no specific 
coding is attributed to PrEP. The prescription database provided de-identified 
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patient-level data on prescriptions, refills, medical claims and patient 
demographics. Between 2012 and the first quarter of 2015, there were 8,512 
unique cases of PrEP use. Bush et al. noted from 2014 to 2015, a 332% increase 
in PrEP users. During this same period, women accounted for 13.4% of PrEP 
users, while 86% were male. Since 2014, the 24-34 age group was consistently 
the main new users of PrEP at 34.6%, while people aged 35-44 years accounted 
for 26.9% of new PrEP users. Bush et al. found higher PrEP utilization in the 
Western and Southern regions of the U.S., with rates of 31% and 30%, 
respectively. The Northeast ranked third in PrEP utilization at 21%, above the 
Midwest at 17%. A total of 3,920 unique individuals used PrEP in 2014. Although 
only the first quarter data for 2015 were available, which showed 1,761 
individuals started PrEP, the projections model calculated a substantial increase 
by the end of 2015 with an estimated 7,044 PrEP users. 
The study database covered 39% of all Truvada prescriptions for PrEP but 
was unable track the vast majority of prescriptions in the U.S. The lack of specific 
International Classification of Disease (ICD) codes for PrEP remains a challenge 
in analyzing utilization. Errors in the exclusion criteria cannot be discounted and 
may be a source of under-reporting of PrEP users in the U.S. 
Laufer et al. (2015), using Medicaid prescription data, provide further 
insight into PrEP uptake across the State of New York. The New York State 
Department of Health/AIDS Institute formulated a strategic framework, through 
which comprehensive and integrated PrEP services could be provided through 
the State within primary and HIV care settings as well as settings serving people 
at risk for HIV and/or STIs. According to Laufer et al., the “State’s Medicaid 
program approved coverage of Truvada for PrEP through the program’s fee-for-
service drug formulary” (p. 1297), supporting the Governor’s Blueprint to End 
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AIDS Epidemic by reducing “newly diagnosed cases of HIV infection from an 
estimated 3,000 to 750 by 2020” (p. 1296). 
Data were drawn for a 3-year period July 2012 to June 2015, using data 
submitted from the managed care plans to the NYSDOH Medicaid data 
warehouse (Laufer et al., 2015). One of the challenges experienced by other 
studies examining PrEP uptake is distinguishing Truvada prescriptions intended 
for PrEP from prescriptions intended for PEP and hepatitis B. These nuanced 
factors were included in the development of an algorithm designed to extract 
Medicaid recipients filling at least one PrEP prescription.  
The results identified New York City as being the leader of PrEP uptake in 
the state, accounting for 80.7% of PrEP prescriptions filled. The results showed a 
moderate increase in PrEP prescriptions from the period July 2012 through June 
2013 to July 2013 through June 2014 of 17% (Laufer et al., 2015). A dramatic 
increase of 338.9% in PrEP prescriptions was recorded for the period July 2014 
to June 2015, a record of 1,330 recipients compared to the previous period of 
303 recipients (p. 1297). The state’s Medicaid program approval of coverage of 
Truvada for PrEP has been identified as a facilitator to PrEP uptake (Collier 
et al., 2017). Although Laufer et al. (2015) indicated that the number of females 
who filled PrEP prescriptions doubled across the study period from 117 to 292, a 
drastic shift in absolute uptake was seen for males, who increased PrEP 
prescriptions from 54.8% to 78%. While Black recipients grew in the number 
accessing a PrEP prescription, 65.7% of all PrEP prescriptions during July 2014 
to June 2015 were accessed by White recipients. 
One notable limitation not mentioned by other PrEP uptake studies is the 
limiting use of “PrEP prescriptions” as a measure of PrEP use (Laufer et al., 
(2015). The filling of a PrEP prescription at least once does not equate to the 
number of people taking PrEP to prevent HIV. Further, people may fill a 
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prescription and not take the medication. In addition, the analysis does not speak 
to adherence to the PrEP regimen as outlined by CDC guidelines. 
Sero-discordant Relationships 
Bien et al. (2017) present PrEP uptake from a health care system 
perspective. Using medical charts from the largest health care system in Bronx, 
New York, Bien et al. sought to describe the “sociodemographic and HIV risk 
characteristics of individuals who received PrEP prescriptions” with a secondary 
aim to review PrEP prescription changes from 2011 to 2015 (p. 1310). Using 
Einstein/ Rockefeller/City University of New York Center for AIDS Research’s 
HIV clinical cohort database, FTC-TDF prescriptions were pulled for individuals 
with a negative HIV test between January 1, 2011 and December 31, 2015. 
Medical records were individually scrubbed, and similarly to Wu et al. (2017) and 
Bush et al. (2015), FTC-TDF prescriptions for PEP were excluded. Bien et al. 
(2017) included patient-level demographics, race/ethnicity, age, SOGI (sexual 
orientation and gender identity) data, clinic sites, and category of clinic site, PrEP 
prescription dates and importantly, HIV risk groups. 
From 177,525 individuals with a negative HIV test during the study period, 
only 108 from 2064 with a FTC-TDF prescription were actual PrEP users (Bien 
et al., 2017, p. 1310). The authors found significant uptake in PrEP after 2014, 
which was denoted by only 10 prescriptions before 2014. A total of 61% of PrEP 
users reported a HIV-positive partner. At the same time 87% of cisgender women 
reporting an HIV-positive partner, the prevailing risk factor identified for women. 
Importantly, Bien et al. elevated the issue of under-representation of women in 
PrEP literature given the population’s high HIV infection rates in New York and 
across the country. The study was limited by the data extraction methods, a 
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common issue noted in most chart review processes. Retrospective chart review 
results in differentiation in chart completion, and the study’s inability to equally 
assess risk behaviors. 
A New York City female-focused study assessed the risk factors associated 
with PrEP uptake and retention in care. Using retrospective medical chart 
reviews in a newly opened community-based comprehensive sexual health clinic 
in the Bronx, Blackstock, Patel, Felsen, Park, and Jain (2017) cross-referenced 
the medical charts against the PrEP registry to assess the number of women on 
PrEP at the clinic. The study was conducted from December 2014 to August 
2016, during which 554 women accessed services. Of this number, 21 
heterosexual women (3.8%) obtained at least one PrEP prescription. Importantly, 
38% were Latina, 28.6% were non-Latina Black, and a majority (81.2%) had 
Medicaid. 
In describing the HIV prevention landscape in New York State, Blackstock 
et al. (2017) provide context to the PrEP assistance framework. According to the 
authors, the combined efforts of Gilead Sciences’ pharmaceutical-sponsored 
drug assistance program and New York State Department of Health, the State-
sponsored PrEP assistance program (PrEP-AP) provides coverage for PrEP 
clinical visits, lab tests, and medication (Blackstock et al., 2017). Interestingly, of 
the 21 women, only 3 specifically sought PrEP services, while referrals 
comprised the sources of PrEP indication of women. The primary risk factor for 
85.7% of women was being in a sero-discordant relationship. A total of 83.3% of 
women reported their HIV-positive partner as being on antiretroviral medications, 
while 66.7% reported viral suppression status of their partners and 16.7% were 
trying to conceive (Blackstock et al., 2017). 
Using CDC PrEP guidelines, Blackstock et al. (2017) delimit retention as 
clinic visit schedule of every three months. In addition to Blackstock et al.'s study, 
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the issue of retention on PrEP in the U.S. has received significant attention. In an 
MSM study in three U.S. cities conducted by Chan et al. (2016), retention among 
men on PrEP showed substantial drop-off. At 3 months, 61.1% had their clinic 
visit, but only 37.5% complete the 6-month visit. One limitation to Blackstock 
et al.'s (2017) study was the inability to determine PrEP eligibility among women 
attending the clinic. Secondly, sexual health clinics may have higher at-risk 
individuals for HIV, a limiting factor for generalizing the results. 
Theoretical Framework 
Three social sciences theories shaped the design of the current study. The 
Diffusion of Innovations Theory (Rogers, 2004) influenced the development of 
the survey instrument and guided the fieldwork. Grounded Theory (Glaser & 
Strauss, 1967) was instrumental in combing through the transcription pages to 
produce codes that made sense given the voluminous data. Although the 
preceding two models were integral in the backbone of the current study, the 
analysis and presentation of results was possible using the PRECEDE Planning 
Framework (Green, Kreuter, Deeds, & Partridge, 1980), which was the third and 
final theoretical model. The PRECEDE Planning Framework provided an explicit 
and intentional style of presenting the results that were in alignment with the aims 
of the current study in explaining factors that motivated Black women in New 
York City to either accept or reject PrEP. 
Diffusion of Innovations in Health Promotion 
Historically, public health has faced strong challenges in implementing new 
biomedical interventions. An example is family planning methods. After many 
years and through the establishment of stand-alone clinics and numerous 
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campaigns, family planning has been successfully integrated into primary care 
delivery systems (Rogers, 1983). Within the discipline of public health and health 
promotion there is recognition that not all innovations will be accepted, nor will 
they be diffused quickly, and quite possibly, may not be diffused on a wide scale. 
The struggle is great but practitioners in the field continue to utilize 
innovative messages and platforms to ensure that potentially life changing 
innovations are diffused quickly and equitably. The Director of the CDC’s 
National Center for AIDS and other Sexually Transmitted Diseases, Dr. Jonathan 
Mermin, stated that “on average, it takes a decade for a scientific breakthrough to 
be adopted.” Speaking directly to pre-exposure prophylaxis (PrEP) as a new drug 
to prevent HIV, Dr. Mermin further expressed the institution’s “hope that [they] 
can shorten that time frame and increase survival” of people at substantial risk of 
getting HIV by optimal use of PrEP (McNeil, 2014). 
Diffusion of Innovations 
Diffusion of Innovations provides a theoretical framework for understanding 
the process of dissemination of new ideas such as PrEP and the rate of adoption 
in a social system such as the U.S. The theory identifies a number of factors that 
influence the diffusion of a new idea or practice. The proposed study draws on 
Diffusion of Innovations theoretical framework to understand reasons Black 
women accept (adopt) or reject PrEP. 
Although depicted as a paradigm based on five variables that determine 
rate of adoption, the current study uses only one variable, the perceived 
attributes of innovation variable described below in Figure 2 (Rogers, 2003). 
Rogers’s five perceived attributes of innovations. Rogers (2003) 
defines five attributes of innovation that will be reviewed for the proposed study: 
relative advantage, compatibility, complexity, trialability, and observability 
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(Figure 2). Although these characteristics are interrelated, Rogers (1983) notes 
that they are distinct and contribute differently to the perception of the innovation 




Figure 2. A Paradigm of Variables Determining the Rate of Adoption of 
Innovation. Source: Adapted from E. M. Rogers (2003). Diffusion of 
Innovations (5th ed., p. 222). New York: Free Press. 
Relative advantage is defined as the “degree to which an innovation is 
perceived as being better than the idea it supersedes” (Rogers, 2003, p. 229). 
Favorable adoption of an innovation is dependent on the motivation of gain to the 
individual. Gain can be quantified as having either a monetary value, or, equally 
or more valuable, an intangible value such as carrying conscience value, or a 
social status value or a combination of values. Undoubtedly, all four 
characteristics of innovation play an integral role in the rate of the innovation’s 
Rate of Adoption 
of Innovators 
I. Perceived Attributes of Innovations 
 1. Relative Advantage 
 2. Compatibility 
 3. Complexity 
 4. Trialability 
 5. Observability 
II. Type of Innovation-Decision 
 1. Optional 
 2. Collective 
 3. Authority 
III. Communication Channels  
(e.g. mass media or interpersonal) 
IV. Nature of the Social System  
(e.g. its norms, degree of network 
interconnectedness, etc.) 
V. Extent of Change Agents’ Promotion Efforts 
Variables Determining the Rate of Adoption Dependent Variable That is Explained 
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adoption, however, “scholars have found relative advantage to be one of the best 
predictors of an innovation’s rate of adoption” (p. 217). 
Rogers (2003) makes a critical observation about slow rate of adoption 
among preventive innovations; that preventive innovations are slow to show the 
immediate benefit of using the innovation, and although addressing the 
precautions of “unwanted future event” (p. 235) these outcomes are harder to 
imagine and be valued by the community. Perhaps with significance to the PrEP 
study, Rogers highlighted two levels of challenges HIV/AIDS and preventive 
innovations face. First, although adopting the activity, for example “safe sex” may 
prevent HIV in the future, the person might not get HIV even though they did not 
practice safe sex. Second, there is difficulty for the individual to perceive the 
actual occurrence or occurrences when they have prevented the unwanted 
outcome from happening. According to Rogers, preventing HIV is both “invisible 
and unobservable,” making the innovation “difficult or impossible to comprehend” 
(p. 234). The beneficial consequences of PrEP as a preventive innovation may 
be even harder to diffuse among people at risk of HIV resulting in a slower rate of 
adoption, as evidenced in the literature by the slower than expected uptake in 
PrEP across the United States. 
The use of incentives to increase rate of adoption has been a strategy used 
to counter the challenges associated with adoption of preventive innovations. 
Rogers (2003) illustrates five types of incentives, noting that more research has 
been done on family planning incentive programs and policies than any other 
incentive program. Although in the literature no incentive programs were noted 
among PrEP studies, the New York State PrEP-AP and the Gilead Sciences co-
pay programs might be considered system-level variations of incentive programs; 
drawing on innovations that Rogers (2003) considers are in the best interest of 
the society, such as fines for not using seat belts. 
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Compatibility is defined by Rogers (2003) as the “degree to which an 
innovation is perceived as consistent with the existing values, past experiences, 
and needs of potential adopters” (p. 240). Therefore, an innovation that is more 
compatible is also less uncertain and aligns closer to the adopters’ thoughts, 
ideas, values and beliefs (Rogers, 2003). One striking concept that is introduced 
by Rogers is leveraging familiarity with new innovations based on decisions and 
ideas made in the past. Rogers contends that measuring an innovation against 
the familiarity of past actions (old idea) decreases the uncertainty attributed to 
the innovation (new idea), thus making the innovation compatible. Although need 
is an important aspect of compatibility, Rogers cautions change agents against 
pushing “need” for the innovation among people who initially did consider the 
innovation, noting that “the felt needs upon which diffusion campaigns are based 
may be only a reflection of the change agent’s needs, rather than those of his 
clients” (p. 246). It is therefore important for people to realize their innate “need” 
for the innovation, as Rogers illustrates that “one dimension of compatibility is the 
degree to which an innovation is perceived as meeting the needs of the client 
system,” resulting in a “faster rate of adoption” (p. 246). 
Practitioners in the field of HIV prevention, by Rogers's (2003) description, 
work within the realm of compatibility. Drawing on tools such as motivational 
interviewing, highlighting discrepancies in goals and behaviors, allows 
practitioners to introduce new innovations such as PrEP to clients who might be 
unaware of PrEP as a prevention tool. Importantly, presenting evidence showing 
where PrEP as an innovation can present benefits, debunking myths and working 
through potential challenges with clients to formulate a tailored prevention plan 




Complexity, according to Rogers (2003), is measured on a “complexity-
simplicity continuum” (p. 257), where complexity “is the degree to which an 
innovation is perceived as relatively difficult to understand and use” (p. 257). 
Research supports a positive correlation between difficult-to-understand 
innovations and low rate of adoption. Innovation at its core, should be simple to 
understand for the potential adopters of the innovation, and inversely, the more 
complex the innovation the lower the rate of adoption. Rogers presents this 
attribute lower on the totem pole than relative advantage and compatibility as 
attributes of innovations. The value of presenting non-complex tools for the 
general population to understand preventive innovation has been supported in 
the literature (Rogers, 2003). 
Although complexity in use and understanding have been evidenced in the 
literature, a broader meaning of complexity in relation to PrEP might also be 
considered in reviewing HIV prevention research, which is the issue of access to 
the innovation. If for example the medication is difficult to obtain because there 
are fewer providers aware of the preventive method (indicated by previous 
research) in addition to uncertainty of insurance coverage and high cost layering 
the maze, then complexity captures much broader socio-economic implications 
impacting HIV prevention and the demand for PrEP. 
Trialability, as defined by Rogers (2003), is the “degree to which an 
innovation may be experimented with on a limited basis” (p. 258). Although the 
main element of trialability is divisibility and the ability of the innovation to be tried 
in installments or on a “limited basis,” Rogers concedes that there is not strong 
evidence to suggest trialability is “positively related to its rate of adoption” 
(p. 258). 
Published studies have found that people who started PrEP in the first 
month did not necessarily remain on PrEP in the third month (Blackstock et al., 
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2017). Such data signify the trial use of PrEP to determine the “best fit” situations 
and to test whether the prevention method is actually suited for the individual’s 
lifestyle. Interestingly, studies also show that prescription scripts were written but 
the medication was never picked up. Rogers and Shoemaker (1971) refer to this 
as psychological trial. An interesting concept that appears to describe the issue 
of non-medication pick-up for prescriptions issued to individuals (Blackstock 
et al., 2017) who initially thought they were ready to adopt PrEP. 
Observability is similar to relative advantage and is also a “characteristic of 
preventive innovations that slows their rate of adoption” (Rogers, 1983, p. 218). 
According to Rogers (2003), observability is the “degree to which the results of 
an innovation are visible to others” (p. 258), suggesting that innovations that are 
not easily observed or “difficult to describe” result in slower rates of adoption. 
Perceived attributes of observability have been widely studied in the 
technology field. The observable innovation of mobile telephones has ballooned 
into a rapid and arguably insatiable market of adopters. As previously stated, HIV 
prevention is difficult to observe and perhaps that has resulted in the rapid 
twinning of HIV prevention messages and the mobile technology. The leveraging 
of social media and PrEP messages is increasingly becoming normalized with 
growing number of PrEP studies focusing on social media and social networks. 
Grounded Theory 
According to the fathers of Grounded Theory, Glaser and Strauss (1967), 
deriving “theory from data” instinctively resonates with both sociologist and 
layman (p. 1). These eminent authors advocate that Grounded Theory, which is 
the iterative and systematic process of discovering theory from data, is important 
in providing “us with relevant predictions, explanations, interpretations and 
applications” (p. 1). Glaser and Strauss are quick to differentiate their inductive 
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qualitative analysis, in which theory is derived from data that are “systematically 
obtained from social research”, from “theory generated by logical deduction from 
a priori assumptions” (pp. 2-3). 
In this study, utilizing Grounded Theory was an intensive process. Every 
effort was made by the Researcher to represent clearly the voice of the 
respondents of the study, which was not to be confused with the Researcher’s 
own voice, beliefs and perceptions of what the results showed. Grounded Theory 
helped to reduce bias and accentuate the volume of the 72 Black women 
interviewed in the study. 
Although Grounded Theory provided a more objective method of seeing the 
data through the perspective of the respondents by creating dozens of useful 
categories for analysis, the Researcher opted to use the educational diagnosis 
phase of the PRECEDE planning framework through which to present the results 
of the analysis. The Researcher realized that moving from an inductive approach 
back to a deductive and more structured approach has the potential of missing 
categories that are expected in a structured approach. The Researcher was 
mindful of this potential limitation and predetermined to indicate in the 
presentation of results categories that did not fit in the predefined PRECEDE 
planning framework categories of predisposing factors, enabling and reinforcing 
factors. 
PRECEDE Planning Framework 
The predisposing, reinforcing, and enabling causes in educational 
diagnosis and evaluation, generally known as the PRECEDE planning 
framework, were useful in presenting the data from the fieldwork associated with 
this current study on PrEP and Black women. The planning framework provided 
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a practical way that reflected the aims of the study to describe the motivations, 
enabling factors and social support relevant to PrEP use among Black women. 
One striking utility of the PRECEDE framework is that it “makes it possible 
to sort the determinants of behavior change that are most responsive to health 
education into categories convenient for planning” (Green et al., 1980, p. 70). 
Based on common findings from literature and theories, the authors have 
identified three categories of factors that act as determinants of behavior change. 
These three categories will be discussed in the ensuing paragraphs. 
PRECEDE is a deductive, intervention-based framework that has been 
adopted by a number of local, city, state, national and international settings and 
used in planning rigorous health education programs (Green et al., 1980, p. 11). 
As noted by Green et al., the applicability of the model addresses a critical gap in 
health education, which is disjointed planning and, through the framework, 
presents a comprehensive pathway to planning and evaluation of public health 
education programs in diverse settings and situations (p. 11). 
The PRECEDE framework works from the premise that diagnosis of the 
health problem must precede the development of an intervention. In a similar 
way that a medical diagnosis precedes a treatment plan, an educational 
diagnosis should precede an intervention plan (Green et al., 1980). Importantly, 
interventions are only created when the factors have been identified and a logic 
plan developed to address the health problem and achieve the outcome. 
According to Green et al., an intervention that is developed prior to diagnosing an 
outcome “will be based on guesswork and runs the risk of being misdirected and 
ineffective” (p. 12). 
Based on the PRECEDE framework, Green et al. (1980) outlined seven 
phases to the PRECEDE framework. The phases continue the idea of starting 
with the health concern or problem and working backwards through the 
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contributing factors to designing the actual health education intervention. The 
phases are described as Phase 1—social diagnosis: an important step to 
“consider carefully social outcomes or quality of life concerns before plunging into 
the intricacies of methodology” (p. 19); Phase 2—epidemiological diagnosis: 
“identification of the health problems associated with an unsatisfactory quality of 
life” (p. 35); Phase 3—behavioral diagnosis: “systematic identification of health 
practices that appear to be causally linked to the health problem or problems 
identified in the epidemiological diagnosis” (p. 52); Phase 4—educational 
diagnosis: “the behaviors identified as linked to the health problem or problems of 
greatest concern in a population are differentiated according to what causes 
them” (p. 68); Phase 5—selection of educational strategies: “planning of the 
health education strategy most suitable for community based on the foregoing 
phases” (p. 86); Phase 6—administrative diagnosis: the “administrative 
considerations including budget and analysis of the factors that will determine the 
ease with which the program is introduced into a system” (p. 116); and 
Phase 7—evaluation and the accountable practitioner: the accountable health 
educator “cultivates an attitude toward professional practice which ensures that 
every new population or patient is approached diagnostically and that every 
program is developed as an experiment” (p. 132). 
Our primary interest in the PRECEDE planning framework is understanding 
Phase 4—educational diagnosis for later application in the results section. The 
following aspects of Phase 4 will be reviewed: the three categories of factors 
impacting health behavior—predisposing factors, enabling factors, and 
reinforcing factors. Additionally, using Green et al. (1980), two additional steps 
will be used in specifying and selecting factors to discuss in the results section. 
The first step is identifying and sorting factors, and the second step is setting 
priorities among the categories for discussion (p. 77). 
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Predisposing factors, according to Green et al. (1980), “relate to the 
motivation of an individual or group to act” (p. 70). The authors suggest that 
predisposing factors can be thought of “as the ‘personal’ preferences that an 
individual or group brings to an educational experience” (p. 70). Comparable 
words that reflect “personal” preferences include “knowledge, attitudes, beliefs, 
values and perceptions,” which are collectively influential and may “either support 
or inhibit health behavior” (p. 70). 
Enabling factors, according to Green et al. (1980), are “the skills and 
resources necessary to perform a health behavior,” further explaining skills in the 
individual context as “a person’s ability to perform the tasks that constitute the 
desirable behavior” (p. 75). Referring to a practical application of individual skills 
in HIV prevention is the ability to properly open a condom packet and putting on 
a condom based on the nuanced criteria. According to the authors, “failure to 
consider the impact of enabling factors on the achievement of behavioral goals 
can lead to serious practical problems” (p. 75). 
Reinforcing factors “are those that determine whether health actions are 
supported” (Green et al., 1980, p. 76). Of noteworthy mention is the changing 
source of reinforcement based on the health education program. According to 
Green et al., the “source of reinforcement will … vary depending on the 
objectives and type of program,” for example, “in patient education settings, 
reinforcement may come from nurses, physicians, fellow patients, and again the 
family” (p. 76). As health educators, it is especially important to understand the 
group of people who have the most influence. Possible solutions lie in research 
and in the assessment previously conducted using the PRECEDE framework. 
Nevertheless, Green et al. shift the burden onto the planners by saying the 
“program planner must carefully assess reinforcing factors to make sure that 
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program participants have maximum opportunities for supportive feedback during 
behavior change process” (p. 76). 
Identifying and sorting—formal methods—the importance of accounting for 
all pieces of data cannot be overstated. In reviewing data, the “list of factors 
generated for each behavior should be as comprehensive as possible” (Green & 
Kreuter, 1989, p. 77). In this way, Green et al. (1980) emphasized this principle 
that the “planner may be able to avoid overlooking a crucial item, a pitfall when 
his or her attention is diverted by each item as it is listed” (p. 77). The formal 
method for developing this list representing a “search through the relevant 
literature can yield information on cultural and social attitudes and descriptions of 
studies defining specific factors on health-related behaviors” (p. 78). The list 
might “show both positive and negative factors” relating to the health problem in 
question (p. 78). 
While it is important to categorize factors to their correct classification, the 
authors acknowledge the cross-cutting relationship between factors. According to 
Green and Kreuter (1999): 
The three categories (predisposing, enabling or reinforcing) are 
not mutually exclusive; a factor can appropriately be placed in more 
than one column. A family may be predisposed to dieting, for 
example, and reinforce (negatively or positively) that behavior once it 
has been undertaken. (p. 78) 
In setting priorities among categories, according to the authors, “there is no 
way that all causes in a complex inventory for several behaviors can be tackled 
simultaneously” and therefore the need to decide on which “factors are to be 
attached first and in what order are therefore important” (Green et al., 1980, 
p. 78). One suggestion offered by Green et al. is that “establishing priorities 
among the three kinds of factors is developmental” (p. 78). The premise is that 
“people will not adopt a set of behaviors to reduce a health risk if they are not 
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aware that there is a risk.” Therefore, the “belief in the immediacy of the risk and 
its implications will have to be developed before attention is given to ways to 






The study utilized a cross-sectional survey design. The research aims 
focused on improving understanding about the views of Black women who self-
report being HIV-negative and were seeking HIV and/or STI screening at a 
Federally Qualified Health Center in Brooklyn, New York. As a precursor to the 
main study, a pilot study was conducted with two primary aims. The first was to 
test the adequacy of the interview instrument and enable the Researcher to 
practice conducting the interview and obtaining informed consent. The second 
focused on the logistics of the recruitment to determine effective ways to recruit 
women to the larger study. 
Pilot Study 
After obtaining approval from the Teachers College Institutional Review 
Board, 34 women were contacted for a pilot test. Between August and 
September 2017, 10 Black women completed the pilot interviews. The 
recruitment strategy utilized during the pilot was leveraging the calls made by 
nursing staff to patients. Recruitment of the women involved contacting women, 
in-person and by telephone, who had recent HIV or STI screens and who were 
recently contacted by the nursing staff for follow-up appointments. The women 
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who were contacted were interested in the study and expressed willingness to 
participate; many, however, faced time constraints, which precluded their 
participation. Although no incentives were provided during the pilot, 10 women 
were willing and able to complete the pilot study. 
Aim 1: Adequacy of the Interview Instrument 
Annexed to the interview was a brief 4-question pilot questionnaire 
(Appendix A). Through the pilot questions, participants were presented with a 
clear message that their feedback was critical in reframing, changing, and 
informing the inclusion of new questions for the larger study. A sample of the 
responses is presented in the table below. Consequently, as a result of the pilot, 
the flow of the instrument was rearranged to first address awareness and 
acceptability of PrEP, with less intensity on risk behaviors, although the latter 
were also important to the study. 
Participants were asked to critically comment on each question. They were 
asked to identify any questions that were difficult to understand, ambiguous, or 
uncomfortable to discuss; needless to say, this process was reflective of 
participants’ perspectives. As seen from the table below, tangible suggestions 
and comments were provided. 
Based on the pilot, changes were made to the main questionnaire. 
Question 2 was revised to now read, “Consider your beliefs about HIV 
prevention, does PrEP align positively or negatively with those beliefs?” Although 
question 5 remained relatively unchanged, its placement of the question was 
changed. The Researcher addressed the concerns by consciously adjusting 
expression and tone when asking the question. Importantly, this shifted the flow, 
wording, phrasing, and length (shorter rather than longer compounding 
questions) of most questions. As an outcome, the updated interview schedule 
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was based on an informed and iterative process that attempted to capture the 
constructs of Diffusion of Innovations Theory framed in the context for women as 
the intended participants. 
 
 





Based on what 
you have heard 
about PrEP (prior 
to this interview 
and during this 
interview), what 
are your initial 
thoughts/belief 
about PrEP as a 
method to prevent 
HIV? Based on 
your initial 
thoughts/belief, 
does PrEP aligns 
with something 
positive or 
negative? Can you 
explain further 
giving examples of 
both, if possible? 
Question could have 
been clearer.  
Question could have been clearer. Unpack the 
question, and make the question simpler. 
Have you ever 
used injection 





Question was uncomfortable to answer. Felt to be 
too personal. 
 Additional questions 
that could be asked. 
1. Was expecting more personal questions. 
2. How would you perceive taking PrEP would 
affect your partner? 
3. Would your partner be alarmed that you are 
taking an HIV medication? 
4. Do you know if your partner has sex with other 
partners? 
5. Do you think the drug is a good thing? 
6. Is the drug relevant to you? 
7. Give more information on the reliability of the 
drug compared to condoms. 
8. How would your partner react if you were on 
PrEP? 
9. How would guys feel about women taking PrEP? 





A striking finding from the pilot study, and a perspective initially left out of 
the pilot questions, was that of the partner’s perspective. The feedback from 
respondents was overwhelming support to include questions on partner 
practices, perspectives, and the influence of partners on the perception of 
women taking PrEP. This is correctly grounded in the diffusion of innovation 
theory as the relative advantage and impact of PrEP on social relations. 
Apparently, there is likely an association between women taking PrEP and their 
partners’ practices and perspectives in the use of PrEP. Additional questions on 
partner and peer reactions to the use of PrEP were included in the revised 
instrument. 
Conducting a face-to-face interview on the topic of HIV and sexual 
practices is challenging and requires great sensitivity. Although the HIV epidemic 
is over 30 years old, stigma persists. The recruitment strategy utilized during the 
pilot was leveraging the calls made by nursing staff to patients. Nursing staff 
communicated about the study to patients who had a recent STI and/or HIV test, 
indicating that the Researcher would follow up with additional information, if the 
patient had no objections. The Researcher utilized a short list of 34 names of 
patients who received a follow up telephone call by nursing staff. The Researcher 
spoke to patients broadly about the interview, however, where participants 
wanted to know more about the type of biomedical medication to be discussed, 
additional fact-based responses were provided. It was easier to arrange 
interviews with women who were already in the Health Center or who had an 
imminent appointment. Nevertheless, approximately half of the participants came 
to the Health Center only for the interviews. A lesson learned for the larger study 
was the importance of an incentive. For the main study, a $20 gift card was 




The study setting was a Federally Qualified Health Center (FQHC), which is 
a private, not-for-profit community health center, located in Brooklyn, New York. 
It serves as a safety net facility. The Center provides a wide range of high quality 
healthcare services, including primary care, obstetric and gynecological services, 
as well as other specialty services such as STI screening and free HIV rapid 
testing. The Center is well situated to serve a community of over 154,000 
residents comprising 64% Black, 20% Hispanic, 11% White, and 2% Asian 
residents (Community Health Profile, 2015, p. 2). According to the NYC 
Department of Health’s Community Health Profile 2015, one in three residents 
lives below the federal poverty level, and of the 59 community districts in New 
York City, this one is cited as the among the 10 poorest neighborhoods in the 
City (Community Health Profile, 2015, p. 6). Using income and death rates 
across the City, the New York City Department of Health and Mental Hygiene 
concluded that 49% of deaths could be averted if the community achieved death 
rates similar to the five most affluent neighborhoods. 
According to information obtained from the Uniform Data Systems from the 
Health Resources and Services Administration (HRSA), in 2017, the FQHC 
served over 15,621 people, of which 85.9% were Black/African American (UDS, 
2017). Although the data do not provide information on HIV prevalence by 
gender, the FQHC reports a HIV prevalence rate of 1.7% of the total patient 
population. The FQHC uninsured rate is approximately 16.1% (UDS, 2017), 
signifying that approximately 2,515 persons who obtained services at the setting 
indicated that they did not have insurance at the time of the medical visit. 
Enveloped in a high poverty, high health burden community, this FQHC providing 
services to central Brooklyn residents regardless of the ability to pay is an 
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integral and relevant health provider addressing health disparities within the 
community. Leveraging such facilities to conduct research captures real-world 
experiences but also provides practical avenues for reducing the striking health 
disparities. 
Target Population Eligibility 
In keeping with CDC recommended guidelines for screening heterosexual 
women for PrEP (CDC, 2014a), five questions were included (see below). 
Although these questions are broad and generic in determining “substantial” risk 
for HIV, they provide a benchmark to help in screening and identifying women for 
PrEP services. 
The recommended questionnaire used to screen heterosexual women for 
PrEP asks, in the past 6 months: 
• Have you had sex with men, women, or both?  
• (if opposite sex or both sexes) How many men/women have you had 
sex with? 
• How many times did you have vaginal or anal sex when neither you nor 
your partner wore a condom?  
• How many of your sex partners were HIV-positive?  
• (if any positive) With these HIV-positive partners, how many times did 
you have vaginal or anal sex without a condom?  
Additionally, the recommended Indications for PrEP Use by Heterosexually 
Active Men and Women (CDC, 2014a, p. 29) include: 
• Adult person  
• Without acute or established HIV infection  
• Any sex with opposite sex partners in past 6 months  
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• Not in a monogamous partnership with a recently tested HIV-negative 
partner 
AND at least one of the following: 
• Is a man who has sex with both women and men (behaviorally bisexual) 
• Infrequently uses condoms during sex with 1 or more partners of 
unknown HIV status who are known to be at substantial risk of HIV 
infection (IDU or bisexual male partner)  
• Is in an ongoing sexual relationship with an HIV-positive partner. 
For the purposes of the current study, the Researcher used STI and HIV 
screens as proxy indicators to indicate “substantial risk” for HIV. Both STI and 
HIV screens were included as determining eligibility for the current study. 
Eligibility for the current study included women self-identifying as Black/African 
American aged 18 years and older with a recent self-reported HIV and/or STI test 
during the data collection period from November 2017 to January 2018. Women 
who met these criteria were invited to participate in the study. 
Inclusion/Exclusion Criteria 
The following inclusion criteria were used to determine eligibility, broadly 
based on the CDC guidelines (CDC, 2014a): 
1. At least 18 years old. 
2. Self-report HIV status as negative. 
3. Willingness to provide informed consent to participate in the study. 
And  
4. Self-report having anal or vaginal sex within the past 6 months. 
Or 
5. Have had a STI or HIV screen in the past 6 months 
Or 
6. Had a STI in the past 6 months. 
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The exclusion criteria included: 
7. Previous participation in the pilot study 
8. Inability to speak English 
9. HIV-positive diagnosis by self-report. 
10. Women of trans experience were not included in the current study. 
Delimitations of the Study 
The study was delimited to examining factors of initial PrEP use and did not 
address maintenance of PrEP medication. Focusing on adoption is a meaningful 
first step in increasing rates of PrEP use by women at “substantial risk” for HIV 
infection. The sampling strategy is delimited in scope to one locality in Brooklyn 
and to women attending the participating Health Center. 
Another delimitation is that the study focused on limited questions, which 
were based on the Diffusion of Innovation Theory but also collected information 
that research has shown can facilitate PrEP uptake. These aspects of the study 
can also be seen as strengths. Little research has been conducted among 
women about this topic and using an existing theoretical framework, which has 
been widely used, may help uncover aspects of the PrEP innovation that are 
more and less acceptable to the African American women at risk for HIV 
infection. 
Another delimitation is that all of the data were collected and analyzed by a 
single Researcher. While the results will clearly not be generalizable to a larger 
reference population, the study is considered a meaningful first step in a longer-
term research agenda relevant to PrEP uptake. 
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Sampling and Recruitment 
The sample design utilized one setting in which to recruit Black women for 
the current study. The setting was within a FQHC in Brooklyn. The use of the 
electronic medical record was not utilized; as this would have required additional 
permission from patients. Recruitment was focused on women who were present 
at the setting or who were contacted, as described in further detail in the 
recruitment strategies. Purposive sampling was used to recruit Black 
heterosexual and bisexual women who were at risk of HIV infection. Prior to 
implementing the recruitment strategy, staff of the FQHC were informed about 
the study, its purpose, eligibility criteria and the approximate time commitment 
required for the interviews. The Researcher sought assistance from the staff in 
recruiting women for this current study. Having approached staff for assistance in 
promoting the current study, there were clarification questions asked by staff, 
which were answered. To aid staff in the familiarity of the current study, the 
Researcher developed a frequently asked question (FAQ) sheet that assisted 
with answering questions about the study. The FAQ sheet (see Appendix B) 
guided the information shared with staff at the Health Center and was also 
provided to staff who were asked to refer clients for interview in the study. 
Prior to implementing the study, it was important for the Researcher to 
discuss study parameters with senior leaders of the agency. The Researcher had 
support from the President/ CEO to conduct the study (see Appendix C). This 
permission afforded the Researcher the opportunity to have open discussions 
with staff, the aim of which was to raise awareness about the study purpose and 
timelines and to solicit assistance in recruiting participants. These initial steps 
were found to be most important in creating a shared understanding about the 
study and gaining initial buy-in before beginning recruitment. 
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The recruitment strategies initially proposed for the study changed during 
the on-site recruitment. One of the proposed recruitment strategies that produced 
no result was leveraging the Health Educators as a referral source for 
prospective participants who they counseled for having a positive STI. This 
strategy did not yield participants. Health education sessions were primarily 
unscheduled and varied based on when the patient had their follow-up visit, most 
of which were walk-in visits, and the times of the sessions were impromptu and 
took place when the Researcher was not available. 
Another recruitment strategy was posting flyers in clinical areas, medical 
rooms and on noticeboards (see Appendix D). The benefits from this strategy 
were unexpected. The Researcher expected that it was the nursing staff that 
would respond most to the flyers in the clinical areas, but the result was that it 
was the medical providers who referred patients to the study. The providers 
indicated that the colorful flyers posted on their computer work-station reminded 
them of the study. This approach resulted in approximately 10 women completing 
interviews. 
Another strategy that resulted in recruitment was personal invitations by the 
Researcher. The Researcher followed up with clinic staff to obtain names of 
patients who had expressed interest in the study. Approximately 55% of the 
women who received a telephone call or in person invitation from the Researcher 
scheduled and showed up for the interview. This strategy resulted in the 
recruitment and successful completion of 21 interviews. 
The strategy that surpassed expectations but which, notably, was not a 
strategy initially proposed was the support of a champion medical provider for the 
study. After briefing the nursing staff, the Researcher went door-to-door and 
spoke to every medical provider about the study. As mentioned, a few 
participants were referred to the study through this strategy. However, one 
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medical provider invited the Researcher to work alongside the provider on 
Thursdays and Sundays. During these times, every patient that the provider saw 
who met the criteria for the study was referred to the Researcher, who assessed 
the woman’s interest and eligibility. This was an unexpected welcomed 
opportunity. To meet the workflow of the provider, the Researcher worked at the 
pace of the clinic to interview participants. To maintain pace with the clinic flow, 
the Researcher completed the interviews in approximately 40 minutes, which 
spanned the time the patient spent with the provider and completed blood-draw 
for their laboratory tests. The refusal rate was low, about 10%. Forty-one (41) or 
57% of interviews completed were as a result of this strategy. 
Almost half of the women who scheduled interviews did not show up for the 
interviews. Reasons that were later obtained by the Researcher included that 
they simply forgot, had a competing obligation such as work commitments or that 
they no longer had the time to meet. To facilitate participation, the Researcher 
conducted interviews on Saturdays and Sundays as well as during the 
weekdays. Another lesson learned was that women were more likely to accept 
the invitation to be interviewed while they were visiting the clinic than they were 
to schedule a time to come back to the clinic for the interview. 
Selected characteristics of the study participants are shown in Table 2.  
More that 40% indicated that they were single, while almost 1 in 5 were 
reportedly married and slightly more than 1 in 10 were living with a partner. One-
third were under 30 and just over 40% were 50 and older. The mean age of 
participants was 41 years (SD = 15.430). The majority had completed high 
school or earned a GED, while approximately 30% had completed at least a 
2-year college or higher. Three respondents reported earning more than $3,500 
per month, and almost 40% reported earning less than $1,500 per month. 
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Table 2. Selected Characteristics of Study Participants 
 Frequency Percent 
Race/Ethnicity   
  Black/African American 63 87.5 
  Mixed   9 12.5 
Current relationship status   
  Married 14 19.4 
  Separated 3 4.2 
  Divorced 3 4.2 
  Widowed 4 5.6 
  Living with partner 8 11.1 
  Committed relationship 7 9.7 
  Single 31 43.1 
  Not sure 2 2.8 
Age   
  18-29 24 33.3 
  30-49 19 26.4 
  50+ 29 40.3 
Educational Attainment   
  Less than high school 8 11.1 
  High school/GED 44 61.1 
  2 year college 7 9.7 
  4 year college 8 11.1 
  Master’s degree and higher 5 6.9 
Monthly Income   
  Refused to report 1 1.4 
  Less than $1500 27 37.5 
  $1501 -$2500 25 34.7 
  $2501 -$3500 16 22.2 
  More than $3500 3 4.2 
Informed Consent 
There was double consent from participants. This was based on whether 
the participant was referred by a staff member or recruited directly by the 
Researcher. If staff referred participants to the survey, staff would obtain verbal 
consent from the participant to either contact the Researcher with the 
participant’s information or to link directly to the Researcher. Additionally, the 
Researcher also obtained verbal consent from women to confirm their interest in 
participating in the study. The second step involved explained the study to 
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prospective participants and each participant completing a signed consent. 
Signed consent was a criterion for participating in the study (see Appendix E) 
and all signed forms were kept secured in a locked file. Signed consent was 
mandated as a condition by the IRB, and all consent forms bore the IRB approval 
stamp (see Appendix F). 
The Researcher arranged to meet eligible participants in private medical 
rooms in the Health Center, which helped ensure that interviews were conducted 
in a completely private setting. Trust and safety are realities that the Researcher 
strongly supported when working with all participants. As cited in Morse and Field 
(1995), a trusting relationship with the interviewer begins with participants feeling 
comfortable in their setting. 
Measurements 
Although the current study drew from three theoretical frameworks, the 
development of the survey instrument centered on the characteristics of PrEP as 
an innovation, found in the Diffusion of Innovation Theory. This theoretical 
framework was used for improving understanding about PrEP as a new 
biomedical intervention. Particular emphasis was given to open-ended questions 
that were developed based on five characteristics of an innovation: (1) Relative 
advantage, (2) Compatibility, (3) Complexity, (4) Trialability, and 
(5) Observability. 
Relative advantage is the extent to which the innovation has advantages 
over current practice. Compatibility is the extent to which an innovation is 
compatible with the culture and values of the intended users. Complexity relates 
to how complicated it is to use an innovation, which in this case would mean 
taking one pill once daily. Trialability is the degree to which an innovation can be 
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tried on a limited basis without much consequence. Observability is defined as 
how easy it is for prospective users to observe others using an innovation or their 
ability to relate to the use of the innovation based on their social environment. 
The interview instrument (see Appendix G) was purposely designed to 
have as its central focus the awareness, barriers, influences, opinions, and 
acceptability of PrEP as an innovation among women. Secondly, standardized 
closed-ended questions were used to describe the demographic, social and risk 
behaviors of the study sample. The instrument comprises three sections: PrEP 
awareness and acceptability, demographic information, and individual risk 
history. 
PrEP Awareness and Acceptability 
Thirteen open-ended questions comprised the first section of the 
instrument. Using Rogers's (2003) Diffusion of Innovations Theory, questions in 
the interview schedule were grouped under Rogers’s five attributes of innovation 
outlined above. PrEP awareness and acceptability questions explored issues of 
awareness, by the participant, family and friends; the role of social media; 
awareness of PrEP subway campaigns; and also the participant’s previous 
knowledge about PrEP as a prevention method. Issues of risk perception were 
explored to understand what risk meant in the context of women and HIV. 
Questions about partners and peer reactions to PrEP and how those reactions 
would influence women’s decision to use PrEP were asked to determine social 
factors that inform PrEP use. This section also included items that asked 
participants to advise providers on key information women need and should 
know about PrEP. All questions had a range of follow-up and probing questions 
that anticipated the respondent’s positive or negative answers. Overall, these 
open-ended questions were intended to encourage the participants to share 
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opinions, feelings, experiences, stories and information about their social world 
as they considered PrEP as an innovation. 
In the second section of the interview, participants were asked to respond 
to demographic questions. Eleven closed-ended questions with two or more 
numbered responses were included in this section and covered eligibility, gender, 
race/ethnicity reason for clinic visit (these three questions were also initially 
asked when participants’ expressed interest to participate), sex partner(s), 
residence, relationship status, age educational attainment, income, housing 
situation, and insurance status. 
The third section had ten closed-ended questions covering the participant’s 
risk history. Questions with a “yes” or “no” response format focused on 
condomless sex, multiple partners, knowledge of family and friend HIV diagnosis, 
injection drug use history, non-injection drug use history, and knowledge of 
partner’s HIV status. Four questions with multiple responses included frequency 
of condom use, history of STIs, HIV testing history, HIV risk perception. 
The interviews were intended to describe lessons that could be learned by 
HIV prevention practitioners and health care networks to scale-up PrEP use 
among this population of women who are vulnerable to HIV infection. Prior 
research by Auerbach et al. (2015) and Whiteside et al. (2011) was utilized in the 
development of the interview schedule. The Auerbach et al. (2015) study sought 
to investigate PrEP’s acceptability and feasibility among women at risk for HIV in 
the US and involved conducting 11 focus groups with 144 women across six U.S. 
cities. Auerbach shared their demographic questionnaire and focus-group 
questions. Both contributed to the development of the present study’s interview 
schedule. Equally useful was Whiteside et al.’s (2011) work in determining risk 
perception for HIV infection and attitudes about PrEP among STD clinic 
attendees. Whiteside shared two questionnaires, which were helpful in 
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developing the demographic and risk assessment questions. Letters from these 
colleagues granting permission to adapt their measures are included in 
Appendix H. 
Data Collection 
All data were collected by the Researcher on-site at the Health Center 
during December 2017 and January 2018. As mentioned above, prior to 
participation, all participants completed a signed consent. After consent, they 
introduced brief but casual conversations at the beginning of each interview to 
help participants feel comfortable before asking direct questions. A description of 
pre-exposure prophylaxis (PrEP) was provided to all participants to introduce the 
topic and to start the interview. As defined in the Introduction section, the 
Researcher presented the concept of PrEP as a “single pill taken once daily that 
can reduce the risk of sexually transmitted HIV infection by up to 92 percent” 
(CDC, 2014a). Asking of the in-depth questions, and thereafter, the closed-ended 
questions regarding personal characteristics and risk behaviors, followed the 
introduction. 
All interviews were audio-recorded. The use of an audio recorder was an 
important tool for capturing detailed verbatim responses by each participant. All 
audiotapes were transcribed, and narratives kept in a locked cabinet. The 
transcripts represent the raw data that were used for analysis. The study 
accommodated and upheld the participants’ right to stop the interview tape at any 
time either to share experiences off tape or to end the taping of the interview. 
During the interviews, no participant exercised their right to stop the interview. 
Most women did not exhibit reservations in sharing stories or situations on 
audiotape. Generally, the Researcher found a generous level of willingness to 
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share experiences regardless of the audiotape. There were quite a few instances 
where participants issued apologies after realizing the depth of their stories, 
believing they had strayed from the question. Although the technique of 
redirecting was used, the Researcher did exercise discretion and generously 
gave women time and a safe space in which to share stories as this quite fittingly 
providing unfiltered views in responding to the interview questions. 
After the audio interviews were professionally transcribed, random checks 
were conducted by the Researcher to help ensure completeness and accuracy in 
the transcription. Accuracy checks were conducted for over 40 interviews during 
the process of coding. Audiotapes were listened to and compared against the 
transcriptions before the Researcher coded the transcribed interviews. 
Coding, Data Analysis, and Synthesis 
Although Rogers’s Diffusion of Innovation Theory was used as a guide in 
conceptualizing the interview questions, the coding and analysis relied on both 
an inductive and deductive approach. The inductive approach was Grounded 
Theory, and the deductive approach was the PRECEDE Framework. Grounded 
Theory was used in an attempt to identify ideas from the women’s voices. 
PRECEDE was used to help ensure that the results would be useful for planning 
future health education programs. 
Three Grounded Theory tools were used: line-by-line coding, focused 
coding, and memo writing. Line-by-line coding involved writing the description of 
each line of each transcribed interview. According to Charmaz (1996), line-by-
line coding “helps you to refrain from imputing your motives, fears or unresolved 
personal issues to your respondents and to your collected data” (p. 37). It is 
intended to reflect as accurately as possible description of the actions, emotions, 
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and events for each line spoken by the respondents. Another consequence of 
line-by-line coding that was found by the Researcher was the increased 
acquisition of knowledge gained from the coding exercise. Unquestionably, “line-
by-line coding keeps you close to your data” through which, “you begin to build 
your analysis, from the ground up without taking off on theoretical flights of fancy” 
(p. 37). Needless-to-say, line-by-line coding was an intense activity and quite 
burdensome when coding hundreds of transcribed pages. 
After several repetitive codes were emerging from the coding process, the 
Researcher switched to from line-by-line coding to focus coding, which captured 
several lines of responses using earlier categories and when necessary creating 
new categories of codes. Charmaz (1996) describes focused coding as “taking 
earlier codes that continually reappear in your initial coding and using these 
codes to sift through large amounts of data” (p. 40). 
Memo-writing is recognized as a type of coding, but it is also a bridge to the 
pre-analysis phase of the study. During the coding process, several observations 
and questions emerged that were written in memo format for later elaboration in 
the results and discussion section of the study. The Researcher found that for 
memo-writing to be effective, a deliberate attempt to question ideas in transcripts 
as they are being coded was necessary. As articulated by Charmaz (1996), 
memo-writing is the “intermediate step between coding and the first draft of your 
completed analysis” (p. 42). It is considered significant in helping to “elaborate 
processes, assumptions and actions that are subsumed under your code” (p. 43). 
After all the transcriptions were coded and all memos were collated, the 
Precede Planning Framework was selected as a way to synthesize the 
information. The Framework’s educational diagnosis and evaluation phase has 
three categories of factors impacting health behavior (which in this case was 
PrEP use): predisposing, reinforcing, and enabling (described in Chapter II). All 
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codes were placed in a table format under the respective factors. During this 
process, the Researcher was mindful to include any coding exception in the 
synthesis, even if codes did not fit into the three factors impacting behaviors. 
Although this study was primarily qualitative, the close-ended responses 
were entered into SPSS Statistics for Windows (Version 24.0), and descriptive 
statistics, including means, standard deviations, frequencies, and percentages, 
were calculated to describe the study sample. 
Credibility of the Research 
Two areas of credibility are considered important in this current study, 
trustworthiness and validity. Yin (2016) describes a credible qualitative study as 
one that “provides assurance that you have properly collected and interpreted the 
data, so that the findings and conclusions accurately reflect and represent the 
world that was studied” (p. 85). Conducting the pilot study prior to the larger 
study built consistency and addressed phrasing of interview questions, 
ambiguity, sensitivity to cultural and social constructions around sex, and 
included perspectives from the population that were repeatedly mentioned as 
influencing and reflective of their reality. This approach aligns with Yin’s definition 
of how to strengthen credibility “choices during the design of your study” (p. 86). 
The pilot study addressed this issue before beginning the larger study. 
Trustworthiness 
According to Yin (2016), creating trustworthiness in qualitative research 
begins with framing the researcher’s “attitude throughout your research and 
during your design work, and not necessarily by employing any specific 
procedures” (p. 86). The field of HIV prevention is an area of passion for the 
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Researcher. As a Black woman working in the field for over six years, it was 
tremendously satisfying to interview women and to tell their stories about PrEP 
and specifically how they relate to HIV risk. The Researcher also believes that 
“looking like” the respondents allowed for easier and frank communication on the 
topics and provided reassurance to respondents of the intended uses of the 
information. 
Validity 
Yin (2016) defines a valid study as “one that has properly interpreted its 
data, so that the conclusions accurately reflect and represent the real world that 
was studied” (p. 89). Using Maxwell’s (2013) validity tests, the following 
strategies were employed: Intensive long-term involvement and “rich” data. 
Intensive long-term [field] involvement means “to produce a complete and in-
depth understanding of field situations, including the opportunity to make 
repeated observations and interviews” (p. 126). Although the data collection was 
not long-term, the Researcher’s involvement with this topic was, and the study 
was field-based, inherently facilitating more insightful and meaningful 
engagements. “Rich” data means “to cover fully the field observations and 
interviews with detailed and varied data” but also requiring that for interview 
studies, such data are generally captured through “verbatim transcripts of the 
interviews” (p. 126). Utilizing professionally transcribed interview transcripts 





The current study was aimed at understanding the motivation of Black 
women to either accept or reject PrEP. The study followed a qualitative 
approach. Results are presented below in a description of the risk characteristics 
of the sample and through a series of individual cases and in-depth thematic 
excerpts from Black women’s narratives. 
Risk Characteristics of the Study Sample 
Using the CDC guidelines (CDC, 2014a), all 72 participants reported one or 
more of the risk factors for PrEP indication. Risk factors mentioned in the CDC 
guidelines are an indication for PrEP use, but final determination of PrEP use is 
based on the clinicians’ medical evaluation. Participants visited the clinic for a 
variety of reasons. Nevertheless, of the 72 Black women in the study, 70 
indicated that they received a combination of an HIV or an STD test and a 
regular check-up. Only two women indicated having only a regular check-up 
without requesting an HIV or STD test. 
Of the two women who indicated no HIV or STD test, one woman indicated 
no condom use and the other had a HIV test within the past three months. 
Almost 30% of the women (n = 21) reported never using condoms, while more 
than 50% reported using condoms every time (n = 30) or almost every time 
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(n = 9). Almost all of the women (n = 70) had an HIV test in the past year, and 
over 75% (n = 55) had an HIV test in the past three months. Almost 10% (n = 6) 
reported having a sexually transmitted disease in the past six months. 
Collectively, these data show that the sample was considered eligible candidates 
for PrEP use according to CDC guidelines. During the course of the interviews, 
almost all of the women indicated that they were currently sexually active. 
Individual Case Presentations 
In this section, nine women’s narratives are presented, which highlight one 
or more themes that emerged from the interviews. These women allowed 
insights into their life, risk perceptions for HIV, and their motivations to accept or 
reject PrEP. All the names used during these presentations are fictitious to 
preserve privacy. The case presentations are also used to help ensure that Black 
women’s voices are heard as individuals whose stories and perspectives are 
valued. 
Case Presentation 1 
Paulette is a Black woman in her mid-60s living in Brooklyn. She reported 
hearing discussions about PrEP on a television program, possibly on The Dr. Oz 
Show. She supports safe sex practices and believes people, regardless of their 
sexual orientation, should use PrEP if they are having unprotected sex. Paulette 
encourages people not to be too overconfident about any one method but to use 
both condoms and PrEP together to ensure safe sex. She reports that she 
always practices safe sex by insisting that her partner put on a “jacket” and will 
even withhold sex if her partner does not use condoms. Although Paulette 
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reports no high-risk sexual behaviors, she reports having regular HIV screens, 
primarily because of a blood transfusion she had a few years ago. 
Paulette reported that she would consider taking PrEP if the medication 
was administered annually through an injection, like the flu shot. These were 
exciting possibilities to Paulette, who was not aware of the clinical trials being 
undertaken in the field. Additionally, Paulette voiced serious concerns about 
PrEP, particularly thinking about possible side-effects of the medication. She 
firmly believed that her decision to use PrEP would hinge on the impact the 
medication would have on her body, because her immune system is weaker as 
she gets older. 
Paulette reports being divorced for several years and that she completed 
high school and earns less than $1,500 per month. Paulette repeatedly mentions 
her age as a possible determining factor in PrEP use, although she admits that 
age is less of a consideration because HIV does not discriminate. Paulette is 
confident that she will definitely not get HIV in her lifetime. 
Case Presentation 2 
Keisha is a woman in her early 20s who lives in Manhattan but feels 
comfortable receiving medical services in Brooklyn. The discussion about risk 
factors was very striking, primarily because even though she reports being 
sexually active over a few years, she reports that her most recent HIV test was 
her first time being tested. She reports that she nudged her partners to get tested 
but has not asked about their results. She hoped that the doctors would provide 
preventive screens and communicate prevention methods, which would also 
benefit her. She has moved forward with her beliefs and is encouraging young 
women with only one risk factor to consider getting an HIV test because they are 
at risk for HIV, since one risk is enough to get the virus. Keisha supports and 
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encourages women to make the best decision for them and to investigate PrEP 
to ensure that the medication has no adverse effects. Keisha reports that her 
mother plays a role in her decisions. She believes that her mother is a strong 
influence in her life and would be a person who could introduce PrEP in a 
positive way. 
Keisha has completed an Associate’s degree and earns between $1,501 
and $2,500 monthly. She reports sex without a condom in the past 6 months and 
indicates that at her last clinic visit she obtained STD and HIV tests in addition to 
her regular checkup. More recently, she reports practicing safe sex and over the 
past 3 months has reported using condoms every time. Additionally, although 
Keisha reports not injecting drugs, she reports using marijuana in the past 12 
months. Keisha is confident that she will definitely not get HIV in her lifetime. 
Case Presentation 3 
Jennifer lives in Brooklyn, and she believes that the government is holding 
back on medication to force people to go to the doctor. This is because, for her, 
the government wants people to spend more money at the doctor. In spite of this, 
Jennifer believes that people are blinded by sex without being mindful of their 
health. Her awakening moment was her STD diagnosis. She is, more than ever, 
vigilant about her need to practice safe sex and to always be protected. She 
believes that when thinking about risk and protection, women should look beyond 
their immediate partners to all previous partners. Therefore, Jennifer believes 
that protection is broader than the commitment to the current partner, but that 
protection is about the unknown. 
Jennifer is a recovering addict who has not used drugs in the past 12 
months. She sees herself as getting wiser and would be open to preventive 
medication to help her live longer and healthier. Jennifer highlights the 
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importance of hearing from female PrEP users who resemble her. She describes 
women who look like her as women not living on welfare and not “sitting around” 
but women who are active, vibrant, and working a fulltime job. 
Proudly, Jennifer reports that she loves her doctor and she follows through 
with her doctor’s advice on her health. She is open about her sex with women 
and asks for guidance from her doctor. She also reports that her mother helps 
her to remain healthy, and if her mother knew about PrEP, it could influence her 
to use the medication. 
Jennifer has completed her Associate’s degree and earns between $1,501 
and $2,500 monthly. At her last clinic visit, she had STD and HIV tests included 
in her regular checkup. Jennifer reports having Herpes within the last 6 months 
but has been treated. Jennifer reports that she is neither in a committed 
relationship or legally married. She reports knowing the HIV status of the last 
partner she had sex with and believes she will definitely not get HIV in her 
lifetime. 
Case Presentation 4 
Margo is in her early 30s and thinks of herself as being not too young nor 
too old. Margo reports that people in her age group do not generally share about 
their experiences and concerns about sexual health. Margo reports that when her 
friends speak about STDs, it is usually negative and disempowering. She 
believes there is a lot of ignorance about STDs among her peers and that it 
alienates people from discussing the topic. Similarly, Margo believes that sharing 
PrEP use will trigger quite negative comments. Although she firmly believes that 
women would not become discouraged by the negative comments, keeping PrEP 
private may be a better option for some women. She believes that women will 
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find ways around negative comments because for many women, their life is 
about living for their children. 
Although Margo reports safe sex practices, she sees the value in using 
both PrEP and condoms. She shares her struggles in mentoring her younger 
sister, who insists on having unprotected sex with her boyfriend. Margo reports 
that her sister’s practices also motivate her to continue to practice safe sex and 
to lead by example. Margo shares the ravages of HIV/AIDS on her family, as 
both Margo’s maternal grandmother and aunt contracted AIDS in the 1980s and 
died years ago. She remembers seeing the weight loss and experienced the 
mourning. Although she reports not knowing anyone currently living with HIV, she 
is vigilant about using protection. 
Margo has her GED and earns between $1,501 and $2,500 monthly. She 
identifies as bisexual, having both male and female sexual partners, and reports 
that she is in a committed relationship but does not live together with her partner. 
Although Margo reports that she uses condoms at every sexual encounter, she 
also reports having an STD in the past 6 months. She reportedly used marijuana 
in the past 12 months but reports no injecting drug use. Margo believes that she 
will probably not get HIV in her lifetime. 
Case Presentation 5 
Denise is in her early 20s and was excited to hear about PrEP. She 
believes everybody needs PrEP and that men and women should equally use 
PrEP. She believes that if PrEP is effective in preventing HIV, it will replace 
condom use, where people are using condoms to prevent HIV. However, she 
believes that if condom use is protecting women from pregnancy or STIs, PrEP 
might not play a significant part in replacing condoms. 
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Denise reports being scared of getting her last HIV test because she almost 
never uses a condom, although deep down she believed that she did not have 
HIV. She is a health worker and has patients who have HIV, which adds to her 
worrying about HIV. Denise reports that she would like for her medical doctor to 
discuss PrEP with her and would begin the conversation about PrEP to learn 
about the side effects, which would help her make a decision about PrEP. 
Additionally, she reports that her mother is also an important person who she 
relies on for guidance on important decisions. 
Denise reports having an Associate’s degree and earns an income ranging 
from $1,501 to $2,500 monthly. Although Denise shares an apartment, she 
reports being comfortable with her living situation and considers her housing 
stable. She reports that in the past 3 months she has received an HIV test and a 
regular medical check-up but does not believe she has done tests for other 
STDs. She reports not knowing her current relationship status, and although she 
knows the HIV status of the last person she had sex with, she reports feeling at 
high-risk of getting HIV. 
Case Presentation 6 
Felicia is in her mid-20s and working in the medical field. She tries to 
protect herself from HIV and encourages her friends to do the same. Felicia 
reports that, if she believes she is not at risk for HIV, she would not take PrEP. 
However, she would be open to discussing her risks with her medical provider. If 
she is at risk for HIV, Felicia reports that she would definitely use PrEP, but 
would need to be certain of the medication’s effectiveness. She believes that 
women should use both PrEP and condoms to be safer. Safety is very important 
to Felicia, possibly because of her work in the medical field. 
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Additionally, Felicia was excited to hear from female PrEP users, their 
opinions and experiences. She believes the input from female PrEP users would 
be essential in her decision to use PrEP, particularly if her friends are also using 
PrEP. They would both have a strong impact on her decision. Although Felicia 
often thinks about HIV, she does not worry about it but instead increases her 
vigilance about protecting herself. 
Felicia reports completing her Associate’s degree and reports earnings of 
$1,501 to $2,500 monthly. She reports that in the past 12 months, her living 
situation is one of doubled up—living with friends. She reported not using 
condoms in the past 6 months but using them in the past 3 months, when she 
has been practicing safer sex by using a condom every time she had sex. She 
reports knowing the HIV status of the last partner and believes she will definitely 
not get HIV in her lifetime. 
Case Presentation 7 
Tanisha is approaching the end of her teenage years. She has only heard 
about PrEP on the television show, “How to Get Away with Murder.” The show 
depicted two gay men discussing using PrEP because one of the men was living 
with HIV. She believes that HIV lives more among the gay population, thus 
reducing the need for Black women to be concerned. 
Tanisha believes that women who use PrEP would be affected by stigma 
and open to judgment and ridicule from people. She explains judgment as people 
believing that the woman is having sex with someone who has HIV or that the 
woman is hiding her HIV status. However, she believes women should be more 
empowered to protect themselves, not being mindful of the judgment of others. 
Tanisha is not enthusiastic about PrEP, although she reports high-risk 
behavior. Tanisha is worried about HIV and reports having increased her 
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unprotected and rough sexual encounters with her boyfriend. Her fears about 
HIV persist, even though she encourages her boyfriend to go to the doctor. 
Tanisha reports that couple PrEP use would be appealing to her, and reports that 
she would feel more comfortable using PrEP if her boyfriend was also using it. 
This sentiment reflects her opinion that women are followers and would be 
influenced to use PrEP if men started to talk about their PrEP use. 
Tanisha indicates that she respects her mother and would look to her for 
direction about PrEP use. She reports that her mother is very supportive and 
knows quite a lot about the world, which is the reason that she would be able to 
convince Tanisha to use PrEP. 
Tanisha reports having completed her GED and lives in a stable housing 
situation. In the past 3 months, she reports receiving STI, HIV, and regular 
check-ups at the clinic. Although Tanisha reports no STI in the past 6 months nor 
drug use, she reports having unprotected sex in the past 6 months and only uses 
condoms sometimes. Although Tanisha asserts that she will definitely not get 
HIV in her lifetime, she was not aware of her last partner’s HIV status. 
Case Presentation 8 
Melonie just entered her 20s. She believes that, although she would go 
ahead and take PrEP regardless of her partner’s reaction, male partners’ 
reactions to PrEP use would impact some women. In addition, she believes 
peers’ reaction would be more of questioning the reason for PrEP use with the 
intention of learning more about the method rather than to influence the woman’s 
decision. 
Although Melonie indicated that she did not “need” PrEP, her medical 
provider actually prescribed PrEP for her. In asking Melonie more questions 
about why she thought the doctor recommended PrEP, she revealed that she 
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had an STI a few months ago. Having reported that she took PrEP, she saw no 
need to continue using PrEP and remained on the medication for only one 
month. After asking her about the importance of speaking to other PrEP users, 
she indicated she may have continued with PrEP if she knew of other women 
who were taking the medication. During her time on the medication, she did not 
inform her partner or her friends about her PrEP use, mainly because she saw it 
as her private activity. 
Melonie refused to indicate her income category, although she did indicate 
that she completed her GED and reported that she has stable housing. Melonie 
reported that her reason for her clinic visit was to do an STI and HIV test, 
possibly due to her reported STD infection. She reports sex without a condom in 
the past 6 months but indicates using condoms every time in the past 3 months. 
Although she reports no injecting drug use in the past 12 months, she did 
indicate that she used marijuana in a similar timeframe. Melonie reports not 
knowing the HIV status of her last partner but decisively believes she will 
definitely not get HIV in her lifetime. 
Case Presentation 9 
Doris is in her early 50s and reports no risk factors for getting HIV. She 
reports celibacy for the last 3 years and sees no reason for using PrEP, although 
she recently had an HIV test in the past 3 months. Doris reports that should she 
take PrEP, it would not stop her from using condoms. The opposite is true; she 
would ensure that she secures her safety by using both PrEP and condoms to 
protect her from HIV and STDs. 
Doris feels that Black women taking PrEP may feel embarrassed about 
taking it because of the reactions from other people. She believes that women 
may feel there would be a perception that they have HIV and, because of that, 
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believes that women may decide not to take PrEP. Additionally, Doris is 
concerned about PrEP contraindications with respect to blood pressure 
medication and side-effects on her health and on her organs. 
Doris reports that her clinic visit was for a regular check-up. She completed 
her GED and reports a monthly income between $1,501 and $2,500. Apart from 
her recent HIV test, she reports no additional risk factors for getting HIV. Doris 
reports condom use and practicing safe sex when she does have sex but 
reiterates her celibacy. Doris also reports knowing people who have died from 
HIV/AIDS but reports not being aware of anyone currently living with HIV. Doris 
reports not knowing the HIV status of her last partner but resolutely believes she 
will definitely not get HIV in her lifetime. 
Summary of Case Presentations 
These brief case descriptions highlight a number of factors that are relevant 
to the study aims. Almost all of the women do not perceive themselves to be at 
risk. If a woman does not believe she is at risk of HIV, it seems unlikely that she 
will take PrEP. The women with a high-risk perception reported rare condom use, 
although other women clearly exhibited high-risk behaviors but did not consider 
themselves to be at high-risk. Some of the other factors that appeared in the 
narratives above, which are described below, are related to concern about side 
effects, potential influence of older women and women who are PrEP users, 
stigma and privacy, and the potential influence of medical doctors. 
Classification of Factors 
This section presents excerpts from the 72 interviews. Referencing the 
classification of factors, both positive and negative responses have been 
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grouped according to their classification of predisposing, enabling, or reinforcing 
factors. Selected factors have been extracted for subsequent discussion and 
illustration in the subsequent section. The credibility of this approach was 
discussed by Green and Kreuter (1999), where priorities are being established 
within categories. The authors mentioned that “if the factor identified is very 
widespread or occurs often, it should qualify for priority consideration” (p. 178). 
 
 
Table 3. Classification of Positive and Negative Predisposing, Enabling, and 
Reinforcing Factors Reported by Black Women Regarding PrEP Use Based on 





protection against HIV is good •  people 
should use protection •  HIV is deadly •  
prevention is critical •  dual protection with 
condoms and PrEP •  causal sex should not 
have a death sentence •  PrEP reduce HIV •  
self-awareness and self-motivation to protect 
against HIV •  discussing PrEP among black 
women creates opportunities to educate •  
conduct research (google/internet) to learn 
about PrEP •  age is a factor when promoting 
PrEP •  will ask GYN and primary care 
doctors (PCP) about PrEP •  monitor partner 
HIV test results •  older women need 
protection •  couple safety is important •  
positive beliefs about PrEP •  women are 
more likely to use PrEP then men •  
protection is used •  not promiscuous •  
abstinence is an option for being safe •  
doctors should present facts about PrEP •  if 
risk is perceived, would use PrEP •  younger 
people will take PrEP more than older people 
•  PrEP should be in demand •  condoms are 
used •  more positive attitude towards people 
living with HIV •  inform children about PrEP •  
PrEP is useful for rape victims •  men and 
women will equally use PrEP •  condoms 
provide reassurance 
not aware of PrEP •  never saw social media 
sign about PrEP •  perception that woman is 
unfaithful –“stepping out” •  not sexually active •  
do not need PrEP •  PrEP does not protect 
against pregnancies and STIs •  many 
unanswered questions •  negative impact on 
relationships •  never tried PrEP •  need more 
information about PrEP •  do not use protection 
•  daily PrEP use is not realistic •  promiscuous 
people use PrEP •  PrEP is not necessary for 
committed relationships •  men are more 
promiscuous multiple partners) than women •  
no advantage to PrEP use •  people are too 
relaxed about sex •  limited awareness about 
risk factors for getting HIV •  one risk factor is 
not as bad as two risk factors •  do not worry 
about HIV •  who should use PrEP? •  HIV is 
man-made •  do not believe PrEP exists •  men 
do not visit the doctor and less likely to take 
PrEP •  men control the relationship •  people 
do not always use condoms •  people are not 
honest about condom use •  more black people 
are getting STIs •  PrEP is for the privileged •  
people engage in raw sex •  not sure if PrEP is 
the right choice •  concern about the 










women by nature will protect themselves •  
injectable PrEP would be more appealing •  
infidelity is a risk factor •  protection is 
motivated by children, family and friends •  
sex with causal partner is a risk factor •  one 
risk factor is enough risk for women •  
understand women’s motivation to use PrEP •  
men and women desire to be protected 
against HIV •  low risk •  people desire the 
pleasure of sex without condoms •  do not 
rely only on doctors •  HIV medication is safe 
•  PrEP vaccine would be a good option •  
male encouragement and sharing their 
knowledge •  PrEP is realistic •  PrEP should 
have been invented years ago •  important to 
be healthy •  doctors provide good medication 
not bad ones •  address the different disease 
affecting women •  power rests with women •  
PrEP gives freedom •  PrEP is a new 
innovation •  conversations about PrEP 
should address safety concerns •  motivated 
to have a long life •  encourage children to get 
tested •  important to learn about new 
prevention methods •  doctors do not judge •  
trust partner •  women would follow both men 
and women in using PrEP •  PrEP is the new 
“freedom pill” •  aware of the seriousness of 
HIV •  PrEP is a “magic pill” •  promote couple 
testing •  educate women at every doctor visit 
•  would use PrEP •  PrEP is an option in 
dating relationships •  men’s use of PrEP will 
reduce women’s risk to HIV 
gay men and anal sex increase HIV • women 
are not always open to doctors •  who invented 
PrEP? •  women’s immune system may protect 
against HIV •  medical staff have limited 
knowledge about PrEP •  partner opinion does 
not matter •  suicidal thoughts •  HIV is one of 
many concerns •  comprehensive sexual 
education is needed •  people are scared of 
HIV •  HIV is invisible •  people are skeptical 
about PrEP because no one knows about it •  
do not agree with risk assessment •  should not 
take pill for HIV •  avoid HIV test •  feel 
invincible from HIV •  no PrEP information on 
college campus •  surprised at low level of 
PrEP promotion •  HIV is not as pronounced as 
STIs •  fragility of condoms •  married and safe 
HIV •  fears – PrEP would reduce sexual urges 
•  was aware PrEP was an acronym •  women 
get talked into not using condoms •  sex is 
usually not planned •  reduce stigma •  PrEP 
associated with transgender and LGBTQ 
people •  length of time to build up in system •  
possibly too early to adopt •  mixed reaction to 
women taking PrEP •  being shunned by 
partner/family/friends because of PrEP use •  
networks do not know about PrEP •  husband 
has multiple partners •  HIV is a touchy subject 
•  no support to take PrEP •  fear HIV is in PrEP 
•  negative feedback would discourage PrEP 
use •  people with multiple partners should use 
PrEP •  men would follow other men in taking 
PrEP •  friends can be judgmental •  people are 
not getting tested •  poorer people are less 
aware of PrEP •  men do not admit to risk •  
men transmit HIV more •  love reduces the 
need for condoms •  PrEP users will use less 
condoms •  PrEP is a conspiracy 
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interested in PrEP prescription •  couples 
collective use of PrEP •  women would use 
PrEP if they were aware •  use of PrEP 
privately •  knowledge of pill-taking •  PrEP is 
similar to vitamins and birth control •  
advancing medical education •  take 
medication on time at the same time •  develop 
steps for adherence •  create routine to use 
PrEP •  use of hand bag as a reminder to take 
medication •  insurance coverage •  easy refills- 
over the counter •  injection option is better 
than pill •  confidential nature of pill taking •  set 
reminders •  use daily pill boxing •   
confused about when to use PrEP • forgetting 
to take pills • will need tools to communicate to 
partner about PrEP use • do not like to take 
medication • concerned about missing a dose 
and the consequences • not adherent to 
medication • loss of insurance • use of the pill • 
length of time on PrEP • did not fill PrEP 
prescription • cost of PrEP • long wait times for 
PrEP appointments • PrEP is time sensitive • 
paranoid about taking medication •   
Reinforcing factors 
Positive Negative 
observed HIV testing signs •  partner can 
influence women to use PrEP •  positive 
messages can encourage community to use 
PrEP •  supportive friends •  promote PrEP in 
doctors’ offices •  would follow doctors’ 
recommendation to try PrEP •  value female 
PrEP users’ opinion about PrEP •  involve 
partner in decision to use PrEP •  benefits of 
PrEP outweigh challenges •  doctors 
(GYN/PCP) have influence and are trusted •  
feel comfortable discussing PrEP with doctor •  
invite partners to use PrEP •  aware of people 
who are living with HIV •   other medical 
providers such as mental health professionals 
and dentists should know about PrEP •  doctor 
plays a role is educating partner/family/friends 
about PrEP use •  doctors should promote 
couple discussions •  key influencers of PrEP 
are older women, doctors and self •  friends 
would be interested in PrEP •  health workers 
can influence PrEP use •  doctor mentioned 
PrEP •  use of video, TV, magazine and printed 
pamphlet to promote PrEP •  female PrEP 
users’ experiences would be more valued if 
they look attractive and who resemble other 
‘normal’ women •  doctors should endorse the 
pill •  an accountability partner •   
need for advertisements on PrEP •  increase 
the number of people who know about PrEP •  
partner would react negatively to women using 
PrEP •  medication contraindications •  never 
heard about PrEP from doctors (GYN/PCP) •  
no discussion with family/friends about PrEP •  
men cannot influence women to use PrEP •  
assumption that women have HIV •  PrEP side 
effects •  allergic to PrEP •  female PrEP users’ 
feedback not important •  potential hair loss, 
weight gain while using PrEP •  concern about 
the prolonged use of PrEP •  women should 
share doctor’s concern about their risk factors •  
people may not report PrEP use •  revealing 
PrEP use is a lose-lose situation •  information 
on clinical trials •  embarrassed to take PrEP •  
life-threatening consequences of PrEP •  
negative reactions from friends •  doctors never 
mentioned PrEP •  adverse side effects •  feel 
isolated •  knew no other woman on PrEP •  
impact on emotions, mood and attitude •  PrEP 
shows positive results with women •  partner 
and family will criticize women for PrEP use •  
negative result on pregnancy and reproductive 
health and effects on baby •  partner/family will 




There were similarities and common themes echoes by most Black women 
interviewed that were captured as predisposing factors, primarily because they 
relate to their motivation. As only two women have actually used PrEP 
previously, the majority of the participants were new to PrEP as a prevention 
method, and therefore their initial reactions to PrEP questions represented a 
point of view that is not a lived experience. Predisposing factors that may predict 
and motivate a decision to consider taking PrEP to prevent HIV are outlined 
below. These factors represent Black women’s beliefs and perceptions in moving 
forward to embrace a health behavior change. This explanation recognizes that, 
inherently, there is a “cross-cutting relationship between factors”, where one 
factor can “appropriately be placed in more than one column” (Green et al., 1980, 
p. 78). The predisposing factors include awareness about PrEP, beliefs about 
PrEP, potential users of PrEP, partner’s influence on PrEP use, negative 
reactions of partners, expected reactions from friends, perceived need for using 
PrEP, and, importance of shared experience and learning from female PrEP 
users. In addition, several beliefs that may be barriers to PrEP use are 
considered, including evidence of PrEP’s effectiveness, stigma, limited nature of 
protection, and the perceived tension between PrEP and condom use. 
Lack of Awareness about PrEP 
Only a few women indicated some prior knowledge about PrEP. The 
responses were categorical and included either yes or no responses. The 
question was “Before today, have you ever heard of PrEP?” Sample responses 
included the following: 
Female #16: I don’t know anything, I want to know everything, I want 
to know where it came from, I want to know when did 
the study start, I want to know who has it been tested 
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on, side effects, long term effects, short term, things you 
have seen, what is the outlook that you have done 
already… those would be the things I would want to 
know. 
Female #10: This is actually the first time anyone has said it to me. 
Female #18: No, this is my first time I ever heard of it. 
Women could more easily identify with “HIV get tested campaigns.” These 
campaigns represent traditional forms of HIV prevention messages that have 
been disseminated through the City at bus stops and on subway cars. Examples 
of responses: 
Female #57: No. Never heard of that.  
Female #5: I saw something but I don’t know unless someone 
explains to me what it is about.  
Dialogue #48 
Researcher: Have you seen any ads in the subways from department 
of Health that speak about get tested, know your 
status? 
Female #1: Yes. 
Researcher: Have you seen anything that says pre-exposure 
prophylaxis or PrEP? possibly at the bottom of ads, it 
just says PrEP—P, r, E, P? 
Female #1: If I did I probably wouldn't remember. 
Dialogue #2 
Researcher: So, before today, have you ever heard of PrEP—pre-
exposure prophylaxis?  
Female: No, I haven’t. 
Researcher: Have you ever seen any ads on the subway that says 
protect yourself? 
Female: Yes. 
Researcher: Can you remember what you saw? 
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Female: It said better safe than sorry, things like that, use a 
condom, and protect yourself.  
Dialogue #23 
Researcher: Before today, have you heard about PrEP? 
Female:  No. 
Researcher: Have you seen any signs, or printed material that has 
PrEP and say have safe sex, or use a condom? 
Female: Well that, yes … I’ve seen advertising in the subway, on 
the bus, on buildings about safe sex, even at the bus 
stop. 
Researcher: Mhm, but any with the word PrEP? 
Female: Umm, I really didn’t take notice if it’s from PrEP, I really 
didn’t take notice. 
Dialogue #6 
Researcher: Have you seen subway signs or printed material that 
carried the word PREP? 
Female: Yes. 
Researcher: In what context? 
Female: I saw the signs on the subway but I never really looked 
at it in depth.  
Researcher: Could you recall words or anything associated with it?  
Female: No, I can’t. 
Women were surprised and quite interested in learning about PrEP: 
Dialogue #14 
Researcher: Is there anything you would like to know about PREP as 
you think about it as an option?  
Female: My question is what form does it come in? 
Researcher: a pill form. 
Female: How often do you have to take it? 
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Researcher: Once a day? 
Female: So, is like birth control? Ok. How new is this? 
Researcher: Approved in 2012  
Female: So, it’s big, so how come I never heard of it? Are there a 
lot of people using it? 
Researcher: Not a lot, but more men than women. That’s my reason 
for interviewing women. 
Female: You have got to be kidding me! More men! Wow. I’m 
shocked because I didn’t even know about it. So, they 
need to put it out there for the women. 
Dialogue #18 
Researcher: So, before today, have you ever heard of pre-exposure 
prophylaxis?  
Female: No this is my first time I ever heard of it. 
Researcher: The short version of the name is P-r-E-P. 
Female: PrEP? Yeah. 
Researcher: PrEP 
Female: Mhm… 
Researcher: Have you seen any subway signs or ads? 
Female: No, not at all, this my first, that’s why I was so interested 
trying to find out what this is all about. 
Among women who knew about PrEP, they obtained the information from 
various sources and with varying degrees of completeness. 
Dialogue #16 
Researcher: Have you seen or heard about PREP in the subways or 
anywhere before today? 
Female: I watch a lot of TV. I actually didn’t hear that name, but I 
heard of a drug that prevents someone else from 
catching HIV if you already have HIV, so I’m not sure if 




Researcher: Before today, have you ever heard of pre-exposure 
prophylaxis or PrEP? 
Female: Yes. 
Researcher: In what context?  
Female: Advertisements on the train.  
Researcher: What did you see? Can you remember what you saw? 
Female: Basically, it looked like some straight people, lesbians 
and gay people in the ad it said PrEP. Um, I guess like 
preventing HIV. I also saw it when I went to my GYN, 
you know, how they have like the information board go 
by. That was one of them. 
Dialogue #3 
Researcher: Before today have you ever heard of PrEP? 
Female: Yes, my doctor prescribes it to me. She explained 
everything to me a few months ago. I never heard of it 
before that. She mentioned it to me as she thought I 
was a good candidate as I am sexually active. She said 
this pill will prevent HIV, I said wow, how come nobody 
knows about this, and they don’t talk about it. I never 
really heard anybody talk about it so I said I would give 
it a try. 
Dialogue #21 
Researcher: Before today, have you ever heard of PrEP? 
Female: At the health center. 
Researcher: Who told you about it? 
Female: A staff member. 
Researcher: What did s/he tell you? 
Female: He just told me that they have a PrEP … you can take, 
so you won’t get … that’s all I heard. 
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Conducting further research was a constant thread running throughout the 
conversations. Providing information is the starting point to increase women’s 
independent study, an important factor for women to become more aware. 
Female #41: My first thought is before taking it go, get your status 
checked out. The next thing is you have to be cautious 
at all times because you never know what can happen 
and if you're not too sure about it, ask more questions. 
Look it up, read the side effects, read what it contains. 
Ask your doctor cause if you're taking medicine for 
something else, does it cause side effects, will it knock it 
off. 
Female #6: She [doctor] would just have to suggest it and I would 
always read about it myself. I always do that, even to go 
on Google and follow up and read about things. If she 
suggested it I know it would be something positive to 
take. 
Female #7: Maybe if I talked to the doctor and researched it and 
know the side effects then yes. But otherwise not just 
because you tell me to do it right now. 
Female #11: It would basically come down to the side effects.… I 
have researched this, and I know if you take this you will 
be ok. It will not mess with other medications. Any 
medication, it’s always the side effects.… 
Female #13: You have to educate the partner, and do your research 
on the medication first and then, if you have one 
partner, you discus if this is the right thing for you. 
Because you take these medications and the side 
effects are deadly. 
It was striking to note that of the six women who had prior knowledge about 
PrEP, three associated its use with LGBT people and people of trans experience. 
Female #5: In all the ads that I’ve seen it’s just the LBGTQ group is 
targeted, so I don’t see where women would use it. 
Female #2: … I don’t know any women who are on it. Umm the few 
people that I have spoken to about it are people who are in 
the LGBT community. So, I don’t know like if straight women 





Female: I don't want to say the wrong advertisement, but maybe 
it's the one with I think transgender women. 
Researcher: So, did it appeal to you in any way to learn more? Or did 
you say, maybe this is something that I could investigate 
for myself? 
Female: Not necessarily. 
Beliefs about PrEP 
Black women were asked to assess their beliefs about health and to 
determine whether PrEP was positively or negatively associated with their 
beliefs. Using Green and Kreuter's (1999) definition, “belief is a conviction that a 
phenomenon or object is true or real” (p. 162). The following dialogue provides a 
rich sense of meaning that is attributed to PrEP. For most women, belief about 
PrEP use is simple, logical and relates to past experiences: 
Dialogue #3 
Researcher: When you think about your beliefs about sexual heath 
and HIV prevention, does PrEP fit positively or 
negatively with your beliefs?  
Female: Definitely positive, the way things are set up now, you 
even touch someone, or you can have one partner, but 
you don’t know who they are sleeping with. So, it’s 
positive. 
Dialogue #6 
Researcher: OK, so when you think about your beliefs about sexual 
heath and HIV prevention, does PREP, this medication 
that you take, does it fit positively or negatively with your 
beliefs? 
Female: I think it fits positively, if this is supposed to prevent. Is 
this to prevent? Would the person take it before sex? 
Researcher: They take it daily before. 
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Female: Anything that will help a person not get it is a good 
thing. That’s just plain and simple. But I also think 
people should use protection also. 
Dialogue #12 
Female: I would say positively, because it’s supposed to be 
against it right? 
Researcher: Yes. So, when you say positively can you explain little 
more? 
Female: I had an uncle that passed away from HIV. I just don’t 
want to see anybody go through something like that.  
Women also provided their individual beliefs about PrEP as a prevention method: 
Female #69: Positive, because it can protect you. But for me, I felt 
like I would take it to protect myself, just in case, so it 
will be positive.  
Female #18: I think it’ll fit in positively with it, with the beliefs, because 
it’s best to be aware of any sexual medication that is out 
there that can help you prevent from getting something, 
it’ll be a help. You know, what you’re up against, cause 
you could be sexually abused, and that’ll be one way for 
you to take the medicine and you won’t have to transmit 
that disease. So, I think it’ll be real helpful. 
Female #43: Hearing about it this morning it could be positive 
because I have two daughters. One is 26 and one 19 
and actually they're home with their boyfriends. Their 
boyfriends spend the night cause they have their own 
room.... I was just explaining to them you got to be 
careful, you know if your boyfriend is sleeping over I 
need to know because I need to know if I my children 
may be exposing themselves sexually… So, I think it's a 
positive thing because I would want to know about it so 
that I can explain to them or even when they come here 
to get information.... 
Female #70: I'm aware that some people don't like taking medication 
at all, but if she was concerned for her being then you 
have to take it on a daily basis. So, I find a lot of people 
ain't crazy about it, but my belief is that it should help 




Female #63: I think it is a positive thing because although it is not 100% 
effective it could possibly prevent you from getting 
something, I say why not, as long as it doesn’t cause any 
long-term health issues. I think it’s good that it’s available. I 
didn’t know anything about that.  As long as it prevents you 
from getting it. 
For some women, their beliefs were contingent upon conditions, questions and 
lingering concerns: 
Female #67: Positively, if it's something that can prevent the disease 
from spreading. I guess my only concern would be like 
the flu vaccine, how they inject you with the strain to 
prevent it from being so bad.  Like I guess that would be 
the thing I would want to understand more about the 
drug … to be sure that there's no strain of the virus in 
the drug at all.  
 Dialogue #41 
Researcher: Based on how you take care of yourself, the beliefs that 
you hold, like getting regular check-ups, maintaining 
good reproductive and sexual health.... Does a 
medication that prevents HIV fit positively with your 
beliefs or does it fit negatively with your beliefs?  
Female: See I'm not too sure, really couldn't say on it because I 
never had that or never know how to believe about 
using it. But if you say it prevents you from getting HIV... 
Researcher: Right. So, it's for persons who do not have HIV that 
takes PrEP to prevent them from getting HIV. 
Female: Then I think it's pretty good. But is it a hundred percent 
accurate? What is the percentage of it? Did somebody 
use it and did it fail? That's, what I want to know. 
Dialogue #35 
Researcher: When you think about your beliefs about sexual health 
and how you keep yourself healthy, does a medication 
that prevents HIV fit positively or negatively in your 
beliefs? 
Female: I mean it could go for me but I’m really not that sexually 
active so I wouldn’t really need…. 
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Researcher: Your doctor prescribed it. So, would PrEP be something 
you recommend or suggest to friends? 
Female: It's like I'm in between  
Researcher: Mhmm hmm 
Female: Like I would recommend it to certain people but for me I 
just feel like it's kind of risky with like the side effects or 
whatever it was because when she told me about it last 
time and I read the like side effects it was a lot …. 
Researcher: Mhmm hmm. 
Female: … So I was scared, that’s why I just never took it. 
There were very few negative associations between PrEP and beliefs. The 
following responses capture the main examples: 
Female #5: If I understand right I don’t think it does. I don’t know if a 
pill helps protect you from these things. It’s just a cover 
up to get people to be on the pill and be more sexually 
active. 
Female #62: … It's kinda in between in a sense only because I feel 
like even though it's very advanced, it's kind of a way for 
people to not be careful because there was a pill for it 
now. So, it's like … I don't need to take that caution 
anymore. 
Dialogue #31 
Researcher: When you think about how you take care of yourself 
in terms of keeping healthy, going to see your provider, 
your OB-GYN, whoever you see … does PrEP, this 
medication that prevents HIV, does it fit positively or 
negatively with your beliefs? 
Female: I say negative … 
Researcher: Mhmm hmm. 
Female:  … Because I don't believe in medicines. 
The skepticism observed primarily originates from a place of uncertainty and 
being unaware of the medication and the science behind PrEP. Most women 
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indicated the need for additional research, which will help in making firmer 
decisions that align PrEP with their beliefs. A few skeptical responses are 
illustrated below: 
Female #48: I don't know. I don't think so. I think it's a gimmick or 
something like that … what is in the pill that could 
prevent you from getting AIDS? 
Female #40: Well, I don't really know much about it but I guess it will 
serve its purpose. Not sure. 
Potential Users of PrEP 
The respondents felt that women would be more likely than men to use 
PrEP. Unlike responses that favored both genders’ use, the justification for 
women-only use was usually accompanied by a perceived distinction between 
genders. 
Female #1: I think women will use it before the men.… I feel like 
women are more health conscious than men; if they are 
sick they will not go to the doctor. They have to be like 
pretty much near death to go. Women are more health 
consciences, we worry about things like this, and we 
study things like that. 
Female #3: I talked about it to a few of my male friends. They don’t 
trust it. That was their opinion.  It was a few of them. I 
don’t know why. But when I talked to my female friends 
about it, they said I’m going to talk to my doctor about 
that. So that’s where my opinion comes from. 
Female #64: I would think that hopefully I will help them take it 
equally, but sometimes I think maybe women might take 
it more than men would. Because they just don't like to 
do things that they don’t feel is okay. But women will 
think about it and we'd be like, okay, that's something 
that I would want to do. And then it's like we would have 
to talk them or push them into doing it.  But I think we 
would take PrEP more first. 
Female #72: The woman probably would take PrEP more than the 
men because the men think they, invincible nothing can 
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ever happen to them. Do you know that belief that I'm 
stronger, I could do this, I could do that. That will never 
happen to me. That could never be me. I would do this 
and I will do that. Yes. Women are more likely. I don't 
want that to happen to me. I'm going to try to prevent it 
as much as possible. 
Female #58: We're likely to use it? Because I think men don't go to 
the doctors often. I think women are more likely to use 
it. 
Female #14: I think more women would than men.  Some men don’t 
even want to use a condom. Women are more into 
health. Men you have to push them. 
Female #25: Hmm, I don’t wanna say that women are more cautious 
when it comes to sex as opposed to men, but I feel like 
we think about the future more than they do, so we will 
be more inclined to use it compared to them. 
Female #19: I think women are more health conscious than men. 
Men don't go to the doctor, unless something falling off. 
I'm serious. Women go to the doctor … I guess because 
we're more family oriented, because we take care of the 
kids. Even if we may not have kids, I think women will 
go to the doctor faster than men. When we go to the 
doctors, maybe two or three times a year, and they only 
go if something hurts or if somebody say, look, you have 
to go Men don't often go to the doctor whether they're 
sick or not. They have to be forced to go. 
Partner’s Influence on Black Women’s PrEP Use 
There is recognition among Black women that men have influence over 
their willingness to use PrEP. Similar influences appear to be associated with the 
decision about condom use in relationships. 
Female #13: Men are the ones who most likely contradict women 
when it comes to sex, because a lot of them don’t like 
condoms, they don’t believe in it, especially West Indian 
men. They don’t like condoms. They say, oh they are 




Researcher: If more men used PrEP would it positively influence 
women to use PREP you think? 
Female: Yes, women are followers, so if men do it they would 
want to do it too just to show they can do it better. 
Researcher: If women were to take PrEP would it affect their 
partner’s reaction? 
Female: I don’t think it would affect it, but it would cause some 
concern—like why you taking that? I don’t have HIV, so 
why you taking that? 
Researcher: You mentioned that women are followers. Do you think 
that reaction will impact their use PrEP? 
Female: Yes, if my partner wants me to be on it, then I will get on 
it. I don’t want to sound any type of way but that’s how 
most women are. And if he says the opposite she will 
stop taking those pills. 
Dialogue #28 
Researcher: If more men used PrEP would it positively influence 
women to use PREP you think? 
Female: I think so, yeah. 
Researcher: Why? Why are you thinking so? 
Female: Well, because I feel like we don’t really have like the 
strong Black men in our community, so I feel like if more 
positive Black men you know what I’m saying…. 
Researcher: Mhmm hmm. 
Female: If it be positive Black men that you know, start talking to 
us and teaching us some knowledge … maybe, you 
know and kinda get us to talk into it, we might be like 
okay, like why not, you know … try it out you know. It 
doesn’t hurt to try. Like if it doesn’t work out for your 




A few Black women were not as accepting of any reality in which male’s PrEP 
use could be an influence over women. Interestingly, there were different 
reasons for that conclusion. 
Female #57: I don't think because a man uses it that more women 
are going to use it.… I think some men may try it, you 
know, but I don't think they actually think, well, why 
should I try it? It's what I know nothing's going to 
happen. 
Female #55: I think men would be more easily influenced. If the 
woman is like, I'm taking this, I'm not trying to get HIV or 
whatever, they'll probably be more on board because 
they want to have sex. 
Dialogue #39 
Researcher: If more men use this medication, would it positively 
influence women to use it? 
Female: No, not necessarily. No. 
Researcher: Um, why you think, why? 
Female: Because men wouldn’t tell you. That's just like men they 
tell you I’m not sleeping with this girl, but normally he is. 
So just because I tell you, okay, I'm taking it and he tried 
to get you to take it that don't make sense taking it in a 
sense. 
Dialogue #14 
Researcher: If more men used PrEP, would this positively influence 
women to use it? 
Female: I don’t think it would, because to me the women would 
be more likely to use it than the men. I would say no to 
that. 
Researcher:  Why? Please explain. 
Female: Because women are more into our health than men. So, 
we don’t need a man using it to make us push to do it. I 
figure we would do it on our own. 
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Impact of Negative Reactions by Partner 
Although there were responses indicating that partners reactions can be 
encouraging to women’s use of PrEP, the sheer majority of responses reflected 
that Black women feared their partners would have negative reactions to their 
use PrEP. In Rogers’s theory (2003), this can be considered an attribute of the 
innovation, namely, impact on social relations. Largely, indication of PrEP use 
was associated with a plethora of disastrous endings, from signs of cheating, 
questioning of HIV status, having a promiscuous lifestyle, to upheaval in 
relationships. These reactions appear to have a negative association with Black 
women deciding to use PrEP. Below are responses and dialogues about this 
perception of PrEP use: 
Dialogue #018 
Researcher: So, if women were to take PrEP would it affect their 
partner’s reaction? 
Female: I don’t think it should, because I’m trying to protect 
myself and if there’s a medication to prevent me from 
having HIV by all means. I would explain to my partner 
too, let’s all get on board. So then that way there won’t 
be any discrepancies between the two of us; you’re on 
it, I’m on it. Let’s just keep it like that, and let’s not go 
outside of our relationship, let’s have a consensual 
relationship … and then you forget to take a pill one day 
and then boom! 
Researcher: What about generally the reaction from men? 
Female: If I was taking a HIV pill to prevent having HIV, I think … 
a lot of men are not gonna be on board because why 
are you taking a pill if you don’t have it? Have you been 
sleeping with…. It’ll be a lot of have you been sleeping 
with somebody that has it and this is why you’re taking 
the pill and telling…. It’ll be a lot of back and forth, it 
wouldn’t be…. Let me see what’s the word I’m looking 
for…. It wouldn’t be a good discussion with a man and a 
woman discussing this situation, but among women 
we’ll feel comfortable talking about it because we’re 
trying to prevent from catching HIV. From a man’s point 
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of view, oh you got it and that’s why you’re taking a pill. 
They gonna turn the table around, you know, they 
gonna turn the table around, that’s what I’m trying to 
say…. 
Researcher: In that reaction, how would it impact your decision to 
use PrEP based on their feedback? 
Female: Well, me, personally, I would take the pill. Even if I know 
I don’t have and I’m not gonna go out there and explore 
with anybody to see if they have it, but you never know. 
Cause that’s just like the virus that the kids can get 
when their 11 years old and they get the shot to prevent 
it. So, I feel like that’s saving me just in case, cause you 
never know. A man is not gonna come forward with his 
STD situation. They’re not, they gonna slither ‘round 
and slither ‘round and “oh you got it from John,” John 
gave it to you, Mary gave it to John, they never gonna 
be honest about that. A woman would be more honest 
about taking that pill to protect herself.… I would take it 
to protect myself, cause you can look like Don Juan and 
you may have the monster. 
Dialogue #5 
Researcher: So, if women were to take PrEP would it affect their 
partner’s reaction? 
Female: Yes, if it was me I would want to know why are you 
taking this pill. If this is about sexual health and HIV 
prevention, it’s like why are you using this pill? Who are 
you sleeping with? I know I don’t have anything.  We 
should be on the same page as far as knowing what 
each other have, what we do on the outside. But why 
would you be taking this pill? Most of the times people 
in that lifestyle have higher chances of getting HIV, or 
AIDS.… 
Dialogue #31 
Researcher: If women were to take PREP, would it affect 
their partner's reaction to them? 
Female: In this society, yes but I don't think it should. 
Researcher: So, when you say yes, what is some of the feedback 
that the man would give to the woman? 
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Female: Well, my friend had a urinary tract infection and her 
boyfriend was like Eww, how you got that?—laughs—
So I’m pretty sure the response won’t be too far from 
that.… it shut her down like to the point she didn’t even 
wanna express anything with him with her body. So, I 
think it’s like how they say it. If you say it like, it’s dirty, 
then, yeah, it’s over. We’re not gonna express anything 
to you. 
Dialogue #10  
Researcher: If women were to take PrEP, would it affect their 
partner’s reaction? 
Female: Nine times out of ten, yes. They are going to assume, 
why are you taking that, what’s wrong? 
Researcher: So, it’s on the suspicious end most times. What are 
other reactions men could have? 
Female: They would probably say they will try to get it and sell it. 
Especially if it does all the things that you say it’s 
supposed to do. The black market is going to get a hold 
of it. 
Researcher: Do you think that the reaction from the men would sway 
the woman in the decision that she makes to use this 
medication? 
Female: Probably. So, if the man says you go ahead and take it 
she will, but if he asks why are you taking it?  She more 
than likely will not want to take it. 
Researcher: Why do you think that women are more swayed by the 
men in these decisions as it relates to sexual health? 
Female: because of the ding-a-ling. 
Women were quite passionate and opinionated about this topic. This was one of 
the questions that was suggested from the pilot study. Their vivid views on 
partner reactions were clear. 
Partners who have negative reactions will impact Black women’s decision 
to utilize PrEP: 
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Female #61: Well, I believe the partner might not trust her anymore, 
you know.  He's going to say, well, I know I don't have it 
and you don't have it, so why are you taking? Are you 
messing around? So, I think that we will mess-up the 
trust factor between them. 
Female #35: … Why you taking that like I have HIV? 
Female #38: Definitely. I do believe that it will affect the partner's 
reaction because the partners are going to say why are 
you taking something?… I think definitely men would 
look at you sideways. I also think the other way around 
as well that the woman will look at the men funny. 
Female # 24: … They’ll think she got something, that’s why she 
wanna use it…. 
Female #57: I think if women would take it, the first thing they’re 
going to see is, so, you're going to go out there and do 
something that would probably be his thinking … the 
only reason you're taking it is either you don't trust me 
or you’re going to go out there and do something to 
protect yourself. So that would be my theory.… Unless I 
think if the woman took it and she explained it to her 
mate, you know why they were taking it, I think maybe 
they would understand better. But sometimes that 
doesn't work because I may feel like you're taking this, 
why are you taking this? They may not understand. 
Female #12: I think my friends would be interested because they are 
usually on top of their health. So, I don’t think they 
would look at it as a negative thing. They would be more 
motivated to try it, too. 
There were perspectives from a PrEP user in the study about her thoughts about 
her partner and how he would react to her using PrEP. She kept her PrEP use 
private from her partner. 
Dialogue #3 
Researcher: OK, if your partner knew that you take PrEP, would he 
have a positive or negative reaction? 
Female: A little bit of both. At first maybe negative, but once I 
explain it to him and become more educated about it he 
might come around. 
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Researcher: Why do you think he would react in a negative way at 
first?  
Female: He would probably think I don’t trust him. That’s the 
main reason. He might say he doesn’t have anything or 
he is not sleeping around.  But it’s just more comfortable 
for me to take it, I feel like I have a peace of mind. 
Researcher: So, if he knew and gave you that negative or positive 
reaction how would it impact your decision to continue 
to use PrEP? 
Female: This is my body. I’m going to use it regardless, as long 
as I don’t have any negative side effects; I’m going to 
keep taking it. So, no matter what he says, it has 
nothing to do with him. 
Researcher: You’re more open-minded. Ok, so if women were to 
take PrEP, would it affect their partner’s reaction? 
Female: Maybe. Yes, because they will ask why are you taking 
that? My partner doesn’t know I take it. 
Expected Reactions from Friends 
Although it does appear that partner influence is much stronger than 
friends, peers, or girlfriends, women do rely on their friends for encouragement, 
and to support their decisions about PrEP use and sexual health. Responses 
reflected mixed reactions and show the void of PrEP education among this 
community. Dialogue and individual responses are captured below: 
Dialogue #28 
Researcher: Okay, what about her friends? Suppose she told her 
friends that she was gonna take this medication, what 
would some of the feedback from her friends be like? 
Female: I think it might be positive. Some of it. And some of it 
might be negative. 
Researcher: Mhmm hmm. 
Female: Because the mentality some people have, some of them 
have childish mentality and some of them are very 
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mature. I think the good ones would be like I’m glad … if 
it can prevent yourself from getting it why not? And it 
could prevent you from giving it to somebody else then 
why not? But like the negative ones will be like, they just 
wanna laugh at you and like make jokes.… 
Dialogue #30 
Researcher: How would their friends react to women using PrEP? 
Female: Their friends will react to it well because they know that 
they will be on the safe side. 
Researcher: And would that cause the woman to use, to go ahead 
and use it? 
Female: Uh yes that will cause her to go ahead and use it. Once 
she has someone to … what’s the word umm … not 
protect her, to umm … not guide her…. 
Researcher: Encourage? 
Female: Encourage, that’s the word … to encourage her, and 
she knows that it’s a true friend, then she will. 
Researcher: Mhmm hmm. 
Female: You have to encourage her, you have to uplift her. 
Researcher: Mhmm hmm.  
Female: And you have to make her … believe that it’s going to 
work.  
Dialogue #35 
Researcher: How would her friends react to her if she told them that 
she was taking this medication and would 
that impact whether she actually takes it? 
Female: At first, if she tells her friends they're gonna to think that 
she has HIV or something … like something in that 
order but if she really explains it … I think that they will 
want to do it too. 
Researcher: Mhmm hmm. And would that cause her to take the 
medication or not take the 
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medication or be indecisive about taking the medication 
based on their reaction… 
Female: If they have a lot to say about it and if it sounds bad to 
them then she probably won't take it. 
Individual mixed responses about friends’ reactions to PrEP use: 
Female #22: I feel like her female friends would be onboard for it 
because we, I guess we…. I don’t wanna sound biased, 
we understand like, that this is for our safety. Like, if 
nobody else looks out for us, we have to look out for 
ourselves and we have to look out for each other as 
well. So, I think they’ll be supportive of it, the female 
peers. I don’t know about the male peers but the female 
peers at least. 
Female #25: To be honest, like, I’ll be honest, I really keep a lot of 
stuff to myself but umm, I got a lot of positive female 
friends so they might say it’s a good idea you know. 
Even though I’m sexually active, I use condoms but it’s 
like, stuff could happen when you use condoms, like the 
condoms could break and stuff so, its pros and cons to 
it, it could be a good idea cause you never know what 
could happen. 
Perceived Need of Using PrEP 
About half of the initial responses to taking PrEP were no. This is not 
surprising because the interview did not attempt to discuss individual sexual 
history as to possibly identifying PrEP as an option. In addition, most of the 
women were not familiar with PrEP. Among married women, responses ranged 
from unequivocally no to PrEP to refusing PrEP on the basis of being married 
and the protection that (is assumed to) be conferred on married women. 
Researcher’s question: Do you feel that you need to use PrEP? 
Female #9: I would say no because I’m married, but who knows.  
Female #14: Me personally, I am not active, but if it comes to where I 
get active, it wouldn’t be a problem to use it. Because 
you really have to be careful now. 
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Female #1: To be honest, you never really know what somebody is 
walking around with, so everybody should, I don’t know 
if it’s a need, but it is kind of a necessity because you 
don’t know what somebody has, so you have to protect 
yourself. I would do it. When I researched it I was like 
PrEP, then I googled it. I was like I would take that as 
long as it doesn’t cause me any risk. 
Female #8: No, because I always get tested and if I’m with 
somebody I make sure they get tested. 
Female #72: No, because I kind of I'm kind of scared [medication]. I 
practice safe sex. That's why I said to myself, I'm 
practicing safe sex and I know that my partner's not 
doing nothing. But if my partner is, I'll be the dumbest 
fool for not taking it…. 
Female #15: No. I think the best way to avoid STDs is to stay 
celibate. But I know women have their needs. It protects 
you but not about everything. So, it should be one pill 
for everything not one pill for one thing, because I am 
not just going to be concerned about AIDS and not 
chlamydia, and gonorrhea. 
Female #70: Actually, it’ll help a lot of women. I think it'd be beneficial 
if more women were taking this medication. That's more 
prevention of HIV … being in prison, I have seen people 
come in and didn't have HIV, but when they went out 
they got HIV, because I was doing the testing. 
Of note, during the interview, the Researcher realized that the word “need” in the 
questions was loaded: “Do you think you need PrEP” was perceived in a 
negative way. Possibly, the language inadvertently suggested inappropriate 
behavior or represented an ‘admission’ of sexual risk or took away agency from 
the women. Although this was rephrased as the interviews continued, a few 
respondents showed their grit by rephrasing the question along similar lines. 
Researcher’s question: Do you feel like you would need PrEP? 
Female #28: I mean I don’t feel like I would need it, but I mean, I 
could use it…. 
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Female #2: Everybody needs PrEP.  You never know whom you’ll 
meet. I could tell you I’m clean and I’m not clean. You 
just don’t know. So I think everybody should…. 
Researcher: Do you see any advantages of PrEP over other 
methods? 
Female: Yes, sometime people just rush into unprotected sex. I 
mean not because they mean to, but the urge is there 
and if you are on PrEP it could reduce the risk of HIV, 
and the pregnancy, if you are not ready to get pregnant. 
I would rather have PrEP than not have it.  
This last quote shows that there is confusion about PrEP and pregnancy 
prevention. 
Dialogue #5 
Researcher: Do you feel that you need to use PrEP? 
Female: No, but to be on the safe side I make sure I am aware 
and cautious about who I am dealing with or who I want 
to be sexually active with. 
Researcher: So, for you, I am hearing that the need is not to swallow 
the pill but the need is to be aware that there is such a 
thing. 
Female: Yeah, I don’t think it’s a need. It’s about being on the 
safe side. Not to say you will go and sleep with so many 
people, but I will take this pill … you can take this pill 
and use condoms and stuff still pass through so it’s 
about being safe. Being aware of what you can get is 
more important than a pill. 
Importance of Shared Experience and Learning 
The survey sparked great interest about PrEP. Therefore, it was not 
surprising that there was almost overwhelming support to hear from female PrEP 
users. Almost every woman indicated that it would be important to ascertain 
“inside” information from other women who used PrEP. 
Researcher: In making a decision about PrEP, how important is it for 
you to hear from other women who take PrEP? 
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Female #4: Yes, because I would like to know their feedback, how it 
affected them. Are there any side effects? Did it really 
work? All of that I would like to know from that person. 
Female #5: It would be very important. I would want to know the 
side effects. This whole HIV, AIDS stuff is scary. It’s a 
scary topic and people don’t care anymore. Nowadays 
people don’t care, you didn’t ask for this and they pass it 
on. But I would ask, did it lower your chances?… The 
best way of being safe is not doing certain things, to just 
wait, this is not an STD or STI, this is serious. You have 
this for life. Use protection and knowing the person you 
are doing it with. 
Female #16: Very important, I want to see what they are going 
through, what are their battles. What positive or 
negative outlook they have on it. 
Female #45: Sure. Side effects, and also feedback about how they 
handle, you know, the negativity about it. And that long 
term goal about taking it and how they’re taking care of 
themselves. So, they just take it and not using 
protection and stuff like that. 
Female #60: The first thing I would ask … why do you feel like you 
need to take it? … if they want to let me know, I'll know 
what those risks are, whatever. So, you're taking it for a 
reason because you have a risk.… if you need to take it 
to feel safe, for yourself. 
Female #8: I would want to know what their daily life is like, how it 
makes them feel, does it affect their emotions, every 
little thing I would need to know. So, I would need to 
speak with other women who are taking it so I can 
know.  
Female #9: … What are the side effects? How does it affect their 
daily lives? Would there be drowsiness? Things of that 
nature I would want to hear from other women. 
Female #43: It's going to be very important to me. For me, I would 
like to hear that opinion here, what it did for them or if it 
they’re passing news onto other females in and the 
other lives in family, how they react. You know, if the 
man was willing to try.… They don't want to go out and 
get a test … we take all these tests and there's no 
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victim. We feel embarrassed, but we take it because 
you want to live…. 
Female #6: … I haven’t heard people talking about it. I would like to 
hear other people’s opinion who have taken it before. 
Yes, it’s very important to me.  
Even when shared experience was not initially considered important, there was 
an acknowledgement of value. 
Female #2: Yes, because I like to read reviews before I purchase a 
product. It’s half and half because at the end of the day 
it’s what I decide. It’s what’s best for me. What works for 
me might not work for them. 
Female #1:  … The only thing that matters is what I want to do and 
how I feel about taking it. But it would be nice to know 
how women feel based on being protected and how it 
makes them feel … whether they like it or not. The only 
thing that matters is if I want to take it. 
Female #7: … It’s not important to me, because it’s really about 
one’s health. I would be happy if other women do it to 
protect themselves, but I can’t push it on nobody else. 
Beliefs That May be Barriers to PrEP Uptake 
A few barriers to the use of PrEP were common among the 72 women 
interviewed, including the question of whether PrEP really works, assessment of 
risk, stigma and promiscuous behavior, anticipated effects of PrEP on condom 
use, and PrEP’s limited functionality. 
Does PrEP really work? One of the recurring questions was whether PrEP 
was effective. Women were keenly interested in the pill’s ability to deliver 
protection against HIV. There were questions about PrEP that, as an innovation, 
requires dissemination of specific information among populations most at risk. 
Until that happens, it seems that uptake will remain low. 
Questions about the drug’s effectiveness were mentioned in many different 
meaningful ways, even when that question was not asked in a specific way. 
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Researcher’s question: Is there anything you would like to know to 
help you make a choice about PrEP?  
Female #9: I would like to know the research, the statistics, how 
effective is it, what are the risk factors and is it worth 
taking those risks. If the drug was not effective would I 
still get HIV?  
Female #3: At this moment, no. I have only been on it for a few 
months so I’m still trying it out. I only have one partner, 
so there is nothing I’m really concerned about right now, 
but maybe in the future. The doctor told me if I should 
be exposed to HIV, that it would fight it.  I was really 
worried about, God forbid, he was sleeping with 
someone, and I was exposed to it, would this really 
work? That was my main concern.  
Dialogue #11 
Female: You said the medication has been out since 2012.  
Researcher: FDA approved it in 2012. 
Female: And they have been giving it to people? How are the 
studies? How did it come about? Is it doing what they 
say it’s going to do, or supposed to do? This is 5 years 
later. Since 2012 till now are the studies 100%, 50/50, 
30/70, is it working? If you get 100 people are all 100 on 
it or what else is there. Has it been doing good on the 
market since 5 years ago?  
Dialogue#15 
Researcher: Is there anything you would like to know to help you 
make a choice about PrEP? 
Female: Since PrEP has been out what are the statistics? What 
has happened since the pill has been out? Did it go up 
or down? 
Researcher: In terms of effectiveness? 
Female: Yes. Is it helping Black women? Since it was designed 
to help us is it really working? If it is such a good pill why 
is it that it is not being talked about more? 
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Assessment of risk, stigma, and promiscuous behavior. The 
assessment of individual sexual risk is a complex issue. Promiscuity (multiple sex 
partners) is associated sexually transmitted diseases such as HIV. The result is 
the perpetuation of stigma associated with behaviors such as PrEP use. 
Discussing HIV prevention in communities of color can improve knowledge of 
new biomedical innovations and may help debunk stigma associated with efforts 
to reduce risk. 
Black women associate promiscuity with HIV and the consequent need to 
take PrEP: 
Female #72: … If I was promiscuous, I know that I do stuff like that, 
I'd be like, yeah, I probably would take it [PrEP] because 
I never know. 
Female #8: To be honest I don’t see myself taking a pill everyday 
just to prevent something.…I know personally people 
that are promiscuous and it should not be a problem for 
them to take it every day. I would question myself, why 
do I need it, I shouldn’t be taking it…. 
Female #7: … But it depends on if you are promiscuous and what 
kind of sex you are having. If you have a single partner 
or you are not seeing anybody, then I don’t see why it 
would be necessary.… Protect yourself, use condoms, if 
you are not using condoms, use birth control, 
something, a cervical ring, just something.  
Female #24: Well, it depends, you know how sexually active you are, 
you know…. If you wanna do it everyday, take the 
medication.… 
An important factor in assessing risk among women is that they also share in the 
in the conclusion of their risk. Without this acceptance, necessary actions to 
prevent risk are not likely to follow. 
Female #4:   If I’m not at risk, I wouldn’t take medication for anything. 
Female #5: Because when other people tell you what’s best for you, 
you don’t want to hear it. They might not understand 
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you. You can give me the good, the bad or the 
negatives and I decide what I want to do. Some people 
give prescription on PrEP or any other thing they don’t 
take it, they may agree to it, but they don’t take it. It’s up 
to the person at the end of the day if they really want to 
be on the safe side and be protected. It’s really not 
about what people or the doctor tells you. The doctor 
can say what he feels is best for me, but it is still up to 
me to make that decision. 
Dialogue #35 
Researcher: Before today, have you ever heard of PrEP, Pre-
exposure prophylaxis? 
Female: Yes. 
Researcher: In what context? 
Female: My doctor brought it up to me…that was like a couple 
months ago. 
Researcher: Mhmm hmm. 
Female:  … She was telling me a little bit about it and asked if I 
was interested and she prescribed it. 
Researcher: She actually prescribed it to you, okay. Umm what did 
she tell you about it? Whatever you remember. 
Female: All I remember is it prevents HIV. 
Researcher: Mhmm hmm. 
Female: …… I mean it could go for me but I’m really not that 
sexually active so I wouldn’t really need it though … I 
just feel like it's kind of risky with like the side effects or 
whatever it was because when she told me about it last 
time and I read the like side effects it was a lot.… 
Researcher: Mhmm hmm. 
Female: … So I was scared, that’s why I just never took it. 
This dialogue shows that women have questions about side effects and 
fear that can result in inaction. 
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PrEP and Condom Use 
There was mixed reactions to condom use and PrEP. Without any doubt, 
Black women would prefer condoms, primarily because PrEP safety is relatively 
unknown. Interestingly, responses about condom use tended to be given in an 
ideal situation, using terms such as "hopefully" or "should" when describing 
condom use. Generally, beliefs about risk compensation by foregoing the use of 
condoms for PrEP is low. Among the responses, there was a tone of advocating 
for the use of both methods, if PrEP use is acceptable. 
Researcher’s question: If women were to use PrEP would there be a 
change in their condom usage? 
Female #3: I just feel like if you can protect yourself with a condom 
you still should.  
Female #2: Well, if the study goes well and PrEP works and if you 
are using condoms just to prevent the disease then 
there should be a change. But if you are using condoms 
to prevent you from getting pregnant then there should 
not be a change. 
Female #16: It wouldn’t change my way, some women yes. You have 
both sides of the fence that have little loopy girls and 
guys. I am trying to inform my little sister. She has been 
with her boyfriend for 3 years and thinks it’s okay to 
have sex unprotected with him. He is 3 years older than 
her. It’s not okay. 
Female #11: Not me personally. It wouldn’t change my perception of 
using condoms. Hopefully it’s 100% but we don’t know 
that.  If I know the condoms and the PrEP would 
prevent me from getting it, then definitely.  
Female #8: Of course, they already don’t use condoms as much as 
they should.… There are more sexually transmitted 
diseases, so can that [condoms] prevents those also … 
They should take other steps also because you never 
know and you can’t get rid of it. 
Female #9: … You have to look at it from birth control.  Are women 
less likely use condoms because they are on birth 
control?  It would have the same effect. 
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Female #1: It might, now they just think they are covered, … it could 
work, and it might not. I don’t think they should just stop 
using it [condoms]. I don’t think they should stop, 
because that just prevents HIV. There are still STD’s so 
I would hope they would still be using condoms. Then 
there is HPV. There is a lot of different things you can 
get from sexual intercourse…. 
Female #7: Maybe, they might get too relaxed. They might think its 
okay now. They have something to protect them and 
everything is not 100% proof. I think condoms are still 
the best thing.  
Some women felt that PrEP use might result in lower condom use or increase in 
risk compensation: 
Dialogue #35 
Researcher: Do you see any advantage in PrEP over condoms? 
Female: Yes. 
Researcher: For you, what are those?  
Female: Because everybody has to wear condoms … 
Researcher: Mhmm hmm. 
Female: So, if somebody could just easily take a pill … they 
would take it because a lot of people don’t like the 
feeling of condoms when they do have sex.  
Researcher: Mhmm hmm, so it definitely could fill that gap when…. 
Female: Yes. 
Researcher: Yeah, if women were to use PrEP, do you think that 
they would change how they use condoms? 
Female: I feel like if they use PrEP they would still not use 
condoms because they feel like they are protected…. 
Researcher: Mhmm hmm. 
Female: … Even though they’re not…you know…but I feel like 




Female: They could both be used.  
Researcher: That’s true. Do you see one having more of a weight? 
Female: So, you said the PrEP work, so I think it would work 
better than the condoms, especially if the condom tears.  
Researcher: So, if women used PrEP would there be a change in 
condom usage?  
Female: Well for me I would use both. I would still use the 
condom with the PrEP just to be a little safer.  
Researcher: What about other women? 
Female: Sometimes the females want to get all wild, so they 
don’t want to use condoms so the PrEP would be an 
alternative. 
Limited Nature of PrEP 
Black women want more comprehensive prevention methods. Focusing 
efforts only on HIV prevention was thought to be too narrow. Among issues that 
fuel their perception is the gap in STI and pregnancy prevention. Black women 
labeled PrEP the “freedom pill” and the “magic pill.” Examples of Black women 
reflecting on PrEP and the gap in protection that they may experience as a result: 
Female #71: … We got this pill and now this new freedom pill so you 
know, we could just axed the condom … people do 
think that way because they have one level of protection 
so they fit right…. But the pill is not going to stop you 
from getting syphilis, gonorrhea, … 
Female #18: … But I still say you’re taking a risk.… The PrEP pill is 
so you don’t catch HIV. It’s not saying that you’re cured 
from all the other STDs … I think you should take the 
PrEP pill and still use the condom, still practice safe sex 
because, it’s other stuff out there … you found one 
magic pill you still have other things that can happen. 
Female #6: But you don’t want to have a baby every time you have 
sex. It’s not just HIV, there are other things too.  
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Female #7: … There is still chlamydia and other STDs so I’m not too 
sure about that one either. 
Dialogue #3 
Female: I just feel like if you can protect yourself with a condom 
you still should. 
Researcher: Following up on that point you were making; if women 
were to use PrEP, would there be a change in their 
condom usage? 
Female: Maybe. It shouldn’t though because it doesn’t prevent 
other diseases. They might say I’m not going to get HIV 
so I shouldn’t use a condom anymore, but everybody 
should still. 
Researcher: Is it that they are thinking that they are more worried 
about HIV than anything else? 
Female: Yes, that’s what it is. Because when you think of HIV 
you think about death. That’s what it used to be … but 
they can still get other diseases. 
Dialogue #15 
Researcher: Do you see any advantages of PrEP over other 
methods? 
Female: No. It’s just like any other method. Take the pill, you will 
be alright, use a condom you will be alright, birth control; 
it’s the same thing as any other method. 
Researcher: Interesting. If women were to use PrEP would there be 
a change in their condom usage you think? 
Female: No, I don’t think so. 
Researcher: Why not? 
Female: I think women are still going to use condoms.… if it’s not 





According to Green et al. (1980), enabling factors are “the skills and 
resources necessary to perform a health behavior,” and they further note that “a 
person’s ability to perform the tasks that constitute the desirable behavior” is 
important to the adoption of the new behavior (p. 75). Categories that emerged 
as enabling factors are pill taking, privacy and PrEP use, and cost and insurance 
coverage. 
Pill-taking Behaviors 
Although there is a list of reasons why women do not take medications, 
many women also provided strategies and skills that they have acquired to 
support pill taking behaviors. Shared examples include: 
Female #9: They could put notifications on their phone, whatever 
they use. People use cell phones every day, so they 
could have an alert on their phone, reminding them to 
take the medications, they could leave sticky [notes] 
around the office or home or whatever they find easier 
as a reminder.  
Female #69: Yes.… What I would actually do is like have a certain 
container for every day and put the pills that are needed 
in each section so I know what to take, what day to take 
them and keep them on schedule. 
Female #29: Sticky notes, reminders in my phone. Always have it in 
my bag…. So that the minute I’m ruffling looking for 
something “oh shit I didn’t take my medicine!” Put it out 
right then and there and take it. 
Female #35: They can keep it in their bag at all times cause that's 
like one of my biggest problems. Like I’ll forget it at 
home…. So they can keep it like one in their bag or put 
it in like a little container where somewhere they know 
they're gonna see it all the time…. 
Female #52: … I’m gonna take that pill but if I forget it, you can, you 
can double up make it as a part of our daily regimen. I 
think she will take it on a daily basis. If you have to take 
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it at nighttime, I think women would take it at night 
time.... When you relax and you calm down…. 
Female #3: It has been difficult because I am not on any 
medications, so I had to get use to it [PrEP]. I had to get 
used to taking something every day. The doctor says I 
have to take it every day. I said every day? I’m one of 
the people that don’t like to take medications. I’m not on 
any meds, not even birth control, and I have to take it 
every day. But this prevents HIV so I said okay. But 
after a while I got used to it…. I set my alarm … when I 
hear the alarm I know what it means. But I had to build a 
certain routine. I would take it every day before I had my 
breakfast, so that’s how I got used to it. 
Additionally, women often prioritize important health concerns by following 
through with taking the necessary measures. Black women saw PrEP similar to 
taking birth control, vitamins and other medications. Examples shared include: 
Female #62: I take my vitamins everyday, but even then, sometimes I 
forget. So, it was like you really have to be on point with 
it, especially if it's something as important as that.  
Female #67: I think most of the women that I know either take 
prescription medicine or vitamins or supplements or 
something. I feel like a lot of women are moving toward 
being more healthy, taking ownership of their health…. 
Female #8: … I would take it like a daily vitamin.  If I have to, I 
would just take it. 
Female #41: So, every day pill. So, it's like a birth control pill 
basically. Gotta make sure you take it cause, say if you 
take it and you stop taking it, a whole different side 
effects your whole body change from taking pills.  
Female #46: I'm already taking a pill every day. Birth control pills. So, 
it's was like, I'm used to taking like, Oh snap my birth 
control pills. So was like, I know like this won't be a 
problem. At first, I thought the control pill was going to 
be a problem, but it's not, it's pretty fine. 
Female #42: If I was considering to take it, just like birth control, sure, 
I would take and set it aside, I have a spot on my 
dresser for any medication I’m taking. Put it to the side 
and set my timer on my phone. 
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Privacy and PrEP Use 
During the interviews, Black women’s tenacity and a strong sense of 
agency came up to mitigate perceived stigma, partner and/or relationship 
concerns and family and friends’ interference to their use of PrEP. Black women 
demonstrated this grit in two ways. The first was by a general consensus that the 
final decision to use PrEP rests only with the women. They claimed agency over 
their health rights. Second, Black women found strength within their ability to 
navigate PrEP use alone and to keep PrEP private. Maintaining privacy over their 
use of PrEP, as a strategy would allow for better control over their safety and 
increase their “peace of mind.” 
Black women shared the importance of discussing PrEP with their partners 
but took agency over their final decisions: 
Female #1: … What other people say shouldn’t be important, I 
guess it’s about knowing yourself. If you’ve been a 
leader all your life whatever you do, you really wouldn’t 
care about somebody else’s opinion. I’ve never been a 
follower. I’ve always had a strong mind. I always did 
what I wanted to do … what you decide might not be 
right for somebody else, but it's right for you. If it works 
for you, what does it matter what anyone else thinks.  
Female #5: … They should be understanding and want to be on the 
safe side with me. If not, then I have to question, are 
you really for me? What are we doing here? Because 
this is something serious. So, it needs much thought 
and conversation.  
Female #12: … My partner’s opinion doesn’t really matter, especially 
if I am protecting myself. If anything, I would try to 
convince them they should take it too. Because it is, 
supposedly, benefitting everybody. 
Female #21: … I have my own choice. Yeah, he be important to my 
life, but I still wanna be safe. 
Female #67: … My health is my job … and I would want to really get 
to the bottom of why this preventative medication would 
be an issue for my partner. 
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Female #35: Because it's my body so if I want to be protective of 
my body…. I don’t care what nobody else say. 
Female #4: If they say you can’t take it, you have to ask them why; 
what’s the reason why you don’t want me to take it? 
You want to protect yourself. They have to have a 
reason why they don’t want you to take it. And if they 
want you to take it, then that’s a good thing. 
Female #3: … It would matter but it wouldn’t change my opinion or 
my mind about it. He is understanding. I don’t think he 
would have anything negative to say. I just haven’t 
mentioned it to him. I don’t know why, it’s just that the 
conversation has not come up…. He may think she has 
HIV, that why she is on that medication. A lot of people 
think that too. So, I try not to scare him. 
Examples of responses related to privately navigating PrEP use alone are 
illustrated below: 
Female #3: … It’s a mind thing for me … my partner doesn’t know I 
take it. 
Female #36: If it’s secretive…If they didn’t want, I guess their spouse or 
anybody that they dealing with to find out, I think they’ll do it 
… secretly though. 
Female #29: I mean nobody needs to know what you’re taking…Put it in a 
bottle that doesn’t have a name on it. Put it in an empty 
vitamin bottle. “Oh, what is that? Vitamins!” … Umm, it’s not 
anything, nobody needs to know. That’s your personal 
business whether you have it or you don’t. 
Female #40: I think everybody experiences it differently … people 
might feel like they might get judged.…But who gonna 
know you're taking it, unless you tell somebody. 
Female #8: ... I mean if they keep it to themselves nobody has to 
know. You don’t have to tell somebody. Why should it 
be known? I don’t see any problems or barriers or 
anything. 
Female #13: I think it would be a good thing for her because that 
would ease her mind, but you have to because lots of 
men in today’s society are going with men and women. 
So, I think for any woman that should be a big influence 
to ease her mind. 
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Cost and Insurance Coverage 
Cost of medication and insurance coverage were huge issues when 
discussing medication among the population of women interviewed. Concerns 
about coverage of PrEP by insurance and possible co-pays are issues that can 
either enable or discourage use of PrEP among Black women.  
Examples of concerns relating to cost and insurance coverage: 
Female #6: … Cost is probably going to be a big factor because 
people might not want to pay out of pocket and a lot of 
people can’t afford it. Your insurance being able to pay 
for it is a big deal. 
Female #1: … Because sometimes these aren’t covered by 
Medicaid or whatever you have. You might have to pay 
for it out of pocket. I guess you have to ask the doctor if 
it’s covered or not.  
Female #23: Cost, side effects, long term use, will it affect anyone 
who is thinking about having a baby.... That’s it, that’s 
all I can think of. 
Female #43: … What kind of price? What kind of money would I have 
to have to put it all together? … can you get it free? … if 
insurance will cover? I want to hear those kinds of 
questions. 
Female #57: What would the cost be? 
Reinforcing Factors 
According to Green et al. (1980), reinforcing factors “are those that 
determine whether health actions are supported” (p. 76). Awareness of PrEP 
among the sample of women was extremely low. Therefore, with the exception of 
two women who previously used PrEP, women’s insights in determining 
reinforcing factors are more perceived rather than actual lived experiences. Five 
common themes that emerged as reinforcing factors: couple use in normalizing 
PrEP; doctors’ role in advancing PrEP among Black women; pointers for health 
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care providers; older Black women as resources of behavior change; and the 
fear of extreme side-effects. 
Couple Use in Normalizing PrEP 
One of the most striking results of the survey was the interest and 
seemingly logical thinking about encouraging PrEP use as couple activity. One of 
the immediate benefits couples’ use provides, aside from reinforcing the 
behaviors among intimate partners, is alleviating possible negative reactions 
from partners. Black women are quite concerned about the impact of PrEP use 
on their relationships and believe that, similar to couple HIV testing, PrEP use 
can be normalized in a similar way among couples. 
Black women perspectives on couple PrEP use:  
Female #6: … If we can do this together and be safe I think that’s a 
plus … just to be safe, let’s both take this.… Anything 
that is going to help people not get HIV is a good thing. 
Female #10: I would find out if they have a partner and invite them so 
they could get schooled together … because everyone 
is not completely honest. 
Female #61: … we would definitely have to discuss it … [if] one of us 
decided for whatever reason to cheat on the other, at 
least we will protect it from that. 
Female #66: Because when you're in a relationship or you have that 
person sharing that type of intimacy … I think you know, 
you should go with too because nowadays somebody is 
going to backslide and go out, you know. So, if you 
could prevent anything, that's the best way. 
Female #5: But for the women I think it’s more serious because she 
is expected to maintain her health. There is a certain 
expectation … but its okay if they take it together. 
Female #24: … You [health provider/doctor] should let them know so 
they can take it together, instead of passing it over. 
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Doctors’ Role in Advancing PrEP among Black Women 
Overwhelmingly, Black women expressed respect and trust for their 
medical providers. Of the 72 women, 69 indicated that they most frequently visit 
either their gynecologists or their primary care providers. Intriguingly, the results 
reveal little to no reluctance to speaking with medical doctors about HIV 
prevention such as PrEP. However, at the time of the study only three women 
recalled conversations with their medical providers about PrEP. Additionally, 
women rely their high levels of comfort with their doctors and, with the exception 
of six women, the majority of women indicated that they would consider using 
PrEP if their doctor recommended its use. 
Importance of doctors in promoting and scaling up PrEP among Black 
women: 
Female #18: Of course, look I know there’s this magic pill around 
here named PrEP, how do I take it? How many times? 
… I would be intrigued to know how can I get this 
medication. 
Female #49: Because she knows how I'm feeling. She knows what is 
good for me. What am I supposed to take? 
Female #2: First, if my doctor recommended … it’s for my safety. 
Female #6: She would just have to suggest it and I would always 
read about it myself.… If she suggested it, I know it 
would be something positive to take. 
Female #17: Show me that this product works, they have to show me 
results… that’s it! 
Female #43: But if the doctor says you have to try it, … I would try it. 
Female #67: … It's good to have a personal opinion, but you know, I 
would want to incorporate some type of professional 
opinion in there too.  
Female #71: … We've had conversations as far as my sexual partner 
and my sexual preference and stuff like that. … as I said 
to you, at the moment I am not as popular as it used to 
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be in that department.… If my doctor was to give me 
instructions, hey, that's a good thing.  
Female #48: … She's a doctor so she's not going to sit here and tell 
me false information to make me take a medication 
that’s really not going to work. 
Female #9: I depend on my physician for medical updates, so she 
would come to me and say there is a new drug on the 
market and I believe it would be very beneficial for you 
and your partner. Then I would definitely consider it.  
Female #13: I think most of the time when you are sexually active 
your doctor would ask you if you are using protection. I 
would think that my doctor would be the person to 
advise me the most because she may have more 
experience in dealing with the virus and know more 
about it than I do. Then sometimes too it depends on 
the information the patient gives to the doctor. This is 
what you should do if you have multiple partners. 
Female #71: I think this is something that you should probably try or 
like here's some information about it.… I would like for 
you to read over it, talk to me about what you think or 
whatever and let me know … we can't stop them from 
having sex. We can't stop them from making poor 
decisions. But if you have more tools such as this 
available to them, perhaps it'll stop some of the inferno 
you know, of what's going on in this inner city. 
Female #42: If he recommended it and I fell into one of those 
categories. Yes.  
Female #6: …I trust her opinion, she is a good doctor, I’ve been 
with her a long time.... So, I value her opinion and I trust 
her. 
Female #40: I don't know what the big deal is. I wanna take 
something to prevent myself from getting HIV. Can you 
help me with that? What's the big thing about asking 
your doctor that? 
Female #4: If I think that I am at risk, then I would ask her to 
[prescribe PrEP]. 
Female #7: I don’t have a problem with that [asking about PrEP], 
because that’s what they are here for. I haven’t seen my 
gynecologist in a while but I would ask her because she 
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recommended the HPV shot. So, she would recommend 
it if she feels that I need it.  She would say something 
about it. 
Pointers for Health Care Providers in Promoting PrEP among Black Women 
There are vast possibilities for increasing awareness and promoting PrEP 
as an option among Black women. A few suggestions for beginning that process, 
which will help to reinforce HIV prevention are captured below. To summarize, 
Black women believe that the environment in which PrEP is presented as a 
prevention option should be comfortable. They encourage providers to speak 
openly about HIV without any attempts to scare them. In addition, it is important 
to talk about risk and to do risk assessment, and they believe that doctors should 
educate women at every visit. 
Lessons for preparing PrEP related health education discussions and 
materials: 
Female #4: So, the doctor needs to say how effective it is, how you 
can prevent yourself from HIV, even more than just the 
regular condoms, other pills or whatever you take and 
just basically educating them about PrEP. A lot of 
people don’t really know about it so they need to 
educate people, so they can talk to somebody else 
about it. 
Female #13: Well, I would say give every patient the option.  Educate 
them about it and give them a choice so they can think 
about it. Introduce it to them so they will know. 
Female #8: There are a lot of women out there that are being 
promiscuous, so they need to speak to all women, … 
and there are a lot of drug addicts.… I think every doctor 
and every nurse should sit down with every patient they 
have and talk to them about it. Personally, I think it’s a 
good drug. 
Female #41: HIV scares everybody. Let's get that out the way. Tell 
them that this is not a scare. This is something that you 
think that is the next best thing to a condom. Just like 
birth control pills. 
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Female #6: I would tell them, just have some information like 
handouts in your office so as you see your patients—
GYN I’m talking about, or regular doctor, just have 
information that people can read, so after your office 
visit say, “check this out and see how you feel about it.” 
I think they need more paper hand-outs. That would 
help a lot. 
Female #5: Just let them know that they could still catch something 
even with the pill. I think they should be realistic, speak 
facts, no matter how young they may be, don’t trick 
people to thinking this is the only option. 
Female #2: … She [doctor] would have to talk to me about it, like a 
mother daughter conversation, make it flow, don’t make 
it seem like an authoritative thing. Just talk to me about 
the importance and what it does. 
Female #3: I want everybody to know that this is here.… A lot of 
people don’t know. My doctor said she spreads the 
word…. 
Dialogue #3 
Researcher: What advice would you give a doctor/nurse/health 
educator to help them communicate effectively to 
women about PrEP? 
Female: just to educate them at every visit 
Researcher: What type of education? 
Female: About what it is, what it does and they should 
recommend it to especially young females, I would 
suggest that. My doctor, she did her job and I know she 
is spreading the word to other young women too, which 
is good. But I don’t know if other doctors do that. My 
GYN doctor didn’t.… 
In the following excerpts, Black women provide the “how to” for practically 
reinforcing the information. Interventions suggested represent local and 
community level strategies that Black women perceive would be effective in 
reinforcing messages for PrEP use among their population. 
Female #3: She [doctor] gave me a pamphlet.… I was waiting for 
her to come back in the room, and she asked if I was 
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interested in it. She explained everything about it, 
including the side effects…. 
Female #70: … Go into the hood to the poorer neighborhoods to be 
more aware of this type of the option. Go to the streets 
and give out the information. You go out to the street 
with signs …. Educate, educate, give flyers out. 
Female #1: … It would be nice if they had flyers on the walls when 
you come in. I see a lot of flyers on the walls for different 
things like the HPV shot. A poster will always help.  
They might see it and say well what is that is for. 
Advertisement is good.… If you put up flyers that’s the 
best way. I feel like it’s always a conversation starter, oh 
what’s that.  
Female #43: Well get educated. Just like what I'm learning here. Get 
your hands on the flyers…. 
Female #9: I think they should have the education in their office, 
whether it be a pamphlet, a short video, especially 
youthful women or if they don’t have the time to sit down 
for an elaborate explanation, they can read on the train 
or they can call the doctor’s office back and say I am 
interested. 
Female #34: The side effects … am I gonna be a crazy person after I 
take it? 
Female #15: Social media, and talking to young people, because 
they are all about sex. We don’t really watch TV we are 
mostly on our phones.  
Female #3: Yes, on the radio, billboards, bus-stop places; maybe I 
missed it, maybe I haven’t seen it.  
Older Black Women as Resources of Behavior Change 
One of the more surprising results was that Black women looked to older 
women for direction and advice about HIV prevention. The idea is that whether or 
not their mothers or respected older women are actually using PrEP, their advice 
is valued.  
Examples of older women in scaling up PrEP use among Black women: 
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Female #34: … it would be my doctors and more than likely my 
mother. 
Female #63: Women, older women … they just need to be like more 
of a, I take this pill every day and I’m safe and 
everything is okay and they'll give me no complications. 
Female #42: I will say people my own age group and maybe women 
a little bit older. I would say like around twenties, forties, 
because I would figure they were, they're still like a little 
bit more sexually active … that age group, that would 
appeal to me.  
Female #36: If my mother was to tell me, “You know, I’m taking PrEP. 
You should do it,” I would do it. 
Female #62: … this may sound generic, but my mom … she would 
have to … be really reassuring in order for me to be like, 
all right, cool.… She would just have to say how it is 
really beneficial going into detail about it, but as if she 
was taking herself and she's trying to like to put me on 
it. 
Fear of Extreme Side Effects 
The most frequently asked questions about PrEP were about side effects. 
Caution was exercised by Black women about medication and it was important 
that before PrEP could be considered an option, to understand the effects of the 
medication. One young lady who received a PrEP prescription but who did not fill 
the prescription indicated: 
Female #28: I just feel like it's kind of risky with like the side effects or 
whatever it was because when she told me about it last 
time and I read like the side effects it was a lot …so I 
was scared, that’s why I just never took it. 
To increase knowledge and to actively reinforce the option of PrEP-taking 
behaviors among Black women, discussing side effects is very important. Black 
women are concerned about the effects on the emotion, their moods, their 
mental agility, their weight, their health, their reproductive, health including their 
ability to get pregnant and pregnancy outcomes, among other factors. 
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Female #48: … I don't take birth control pill because it makes me 
gain weight. That's the reason why I choose not to take 
it. If I didn't gain weight, I’d probably kept taking the pills. 
So, you have to put all the side effects to the pill out 
there. 
Female #8: No, the side effects, pregnancy; those are the major 
stuff. 
Female #4: What are the side effects? … that’s basically what I 
want to know. 
Female #59: My thing is the side effects, because sometimes even 
though the medication might be good for one thing, side 
effects off of a medication …  lady for the side effects. 
I'll just stay with what I got. You know. 
Female #72: Yes, the medicine does sound like a good idea.… But 
I'm a scaredy cat. I do not like the side effects. Tell me 
the side effects … deaf, bleeding out the nose. Not 
Pancreatic. Your pancreas may blow up.… I don't like 
the side effects. The most medicines, the side effects 
scare me more than the disease do. Sometimes she'd 
rather be sick. muscle loss … heart murmurs, all that. 
No, no, no. 
Female #43: I would want to know the side effects … when I hear 
about a medication and the side effects, sometimes 
even worse than the sickness you have, so I decided 
effects would make me go crazy. I wouldn't take the 
medication. I will want to know exactly what it would do 
to my brain? 
Female #43: I want to get pregnant. She would think about what 
would happen if I take this.… But I know for sure if 
they're going to get married and they want to have 
babies in the future that would bother them, you know. 
Female #5: I have taken a lot of pills prescribed to me; for sleeping, 
anxiety or mood, and it harmed me, it didn’t do me any 
good and the longer I was on this pill the more things 
started happening to me…. Our people always get 
tricked up to thinking this is to help us and people are 
the cause for a lot of things in our community. Have you 
given them an option? What is this really doing to my 
inside, my organs, since I have to take it every day and 




Researcher: The last open-ended question, is there anything you 
would like to know about PrEP to help you make a 
decision? 
Female: Side effects. 
Researcher: OK, what about side effects? 
Female: What are the side effects of PrEP? That’s what I would 
want to know. It’s not just about PrEP. It’s me and every 
medication. How it makes my face look. 
Researcher: Do you mean like acne? 
Female: I mean any medication I look at the side effects before I 





This study sought to describe the awareness, beliefs, perceptions, and 
motivations to either accept or reject PrEP among African American women and 
to describe lessons that could be learned by HIV prevention practitioners and 
stakeholder networks as they design and implement interventions to scale up 
PrEP use among Black omen. The conclusions outlined below focus on 
awareness of PrEP; willingness to accept or reject PrEP; impact of partners’ 
reaction to PrEP use; barriers to PrEP use; adherence concerns; privacy in PrEP 
use; and the doctors’ role in advancing PrEP use among Black women. 
Awareness of PrEP 
Using Smith et al.'s (2015) calculation based on the CDC guidelines, over 
468,000 U.S. women have PrEP indication. One benefit the CDC guidelines 
provide to high burden communities is that the screening of heterosexual women 
should be a priority in health care settings. Referencing the 2017 NYC annual 
surveillance report, the results of this study revealed that Black women are 
experiencing disconcertingly low rates of awareness of PrEP. Of the 72 Black 
women who participated in the current study, only 6 had prior knowledge about 
PrEP before the study. 
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As such, time was made available in the interview to provide information 
about PrEP. In spite of the pronouncements about PrEP in New York City, three 
of the women with knowledge about PrEP believed PrEP was not for Black 
women, but instead believed PrEP was for gay people or people of trans 
experience. These findings are consistent with those of Whiteside et al. (2011), 
who reported that in their cross-sectional study of 405 clinic attendees, over 81% 
indicated they were not aware of PrEP. Although Whiteside et al.'s findings were 
six years earlier, the rate of awareness among Black women remains appallingly 
low. Additionally, Goparaju et al. (2015), in the Women’s Interagency HIV Study 
(WIHS) in Washington, DC, also found low PrEP awareness. In the WIHS study, 
39 women participated in eight focus groups separated by sero-status. The 
groups comprised 20 sero-negative women and 19 sero-positive women, with 
African American women representing 80% and 100%, respectively, of the racial 
composition of the groups. In the WIHS study, sero-negative women were 
excited and interested to learn more about PrEP, a finding consistent with the 
current study. 
Calabrese et al. (2016) interviewed 18 medical PrEP providers in the 
Northeast and South regions of the U.S. by either email or in-person interviews 
and theorized that one challenge experienced in PrEP implementation was 
“accessing and engaging priority populations” in PrEP care (p. 9). Optimizing 
traditional settings to increase awareness of HIV prevention tools is a viable and 
readily available option in inner-city communities. In the current study, although 
only one community-based clinic was sampled, all 72 participants were at varying 
risk levels for HIV. Scaling up early prevention outreach efforts at clinics such as 
this should be prioritized as part of a wider set of strategies to increase 
awareness and interest among women. Clinics routinely provide care to high-risk 
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populations, such as Black women, and are therefore a reasonable setting for 
reaching and engaging priority populations in PrEP care. 
Accepting/Rejecting PrEP 
Many women refused the use of PrEP primarily for two reasons. First, they 
knew nothing about PrEP; it was the first time the medication was being 
introduced to them. Understandably, this lowers the chances that PrEP would be 
accepted during these initial discussions. Second, Black women in the current 
study did not believe they were at high-risk of getting HIV. Whether it was being 
married, not being sexually active currently, using condoms during sexual acts, 
or favoring PrEP for "other" women, in many cases, the respondents did not 
believe they would use the medication. This finding is supported by studies that 
show that low perceived risk of HIV equates to low PrEP uptake (Kwakwa et al., 
2016; Whiteside et al., 2011). One of the findings emerging from this study was 
that Black women associated PrEP with being promiscuous, and the women in 
the study did not perceive themselves as being promiscuous because, for 
example, they only have one partner or they do not sleep around. Black women 
wanted to distance themselves from being perceived as “in need” of this 
medication. 
Among Black women in the current study who were more willing to consider 
PrEP use, factors contributing to their decision were their fears about HIV, 
encouragement by older women, advice from their medical providers, knowledge 
of partners using PrEP, and if they perceived themselves at risk of getting HIV. 
After gathering more information about PrEP, Black women expressed their 
willingness to consider using PrEP. Black women indicated that they would learn 
more about PrEP by reviewing additional information and conducting their own 
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research into the medication’s effectiveness and side effects, and by asking their 
medical doctors about PrEP and whether it was the right option for them. In a 
similar FQHC setting, Kwakwa et al. (2016) found that willingness to use PrEP 
was triggered by fear of HIV, importance of a prevention strategy, and high-risk 
perception. 
Impact of Partners' Reaction to PrEP 
The current study revealed a recognition that men reportedly have strong 
influence over Black women’s willingness to use PrEP. Black women showed 
high agreement that men’s use of PrEP would also result in women using PrEP. 
Men using PrEP was favored by women, as this was associated with reduced 
risk for women to get HIV. 
At the same time, if Black women were to initiate PrEP use, they 
anticipated that their partners would respond in an unfavorable way. Black 
women feared that their use of PrEP would result in underlying relationship 
concerns levied by their partners. Women were concerned about accusations of 
“stepping-out” of the relationship, which is considered cheating. Further concerns 
were that partners would look at them “side-ways” if they mentioned using PrEP.  
Overall, there was concern that PrEP use would create trust issues resulting in 
disastrous consequences for relationships. This finding was consistent with that 
reported by Flash et al. (2014) in relation to condom use. Flash et al. recruited 26 
Black women aged 20 to 50 years old in Boston, Massachusetts, and conducted 
five focus groups. Flash et al. found that barriers to condom use included “fear of 
perceived unfaithfulness, financial barriers, personal perception of being at low 
risk, educational status, desire to conceive and intimate partner violence” 
(p. 635). The barriers identified for both PrEP and condom use might represent 
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broader behavioral barriers that exist regardless of the HIV prevention methods 
being discussed. Therefore, the broader intervention of HIV prevention, sexual 
health rights, women’s rights, and behavior change should be more integrated 
and complementary in program execution and less fragmented in 
implementation. 
Although Black women in the current study were not asked about intimate 
partner violence (IPV), as mentioned in Flash et al. (2014), IPV is a barrier to 
safe sex. The Garfinkel et al. (2016) study in Baltimore City and in Baltimore’s 
northern suburbs recruited 75 women aged 18 to 35 years from two family 
planning clinics. Although only 50% of the sample was Black, women who 
experienced forms of IPV were less likely to accept PrEP compared to women 
reporting no IPV. One strong recommendation from Garfinkel et al. was the 
appeal to raise IPV as a national priority by addressing violence and trauma as 
part of wider interventions to reduce HIV among women, which the Researcher 
from the current study strongly supports. 
Barriers to PrEP 
In decisive ways, Black women articulated their perceptions of barriers to 
PrEP use. Among barriers identified were questions about effectiveness of PrEP, 
low risk perception, stigma and promiscuous behavior, limited use of PrEP, and 
the effect PrEP will have on condom use. Black women raised concerns about 
the medication actually fulfilling its purpose of preventing HIV. Black women were 
interested in the statistics that showed the effectiveness of the medication and 
the results from studies since the FDA approval in 2012. Another reason for the 
concern is the idea that good innovations tend to be known. Women were 
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conflicted about trusting PrEP because it was neither known nor was PrEP 
“talked about.” 
One of the striking findings about assessment of risk is the importance of 
Black women owning their risk assessments. Women who were told by their 
doctors that they are at risk would either go along with the assessment for a short 
period of time or dismiss the assessment altogether as not being representative 
of how they define themselves and their behaviors. It seems clear that if women 
do not consider themselves to be at risk, they will not be motivated to obtain a 
PrEP prescription, or ultimately fill the prescription, and will be far less likely to 
take the medication once it is prescribed. 
Blackstock et al. (2017) found that of the 554 women who accessed 
services and had PrEP indication in Bronx, New York, only 21 heterosexual 
women (3.8%) obtained at least one PrEP prescription. Of the 21 women, only 
28.6% were non-Latina Black women. A study by Kwakwa et al. (2016) found 
that Black women appear to have a low risk perception of getting HIV. In that 
study, among the nine women testing positive for HIV, only one indicated a 
moderate to high-risk perception of getting HIV. The other women perceived 
themselves as at low risk of getting HIV and also expressed that before their new 
HIV diagnosis, they had low interest in PrEP. 
In the current study, although the results show that there were perceptions 
that PrEP use might result in lower condom use, thereby increasing risk 
compensation by using PrEP, the perceptions were mixed and varied by 
situations. The idea of PrEP being a “freedom pill” and “magic pill” does flash 
scenes of a “free for all” sexual revolution. However, fewer Black women thought 
that would be the norm, with more women advocating the use of dual protection, 
and for like messages to be reflected on flyers and social media campaigns. The 
use of dual messaging was considered as the best way to increase protection 
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and reduce HIV. Another reason for concurrent condom use was primarily 
because of the limited nature of PrEP. Black women were deliberate in the use of 
dual protection because PrEP is limited in protecting them from pregnancies and 
STIs. Repeated feedback from women highlighted the need for comprehensive 
protection, which is not obtained from PrEP. This finding was consistent with 
results reported by Whiteside et al. (2011), which indicated that women were 
supportive of dual protection, using both condoms and daily-PrEP to reduce HIV 
infections. 
Although the literature is limited in female-focused PrEP studies, Smith 
et al.'s (2012) findings also present areas of similarities. Findings of mixed-
gender focus groups found barriers to PrEP uptake, including “side-effects, 
medication cost, partial effectiveness, low perceived personal susceptibility to 
contracting HIV, burden of taking a daily medication, [and] reaction of peers to 
taking HIV medication” (p. 413). One clarifying point regarding peers’ reaction as 
a factor for PrEP use is that, in this current study, although reaction of peers was 
a factor, it was less of a factor compared to reaction from a partner, which elicited 
stronger and more visceral reactions. 
Adherence Concerns 
Another important finding from the current study, which is controversial in 
the literature, is adherence. Adherence to PrEP is essential for preventing HIV 
(Baeten et al., 2012). In their review of literature, McMahon et al. (2014) found 
adherence as a significant concern among medical providers. Other authors 
found that 77% of providers were concerned about adherence to medication and 
the possible risk for future resistance to antiviral medication (Karris et al., 2014). 
Karris et al.'s study surveyed 1,175 active members of the Infectious Diseases 
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Society of America’s (IDSA), which is a provider network of infectious disease 
clinicians. Given the evidence for PrEP in 2013, Karris et al. also presented 
additional clinicians’ concerns, which included concerns about toxicity and 
insufficient evidence to support real-world efficacy of PrEP. 
In the current study, Black women reported a similar concern, primarily, that 
consistent pill taking is challenging. Examples were provided about forgetting to 
take either prescription or over-the-counter medications. However, there was 
consensus in the belief that Black women have developed skills in pill taking, and 
although there are excusable misses of daily doses, they can be adherent to 
taking pills. Strategies included using phone alarms, sticky notes as reminders, 
creating set times for taking medication, and the use of the handbag in pill 
reminders. Additionally, birth control and vitamin use were also widely cited to 
show where Black women have exercised deliberate practice in managing their 
health and reproductive goals. These perspectives were supported in the 
Partners Study, where Matthews et al. (2014) found 97.7% adherence among 
non-pregnant women in the study. 
In spite of participants’ strategies for promoting medication adherence, prior 
studies have found adherence to be a major challenge. According to the FEM-
PrEP and VOICE studies, the findings showed that low adherence by women 
was viewed as the primary reason for the failure of the intervention. According to 
Marrazzo et al. (2015), the VOICE trial experienced less than 30% adherence to 
medication, which resulted in 312 sero-conversions among 5029 women enrolled 
in the three treatment arms and two control arms of the trial (p. 513). In an 
additional study, Boffito et al. (2014) found women to have difficulty in adhering 
to the daily pill regime, resulting in “missing doses or treatment fatigue to 
prescribed medication” (p. 7). 
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Privacy in PrEP Use 
Black women exercised agency in making final decisions about PrEP use 
and the best way to navigate PrEP. In the current study, it was important for 
some women to navigate PrEP use alone, as privacy was felt necessary for 
keeping them safe. Stigma toward HIV is a reality that is closely aligned to PrEP 
use. Black women indicated that, although their partners would most likely 
discourage PrEP use, their family and peers would also provide negative and 
unhelpful remarks about using PrEP. To navigate these realities, Black women 
believed that using PrEP privately would not only increase their safety, but also 
boost their “peace of mind” when protecting themselves from HIV. Flash et al. 
(2014), in their U.S. women PrEP study, found that “women thought a pill would 
be easy to conceal and to ingest surreptitiously, thus eliminating the need to 
discuss concerns about their partner’s level of risk” (p. 638). Therefore, 
emphasizing the benefits and value of PrEP as a female-controlled modality 
becomes absolutely critical in PrEP education and navigation that involves Black 
women.  
Black women also advocated for clinical PrEP research to evolve beyond 
the use of oral medication toward injections or vaccines, or other long-acting 
methods of protection that allow for “6-month” dosing. In the broad body of 
research, these perspectives are considered to be female-controlled modalities, 
therefore indicating a preference for added privacy as a priority consideration. 
Doctors’ Role in Advancing PrEP among Black Women 
Another finding in the current study was that medical providers had a 
significant influence over their willingness to use PrEP. Black women expressed 
respect and trust for their medical providers, who primarily comprised 
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gynecologists and primary care providers. Although, medical providers did not 
impact Black women’s awareness about PrEP, women expressed comfort and 
willingness to openly discuss PrEP with their providers. To facilitate PrEP 
awareness to Black women, providers are expected to be educated and 
equipped with PrEP tools. Initiatives to increase providers’ awareness about 
PrEP and to encourage PrEP prescribing practices are significant in scaling up 
PrEP among Black women at risk of HIV. Undoubtedly, further work in engaging 
providers to openly discuss PrEP among Black women is strategically beneficial 
in ending the epidemic. Although there are gaps in practice, Smith et al. (2016) 
report evidence that, in 2014, clinicians were increasingly more aware of the 
CDC guideline for prescribing PrEP. Further, Calabrese et al. (2016) noted, 
“Either the community isn’t aware enough about it or their primary care providers 
are still not talking about it enough, are not confident enough, or are not able to 
answer their questions, so that there’s a gate and the gate is really closed off 
before people actually get to me” (p. 9). 
As expected with gaps in female-focused PrEP research, additional factors 
that impact women’s decision on using PrEP were not readily identified in the 
literature review. These include couple use in normalizing PrEP, leveraging older 
women as resources for behavior change, sharing experiences among PrEP 
users, and managing perception of extreme side effects. These will be reviewed 
in later sections. 
Limitations of the Study 
The conclusions outlined above must be considered in light of the study 
limitations, which are outlined below. The limitations include sample deficiencies, 
lack of triangulation, cross-sectional design, and researcher’s potential bias. 
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These limitations point to the need for more robust future studies. They also 
provide context in which the results from this current study can be understood in 
its implications for practice and future studies. 
One limitation was the study sample, which was purposive and selected 
from a particular reference population who were willing to participate in the study. 
The current study used two CDC guidelines for female PrEP indication to recruit 
Black women who received care at a health center in Brooklyn, New York. The 
current study sample was not random in participant selection and utilized one site 
for recruitment. Another problem with the study sample was that since they had 
limited awareness about PrEP, they may not have been in a good position to 
reflect on the interview questions. The current study clearly represents 
exploratory work that requires further research to verify the findings. 
Another limitation is lack of triangulation. The ability to “apply the principle 
of triangulation throughout your study, continually watching for opportunities to 
triangulate your steps,” further strengthens the credibility of a study (Yin, 2016, 
p. 87). According to Yin, triangulation involves the principle of “seeking at least 
three ways of verifying or corroborating a procedure, piece of data, or finding” 
(p. 87). Drawing from Patton’s (2002) work, Yin (2016) cites four ways in which 
data can be triangulated: 
1. data sources (data triangulation) 
2. investigators who have worked on the same study team (investigator 
triangulation) 
3. perspectives about the same dataset (theory triangulation) 
4. methods (methodological triangulation) (p. 87). 
In the current study, only one source of data was used, namely, self-reports 
from the participants; only one researcher conducted all of the interviews, and 
interviews were the only method of data collection. 
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Another limitation of the current study was the cross-sectional design. The 
study was implemented over a 3-month period from November 2017 to January 
2018. Participants were interviewed only once, and there was no overlap of 
participants in the pilot study and those in the larger study. According to Carlson 
and Morrison (2009), cross-sectional studies are often “described as taking a 
'snapshot' of a group of individuals” (p. 77). The authors highlight one advantage 
of cross-sectional design as its ability to understand the prevalence of various 
conditions, treatments, services, or other outcomes and the factors associated 
with such outcomes (p. 78). Although the current study is helpful in identifying 
factors that may impact Black women’s motivation to either accept or reject 
PrEP, a limitation in conducting this type of study is that no causal associations 
between factors identified for either accepting or rejecting PrEP can be made. 
To a great extent, the veracity of this study relied on the Researcher 
herself. It is, therefore, important to reflect on how her background, prior 
experiences, and orientations may have influenced the results. Recognizing that 
the Researcher was not only involved in the collection of the data but was also 
personified in the questions asked, the responses given, the respondents’ 
openness, the completeness of the interview, the ethical concerns, and later 
activities that included the transcription, coding, analysis, and presentation of 
results, it is therefore pertinent to understand the Researcher, her story, and 
possible impact to the study. Roberts (2002) furthers this statement by eloquently 
stating that to “place the researcher fully within the research is to recognize that 
we all have stories and it seems a fundamental part of social interaction to ‘tell 
our tales’” (p. 13). The Researcher is a Black woman in her 30s who contends 
with various social roles, including sex, gender, wife, motherhood, religious 
beliefs, daughter, employee at the Health Center, and student. She must grapple 
with what it means to thrive and excel in all these roles while maintaining a 
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full-time job. Presently, the Researcher leads an HIV prevention team at the 
Health Center in Brooklyn, promoting and implementing HIV prevention 
strategies, while also navigating newly diagnosed and people living with HIV into 
medical care. 
Psychologically, it was utterly rewarding interviewing Black women in 
Brooklyn in my workplace. The fieldwork was comfortable and safe, as these 
women were considered my sisters, mothers, friends, and community. Yet I was 
also uncomfortable and insecure because of the topic. I knew what HIV means in 
the community and knew that the stigma was real. However, I believed, although 
the realities may be different, that women in New York City are all at risk of HIV. 
This was a reassuring factor in pushing the boundaries of the study. Of course, it 
also helped that I conducted a pilot study, which was useful in finding rhythm in 
asking the questions, working on my expression (which women are quick to point 
out), and learning from women’s reactions about possible offenses caused by 
questions or how they were asked. 
Interviewing 72 Black women who had different attitudes, beliefs, ages, 
perspectives, and cultures was tremendously humbling. There were many times 
when in my mind I may not have agreed with the perspectives being shared, but 
those were the times I was deliberate in my expressions; seen through a gentle 
“smile” or a “nod of support” to urge the respondents to continue. I was always 
trying to be mindful of reactions, while creating an enabling space where women 
felt safe sharing their experiences. Women shared stories of resilience, 
successes, and strength but also shared stories of abuses, family conflicts, and 
fear. There were times I wanted to give advice but restrained myself. Yet there 
were decided moments when women asked specifically for advice. At those 
times, I shared my experiences, with the hope it could be helpful. Needless to 
say, women were quite forthcoming with their advice, particularly when they 
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learned the study was related to the Researcher’s graduate degree. In keeping 
with her culture, advice was taken with appreciation, and, where appropriate, 
hugs and well wishes were exchanged. 
By way of professional experience, the Researcher started her work in the 
field of HIV prevention in 2009 when she lived and worked in South Africa. 
Currently, she manages federal-, state-, and city-funded HIV prevention and 
access to health programs in Brooklyn, New York. 
Implications for Practice 
The findings from the current study have pronounced implications for 
practice. The areas that are reviewed include understanding the disconnect 
between perception of PrEP uptake and practice; increase education of 
providers; and a new PrEP navigation model for Black women. These are 
implications that should be interwoven into health education and health 
promotion programs for Black women. 
Disconnect Between Perception of PrEP Uptake and Practice 
In the U.S., Bush et al. (2015) reviewed PrEP prescriptions through a 
national database over a 3-year period from 2012 to the first quarter of 2015. The 
authors found over 8,500 PrEP prescriptions. Bush et al. found a 332% increase 
in PrEP users from 2014 to 2015. During this same period, women accounted for 
13.4% of PrEP users, while 86% were male. As expected, the results showed 
incremental PrEP increase over the 3-year period, which would correspond to 
FDA approval in 2012 and CDC’s release of guidelines for clinical practice in 
20014. Similar trends have been found in other studies (Bien et al., 2017; 
Blackstock et al., 2017; Laufer et al., 2015). Although Black women in the current 
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study believed that more women would use PrEP, based on an assumption that 
they are more connected to the health care system than men, the findings of 
other studies (Bien et al., 2017; Blackstock et al., 2017; Bush et al., 2015; Laufer 
et al., 2015) clearly reject that perspective. Based on new HIV diagnoses 
reported in the literature, compared with Black women, the rate in New York City 
among MSM is three times greater. This is consistent with use of PrEP primarily 
among MSM. Nevertheless, there are noticeable disparities in PrEP prescriptions 
and PrEP uptake among Black women. 
As health educators, the question of access to PrEP becomes very 
important. Understanding where PrEP information is being shared is an important 
element in piecing together PrEP uptake and HIV prevention messages. 
Identifying what sources Black women use to learn about PrEP with an aim of 
replicating such education in settings where Black women obtain health care 
services may be helpful in increasing awareness and interest about PrEP among 
this priority population. 
Increase Education with Providers 
The findings of the current study show that medical providers did not 
educate Black women about PrEP. Of the 72 Black women interviewed, 6 had 
knowledge about PrEP, and only 3 received information from their medical 
provider. This finding is congruent with the body of literature that exists. 
According to Karris et al. (2014), although 74% of providers supported the use of 
PrEP, only 9% ever prescribed PrEP in their practice. Of the 74% of providers 
who supported PrEP, 43% would prescribe PrEP, but 34% believed PrEP was 
not relevant to their practice (p. 464). The clinical support for PrEP as a 
biomedical prevention in ending the epidemic has to drastically increase. As 
health educators in the field, working alongside clinicians to increase buy-in and 
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support for the entire tool kit of HIV prevention methods is a persistent need that 
should be included in work plans and health education interventions. Identifying 
the kinds of educational approaches that are most acceptable to various groups 
of women and most feasible to implement in various health care and other 
settings remains a current need. Creative partnerships with health care systems 
should be focus areas for health educators to ensure that vulnerable 
communities are accessing tools to prevent new HIV infections. 
New PrEP Navigation Model for Black Women 
Navigation and linkage to care are critical to the New York’s Blueprint for 
Ending the Epidemic by 2020. Among priorities for the plan is the component of 
“facilitating access to pre-exposure prophylaxis (PrEP) for high-risk persons to 
keep them HIV-negative” (Blueprint on Ending the HIV Epidemic in New York 
State, p. 4). Increasingly, as Black women are engaged in PrEP conversations, 
the goal of linking women to PrEP care is critically important. However, a shift in 
navigation for women must be consciously made for linkage to PrEP services to 
be successful. The findings of the study speak clearly to the importance of a 
gender-specific PrEP navigation approach for Black women. 
The findings from the current study create a ground-up perspective in 
understanding key components that should be involved in PrEP navigation for 
Black women. The components are risk assessment and shared understanding 
of the identified risk; the use of female-specific PrEP materials, including flyers, 
posters, and videos; connection to female PrEP users; initial thoughts about 
disclosure or non-disclosure; linkage to medical providers for PrEP prescription; 
and post-prescription follow-up. 
Risk assessment and shared understanding of the identified risk are 
important first steps for women who are aware of PrEP. From the current study, it 
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was revealed that one reason for not taking PrEP prescription is that women do 
not share the concern about risk as the provider or PrEP navigator. As practice 
becomes responsive to the research, approaches for assessing and, where 
appropriate, changing Black women’s risk perception of HIV infection need to 
change. Health educators are challenged to reframe PrEP risk assessment 
questions to help Black women explore individual reasons for being at risk of 
HIV. In settings of HIV testing or HIV prevention workshops, including reflective 
questions helps to elicit personal reasons for feelings of risk. 
After risk assessment is completed and there is acknowledgement of 
shared risk perceptions, introducing female-specific PrEP materials would be a 
practical next component. Materials are needed to answer questions such as: 
What is PrEP? What are the benefits? Is it recommended for use with condoms? 
What are the possible side effects? How effective is PrEP? How much will it cost, 
and will my insurance cover the cost? From the current study, in-depth 
communication about side effects and possible interactions with other 
medications, including birth control, is critical at this stage, although realizing that 
additional information will be shared by the medical provider. 
Black women who are interested and have PrEP indications may benefit 
from connecting with female PrEP users. Based on current literature, this 
component does not exist. The findings in the current study are clear on this 
point. All Black women either associate strong importance to this component or 
recognize its importance. Two options are utilizing Black female PrEP users as 
navigators, which helps in first-hand peer-to-peer exchanges about the benefits 
of PrEP and utilizing a PrEP navigator. 
Weekly or bi-weekly PrEP groups discussing and share testimonials about 
their PrEP journeys are available options. Ideally, this component would be 
important before medical providers prescribe PrEP; however, individual journeys 
  
158 
are different, and timing to begin PrEP is also a factor. This component can also 
follow post-prescription for strongly motivated Black women and would become 
more of a support intervention, encouraging PrEP maintenance. 
Once there is a decision that PrEP is an option, it is important to have 
conversations about Black women’s initial thoughts about disclosure or non-
disclosure of their PrEP use. This component can be a stand-alone conversation 
but, ideally, will form part of either risk assessment discussion or discussion after 
the connection to Black female PrEP users, realizing that time is a factor and 
another opportunity may not be present before the medical appointment. Black 
women should have a clear strategy of how they intend to take the medication. 
This may translate into keeping PrEP private, changing the pill bottle and 
creating a routine for taking the pill. In addition, as mentioned by women in the 
current study, developing “know-how” response to questions about the pills is 
important and prepares the woman for real-world settings. Moreover, if PrEP use 
will be revealed to a partner and or friends and family, understanding how to 
navigate those conversations, flagging key points to use, is also important for 
reinforcing safety and “peace of mind” for Black women. This component has not 
been mentioned in the literature but may be an important component in PrEP 
initiation and maintenance. 
Currently, the most mentioned component in PrEP navigation is the linkage 
to medical providers for PrEP prescription. Arguably, the outcome of all PrEP 
navigation is for medical providers to prescribe PrEP. However, the simplicity of 
this act is overshadowed by the complexity that not everyone who receives a 
prescription actually fills it, and further, they may fill the prescription but never 
take the pill (Laufer et al., 2015). The importance of the preceding components 
works together to increase the impact the medical interventions will have in 
facilitating anticipated behavior change. Additionally, the medical provider is 
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expected to address lingering concerns, but should reassure Black women of the 
effectiveness of PrEP in protecting against HIV, citing clinical studies occurring in 
real-world settings, even their own experiences. Another important element in the 
conversations with Black women is managing the perception of extreme side-
effects. Working with Black women to review their current medications, whether 
prescribed or non-prescribed, to assess potential contraindications cannot be 
overstated. Finally, the PrEP navigator follows up with the Black women to note 
the date of PrEP start, but also to address any lingering concerns. 
Implications for Future Research 
Further research is needed to advance HIV prevention interventions and 
strategies to end AIDS in vulnerable communities. Three gaps are identified, 
leveraging older women as resources for behavior change; couple use in 
normalizing PrEP; and understanding the future of PrEP prescription for Black 
women. 
Leveraging Older Women as Resources for Behavior Change 
Undoubtedly, gaps exist in the literature for Black women and PrEP use. 
Based on the findings of the current exploratory study, further research is needed 
to understand the extent and role of older women in communities of color to 
expand messages about PrEP and, quite possibly, other public health problems 
affecting Black women. This insight indicates another, more indirect, strategy for 
educating this target population. Further research would be useful in 
understanding the practical and possible impact that can be effected by 
leveraging older women in communities, who may be easier to reach in order to 
connect with hard-to-reach populations. Inherently, measuring the outcomes may 
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require innovation to ensure that the education is actually reaching the intended 
priority group would be an area of concern. Presenting models, not only for 
reaching hard-to-reach populations through older Black women as an 
intervention model, but also exploring ways of measuring outcomes of these 
interventions, are tools that would most definitely help end AIDS in our 
communities. 
Couple Use in Normalizing PrEP 
Another viable strategy for PrEP uptake among Black women is 
normalizing PrEP use among couples. This was a surprising finding from the 
current study, as Black women identified the importance of reinforcing positive 
behaviors of PrEP if implemented as a couple’s activity. The results of the current 
study indicate that women are generally interested, as a first option, to discuss 
PrEP with their partners and to involve them in their decision-making process. 
Although Black women were quick to indicate their agency in making these 
decisions, there was a general agreement that positive input from partners would 
be helpful as they make their decisions. 
Additionally, findings from the current study suggest that couple PrEP use 
also helps to alleviate possible negative reactions from partners and avoid 
potential negative strain on relationships. The concept is similar to couple HIV 
testing, which has slowly been accepted as part of the HIV testing landscape and 
is empowering couples across the world (Matovu et al., 2015; Rendina et al., 
2014; Wagenaar et al., 2012). Couple PrEP initiation and use are an unknown 
area in the literature, and further research in understanding approaches, benefits, 
and means of engagement will help grow this area of HIV prevention. 
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Future of PrEP Prescription for Black Women 
Although the CDC-recommended guidelines for PrEP indication are not 
limited to sero-discordant relations, most PrEP prescriptions among women have 
been provided because of discordant relationship status. However, of the less 
than 4% of PrEP prescriptions generated for women, sero-discordant relationship 
is the dominant risk factor (Smith et al. (2015). In their study, McMahon et al. 
(2014) believed that HIV-sero-discordant couples are the most “ideal candidates 
for PrEP” (p. 464). In the U.S., Smith et al. (2016) found that PrEP prescriptions 
were highest among sero-discordant couples, where one partner has HIV and 
the other partner is free of HIV. Additionally, in New York City, Blackstock et al. 
(2017) found that of the 21 women who received a PrEP prescription, 85.7% had 
as their primary risk factor being in a sero-discordant relationship. 
Collaboratively, agreeing that sero-discordant relationship is one of the “low 
hanging fruit” that validates risk assessment indicates that further research is 
needed to provide direction to practicing clinicians and health educators in 
strategies for conducting effective risk assessments. Vulnerable Black women 
require greater attention and should be factored in when prescribing practices for 
PrEP beyond discordant relationships. This will become even more critical amidst 
the movement of U=U. The “Undetectable=Untransmissable (U=U) slogan was 
launched by the Prevention Access Campaign” (Editorial, 2017, p. e475). The 
campaign promotes the finding that people living with HIV who remain virally 
suppressed cannot sexually transmit HIV to other people. This is now accepted 
in the HIV/AIDS community. According to The Lancet’s Editorial (2017) in early 
2016, the “campaign has been rapidly gathering momentum, having been 
endorsed by more than 400 organizations from 60 different countries since its 
launch,” with the U.S. Centers for Disease Control and Prevention (CDC) joining 
the “movement by endorsing the science in a letter released on National Gay 
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Men’s HIV/AIDS Awareness Day” in October 2017 (p. e475). As practitioners, 
framing the U=U discourse for Black women is strikingly urgent. How is the U=U 
discourse resonating with Black women in sero-discordant relationships? Do they 
still need PrEP? Is U=U discourse unintended consequence that may jeopardize 
the need for PrEP among Black women? Whatever the outcome, as practitioners 
and clinicians in HIV prevention, there are huge signals to move past low-
hanging fruit to reach to those behaviors further up the tree of HIV risk in order to 
end AIDS. 
Final Comments 
First, as a final comment in this current study, although there is a dearth of 
female-focused PrEP studies to compare with findings of this current study, the 
barriers faced by Black women are unique. In addition, more women were 
diagnosed with HIV in New York City; quite noticeably, 68% of new diagnoses 
occurred among women aged 30-59 years with Black heterosexual women 
accounting for 38.3% of those new HIV diagnoses (NYC DOHMH, 2017). This is 
also framed within the reality that HIV stigma remains quite pronounced among 
Black Women. HIV prevention activities will continue to experience strong 
resistance, making health educators’ and public health professionals’ work even 
more difficult. Creative programming within high burden communities is even 
more critically important to penetrate with messages of new innovations and best 
practices. Smith et al. (2012) shared similar comments by highlighting the 
importance to scale up PrEP education and counseling efforts among African 
American men and women. The results of the current research speak volumes to 
the continued work needed to educate communities with prevention messages. 
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Second, the current study was conducted in a traditional setting in which 
HIV prevention messages should be routine and integrated in primary care. 
However, there is a ravine that exists between implementation and State 
recommendations. Quite possibly, this discrepancy may be due in part to low 
levels of provider awareness of PrEP as an HIV prevention method that is also 
suitable for women. This study indicates the need for collaboration and 
partnership between health departments and traditional and non-traditional 
settings to push targeted and newer innovations and practice models about HIV 
prevention to high-risk populations. The forging of these partnerships and 
iterative dialogues can stem the tide and drastically reduce new HIV infections 
among Black women in New York. 
Third, the last comment seeks to be an encouragement for researchers. 
One lesson that has become quite obvious to this researcher is the need to be 
transparent and inclusive with the community about the research being 
attempted in the community. Historically, within Black communities, there exists a 
level of mistrust of research. Going beyond the description of research flyers to 
discuss the importance and driving force behind the research is not only an 
opportunity to build advocacy for the research, but it also breaks down skepticism 
and mistrust toward the research. After explaining the relevance of the research 
to potential participants, this Researcher found that Black women were also able 
to share the value of the research and increase their interest. Whether the 
research is quantitative or qualitative, generating support for the research, 
particularly within high burden communities, is one strategy to increase uptake of 
the research and boost participants’ involvement. The experience from the 
current study was that communities were welcoming of research when they 
believed the research objective was to help the community. As researchers, it is 
our responsibility to demonstrate to communities that our work is to empower 
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people, support improved policies, reflect light on persistent health challenges, 
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1. When you think about the questions I asked, were there 
questions that: 
 
a) were difficult to understand? Can you remember the question?  
 
b) could have been clearer?  
 














For Women in the PrEP Study Briefing 
for Nursing and Health Educator Staff 
The following questions and answers help to provide a consistent and clear 
message about the study to the nursing and health educator staff of the Health 
Center. Through this tool, staff will be clear about the study’s purpose and 
ultimately increase the number of women referred to the study. Participants will 
get one consistent and clear message about the study to help them in their 
decision to participate in the study. 
Q. What is the Purpose of the study? 
A. The purpose of this study is to describe Black females’ awareness, 
beliefs and perception of PrEP, and to identify factors that may influence Black 
women’s willingness to consider PrEP as an HIV prevention strategy. 
Q. Importance of the study? 
A. 
• This study is intended to support existing programs, to scale-up PrEP 
use among groups identified as at “substantial risk” of HIV infection, of 
which the population of Black women is of immediate importance.  
• The results of the study elevate and will contribute to better 
understanding of the concerns women have as they navigate their 




• The study will provide tangible directions to HIV prevention practitioners 
that they can use to scale-up PrEP use among Black women. 
Q. Who is supports the study? 
A. The study is supported by Teachers College, Columbia University. 
Specific oversight is provided by dissertation advisors in the faculty of Health and 
Behavior Studies and Sociomedical Sciences at Teachers College and Mailman 
School of Public Health at Columbia University.  
Q. Who will have access to the Data? 
A. Data that is collected is restricted to the Researcher and the 
Researcher’s advisors. 
Q. What is required of participants? 
A. Agree to participate in the study and sign the informed consent form. 
Q. Who is eligible for the study? 
A. Individuals who: 
1. Are at least 18 years old. 
2. Self-report having anal or vaginal sex within the past 6 months. 
3. Have had a STI or HIV screen in the past 6 months or had a STI in the 
past 6 months. 
4. Self-report HIV status as negative. 
5. Are willing to provide informed consent to participate. 
Q. What are the incentives? 
A. As a small token of appreciation, each participant will receive one Visa 


















Teachers College, Columbia University 
525 West 120th Street 
New York NY 10027 




Protocol Title: awareness, beliefs and risk perceptions and decisions to use 
preexposure prophylaxis among African American women in New York City. 
 
Principal Investigator: Suzanne Robinson Davis, Teachers College  
646-525-1359, sr3275@tc.columbia.edu 
INTRODUCTION 
You are being invited to participate in this research study called “Black female’s 
awareness and perceptions about PrEP in New York City.” You may qualify to take 
part in this research study because you are over 18 years old and HIV-negative women 
or women who are unaware of their HIV status. If you are HIV-positive or currently taking 
PrEP you cannot be part of this study. Approximately 100 people will participate in this 
study and it will take 60 minutes of your time to complete. 
WHY IS THIS STUDY BEING DONE?   
Only few studies have looked at women perceptions about PrEP but none in Brooklyn 
focusing on Black women. The study will provide insights into lessons that could be 
learned by practitioners and networks working in the area of HIV prevention to scale-up 
PrEP use among Black women.   
WHAT WILL I BE ASKED TO DO IF I AGREE TO TAKE PART IN THIS STUDY?  
If you decide to participate, you will be interviewed by the Principal Investigator. During 
the interview, you will be asked to discuss your perceptions about PrEP, and questions 
about condom use and sexual practices. This interview will be audio-recorded. After the 
audio-recording is transcribed the audio-recording will be deleted. The interview will 
take approximately sixty minutes. Your identity will be kept confidential.  
WHAT POSSIBLE RISKS OR DISCOMFORTS CAN I EXPECT FROM TAKING PART 
IN THIS STUDY?  
Participants may experience minimal risk such as feelings of judgment, embarrassment, 
stigma, and general hesitation in discussing sexual practices but not greater than you 
would ordinarily encounter in daily life while taking routine physical or psychological 
examinations or tests related to HIV infection. An attempt to reduce such feelings will be 
made by reassurance from the interviewer that the discussion is confidential. Also, you 
do not have to answer any questions you don’t want to talk about. You can stop 
participating in the study at any time without penalty. The Principal Investigator is 
taking precautions to keep your information confidential and prevent anyone from 
discovering or guessing your identity by keeping all information on a password 
protected computer and locked in a file drawer.  
WHAT POSSIBLE BENEFITS CAN I EXPECT FROM TAKING PART IN THIS 
STUDY?  
There is no direct benefit to you for participating in this study. Participation may benefit 
the field of public health education to better understand the best way to engage women 
of color about HIV prevention. Additionally, if you are interested in PrEP, a referral can 
be made with a provider at the health center, which could be seen as a benefit.  



















How is it going? Have you done interviews before? How did you feel about it? Well, 
together we will work to create a safe space while exploring your thoughts and feelings 
about this topic.  
 
 
Section 1: PrEP Awareness & Acceptability  
 
Observability/ Awareness  
1. Before today, have you ever heard of PrEP? Have you seen subway ads, printed 
materials, or any campaign on social media/Facebook about PrEP? 
  
2. Have you heard friends talk about PrEP?  Do you have friends who have used 
PrEP? What have you heard and what are some of the experiences 
friends/people have shared?  
 
Compatibility  
3. Consider your beliefs about sexual health and HIV prevention, does PrEP fit in 
positively or negatively with those beliefs? Can you explain further giving 
examples?  
 
4. Do you think that men and women are equally likely to use PrEP, or is one group 
more likely to use it? If more men use PrEP, would this positively influence 
women to use PrEP? Why/why not? If women were to take PrEP, would it affect 
their partner’s reaction? How would it impact your decision to use PrEP? What 




5. Do feel like you need PrEP?  Do you see any advantages of PrEP over other 
methods?   If women were to use PrEP, would there be a change in their condom 
usage? Give reasons. In your experience, what are reasons for not using 
condoms? Do you think PrEP could fill those gaps? If yes, how would you 





6. Can you describe three risk factors for getting HIV? Would you consider a 
woman at risk if she just had one risk factor? If yes, which?  If no, how about two 
risk factors? 
 
7. Can you identify two barriers you think women would face in taking a daily HIV 
medication that can prevention HIV? How could they overcome those barriers? 
Examples.   
 
Trialability/ Observability  
8. Have you ever tried PrEP?   If yes, how did you like it?  If no, would you consider 
taking PrEP if your doctor recommended it?  Is PrEP something you could 
incorporate into your life? Why/why not. In making a decision about taking PrEP, 
how important is it for you to hear from other women who take PrEP? Explain.  
Would your partner’s opinion matter to you?  Please explain.  
9. Who would you say could most influence you to take PrEP and why? 
What would they need to say or show you to convince you to use PrEP?  
Trialability/ Compatibility  
10. Do you know of anyone who has HIV? Do you worry about getting HIV? 
Why/why not? Would taking PrEP every day be a realistic option for you? 
Why/why not? What is another option for keeping you safe and free of HIV?  
Complexity 
11. What advice would you give to a doctor or nurse to help them 
communicate effectively to women about PrEP? What three key points 
should women know when they consider PrEP? 
Compatibility 
12. What type of medical provider/specialist do you see most often? Has s/he 
ever mentioned PrEP?  Would you feel comfortable asking your provider 
to prescribe PrEP? Why/why not? 
Observability 
13. Is there anything you would like to know to help you make a choice about 




Section 2: Patient Demographics 
 
1. What is your gender:  
1. Female ___ 
2. Who do you have sex with?  
1. Male (Men) ___ 





3. What is your race/ethnicity? (circle the selected answer). 
1. Black or African-
American  




4. Please provide the name of the city and state where you live:  
Borough: _______________________ Zip code: ___ 
5. Reasons for last clinic visit: STD test___ HIV test___ regular check-up ___  
 
6. What most accurately describes your current relationship / marital status? 
(circle the selected answer). 
1. Legally Married  
2. Separated  
3. Divorced  
4. Widowed  
5. Not Married  
6. In a domestic partnership (living 
with a committed partner) 
 
7. In a committed relationship (not 
married and not living together)  
8. Neither in a committed 
relationship or legally married 
(i.e. Dating)  
9. Don't Know 
10. Other:_______
 
7. What is your year of birth: (yyyy) __________ 
  
184 
8. What is the highest level of education you have completed? (circle the selected 
answer). 
1. Less than high school   
2. High school/GED 
(Some college)  
3. 2-year college degree 
(Associates)   
4. 4-year college degree 
(BA, BS)  
5. Master’s degree or 
over  
 
9. What is your monthly income from all sources? (circle the selected answer).
1. Less than $1,500 
2. $1,501-$2,500 
3. $2,501-$3,500 
4. More than $3,500 
 
10. What is your current housing situation?  
1. Stable___ 
2. Unstable___  
3. Homeless ___ 




Section 3: Individual Risk Questions  
1. Have you had condomless anal or vaginal sex in the past 6 months? Yes___ No 
___ 
 
2. When you think about the past 3 months, have you had more than one partner? 
Yes___ No___ 
3. When you think about your sexual encounters in the past 3 months, how often 
did you use a condom: (circle the selected answer). 
1. Never  
2. Almost never  
3. Occasionally/sometimes  
4. Almost every time  
5. Every time 
 
4. Have you ever had a Sexually Transmitted Disease (STD) in the past 6 months? 
Yes___ No___.  
If Yes, which ones (circle all that applies): 
1. Chlamydia  
2. Gonorrhea 
3. NGU  
4. Syphilis  
5. Herpes  
6. HPV (warts)  
7. Trichomonas  
8. Unknown 
 
5. Have you ever used injection drugs in the past 12 months? Yes___ No___ 
6. Have you ever used non-injection drugs in the past 12 months (crack or 
marijuana or crystal meth, etc.)? Yes___ No___  
7. Do you have knowledge about a family or friend who has been diagnosed with 
HIV? Yes___ No___  
8. When last did you have a HIV test? (Circle the selected answer). 
a) 0-3 months ago 
b) 4-6 months ago  
c) 7 months-1 year ago  
d) Over 1 year ago  





9. Thinking about the last person you had sex with, do you know their HIV status? 
(such as if they were HIV-positive or negative?) Yes     No  
 
10.   Rate your perceive risk of getting HIV. 
  
a) Definitely  
b) Very probably  
c) Probably 










Emails from Researchers 
 
 
Robinson-Davis, Suzanne <sr3275@tc.columbia.edu>  
  
Request for Instruments Auerbach, Judith 
<Judith.Auerbach@ucsf.edu> Wed, Dec 21, 2016 at 3:02 PM  
To: "Robinson-Davis, Suzanne" <sr3275@tc.columbia.edu>  
Dear Suzanne,  
Thanks for your message, and for your interest in addressing PrEP use 
among Black women in New York. This is a very important topic, and I'm 
pleased to know you are pursuing it in your doctoral research.  
For our study, we used focus groups, not interviews, as our method. I have 
attached the focus group guide here. I've also attached a questionnaire we 
used to collect basic demographic information about the focus group 
participants. Feel free to use or adapt either or both of these. 
Acknowledgement of their source is much appreciated.  
Also, in case this is helpful, here's the link to the updated version of the 
fact sheet we used at the beginning of our focus groups: 
http://www.thewellproject.org/hiv-information/prep-women. Much has 
happened in the area of women and PrEP since we did our research, so 
this fact sheet and associated videos are an excellent up-to-date resource 
for you.  
I hope all of this is helpful.  
Best regards, Judy  
From: Robinson-Davis, Suzanne [sr3275@tc.columbia.edu] Sent: 
Tuesday, December 20, 2016 5:53 PM To: Auerbach, Judith Subject: 
Request for Instruments  
[Quoted text hidden]  
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2 attachments AU PrEP Focus Group Questions.pdf  
 
PrEP preFG questionnaire.pdf  
 
 
Request for Survey Instrument(s) Yohance Whiteside 
<yowhiteside@gmail.com> Mon, May 15, 2017 at 8:53 PM  
To: "Robinson-Davis, Suzanne" <sr3275@tc.columbia.edu> Hello 
Suzanne,  
I've attached two surveys that we conducted. One was the HIV PrEP 
survey for STD clinic attendees and the other was a PrEP survey for 
seronegative partners of HIV positive individuals. Good luck.  
Best,  
[Quoted text hidden] -- Yohance Omar Whiteside, MSPH, PhD  
